The treatment of postmenopausal osteoporosis by Middleton, Edward Thomas
1THE UNIVERSITY OF HULL
The treatment of postmenopausal osteoporosis
being a Thesis submitted for the Degree of Doctor of
Medicine in the University of Hull
by
Dr Edward Thomas Middleton, MBChB, B Med Sci
May, 2008.
2This thesis is dedicated to my wife, Louise, for her love
and support during both my MD and all of our time together.
I also dedicate it to my children, Sophie and Ava, for all the love,
joy and trouble they bring to my life.
3Thesis summary.
Introduction: Osteoporosis is a skeletal condition in which bone strength is
compromised leading to a propensity to fragility fractures. Osteoporotic fractures have
significant consequences for both the individual, due to the resulting morbidity and
mortality, and for society in terms of resource implications. Fortunately, in recent years
there have been an increasing number of treatments available. This thesis aims to
investigate current topical areas regarding the treatment of osteoporosis.
Method: This thesis contains 5 different studies with different methodologies. One is a
reanalysis of data previously collected as part of a prospective osteoporosis screening and
follow up study. Three studies are derived from clinical databases at our centre. The final
study is a prospective study specifically conducted as the centrepiece for my MD.
Results: 1): Routine VFA screening detects vertebral fractures in 20% of women
attending for DXA, the majority of which have osteopenia in whom the presence of a
fracture may directly effect their treatment. Targeted VFA screening only detects around
10% of women who have vertebral fractures. 2): A short course of HRT has prolonged
benefit in terms of BMD. 3): Prior bisphosphonate use does not result in blunting of the
BMD response to teriparatide. 4): The BMD response to strontium ranelate is blunted by
prior bisphosphonate use for the first 6 months of therapy at the spine and for 12 months
at the hip and heel. 5): Vertebroplasty using Cortoss cement reduces pain from vertebral
fractures with results comparable to those achieved with PMMA vertebroplasty.
Conclusion: Osteoporosis is a disease with an increasing number of treatment options.
While modern treatments are all proven to reduce fractures in treatment naïve women
their place in the overall treatment of women with osteoporosis is less well studied. This
thesis provides further insight into areas such as improving fracture risk assessment in
order to guide treatment initiation, initial treatment options, the effects of switching
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This thesis examines the clinical aspects of the treatment of osteoporosis. In order to
maintain a focus on postmenopausal osteoporosis other areas of osteoporosis, such as
male osteoporosis and glucocorticoid-induced osteoporosis, are not covered in this thesis.
The first three chapters provide an overview of the literature on postmenopausal
osteoporosis to set the scene for the research studies, which follow in chapters 4 to 8.
Chapter 1 defines osteoporosis and covers the epidemiology and pathophysiology.
Chapter 2 discusses in turn the different treatments available for osteoporosis including
current topical issues and areas studied later in this thesis. Chapter 3 provides information
on means of monitoring the response to treatment, which are used in my research.
Chapters 4 to 8 are my research studies, which have all been published, with the
exception of my strontium study has been submitted for publication. As these studies do
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Chapter 1:





Osteoporosis is a skeletal condition in which bone strength is compromised leading to a
propensity to low trauma (fragility) fractures, which are the clinical manifestation of the
disease. While the bone tissue itself is histologically normal, there is a reduction in the
amount of bone and deterioration in the structure of the bone leading to a reduction in
bone strength. This is reflected in the 1993 Consensus Development Conference
definition of osteoporosis as “a systemic skeletal disease characterised by low bone mass
and microarchitectural deterioration of bone tissue leading to enhanced bone fragility and
a consequent increase in fracture risk” (Anon 1993).
While this is a pathologically correct definition, it has limitations in clinical practice.
Bone microarchitecture is difficult to image routinely and bone mineral density (BMD),
as measured by dual energy x-ray absorptiometry (DXA), is used as a surrogate for bone
mass. As such the World Health Organisation (WHO) has proposed a BMD cut off 2.5
standard deviations (sd) below the average peak adult BMD as a means of defining
osteoporosis (Kanis 1994). This led to the development of the “T score” which expresses
a patient’s BMD in terms of the number of standard deviations above or below the
average peak adult BMD (based on data for 20-29 year olds from the NHANES III
database) (Kanis 2002). Defining osteoporosis as a T score of -2.5 or less identifies
approximately 30% of the postmenopausal female population as osteoporotic which is
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approximately equivalent to the life time risk of osteoporotic fracture (Kanis 1994). Table
1.1 demonstrates the WHO thresholds for bone mineral density.
Table 1.1. WHO diagnostic categories for BMD (Kanis 1994).
Diagnostic category Description T score
Normal BMD is not more than 1 sd below young adult
mean value
T ≥ -1.0
Osteopenia BMD is between 1 and 2.5 sd below young
adult mean value
T <-1.0 to >-2.5





BMD is 2.5 or more sd below young adult
mean value and a prevalent fragility fracture
T ≤-2.5
The limitation of the T score definition of osteoporosis is that fragility fractures do occur
in women with osteopenic or even normal BMD. Furthermore, not all patients with a T
score diagnosis of osteoporosis will suffer a fracture in the near future. This is illustrated
in 2 population studies by Siris et al (2004) and Schuit et al (2004). In both of these
studies, although the risk of fracture was higher in those women with a T score below -
2.5, most fractures occurred in women with osteopenia due to the larger number of
women in this category of BMD.
As discussed later, there are many factors affecting bone strength and the propensity for
fracture, which increase the risk of osteoporotic fracture independent of the patient’s
BMD. As such there is currently a move towards using both BMD and clinical risk
factors to estimate an individual’s risk of fracture. The WHO has recently produced an
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algorithm, which estimates the 10-year probability of fracture for both men and women
(Kanis et al 2008). In the future, the T score definition of osteoporosis may become less
important and it is likely that treatment decisions will be based on absolute fracture risk
rather than the current BMD based threshold for intervention.
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Chapter 1.2:
Epidemiology of postmenopausal osteoporosis and the
consequences of osteoporotic fracture.
Prevalence of low BMD.
The WHO definition of osteoporosis is solely based on low bone mineral density
compared to the peak adult bone mass of young healthy adults. Prior to the menopause,
BMD remains fairly constant and within the population BMD is normally distributed.
The prevalence of osteoporosis in the population prior to age 50 is approximately 0.5%
and the prevalence of osteopenia is 15% (Kanis 2002). After age 50 bone loss occurs and
the prevalence of osteoporosis then increases exponentially with age. Osteoporosis
affects 5-8% of women aged 50-60 and in women aged over 85 the prevalence is more
than 60% (Kanis 1994). This data is based on femoral neck BMD which is the
recommended site for the diagnosis of osteoporosis. The prevalence of osteoporosis will
vary if other skeletal sites are used. In one study the prevalence of osteoporosis varied
from 12% to 31% depend on the skeletal site assessed by DXA (Arlot et al 1997). In a
study of Hull’s local population, 9% of women aged 60-70 had osteoporosis and 39% had
osteopenia based on femoral neck BMD (Ballard et al 1998). If spinal BMD was used
then 20% and 36% of the population was defined as osteoporotic and osteopenic
respectively.
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Epidemiology of osteoporotic fractures.
The clinical significance of osteoporosis lies not in low BMD but in the resulting low
trauma fractures. The classical osteoporotic fractures are those of the wrist, spine and hip
although fractures of the humerus, rib, lower leg, pelvis, hand, and clavicle have also
been shown to be attributable to low BMD (Seeley et al 1991). In the same study
fractures of the ankle, elbow, finger, and face were not associated with BMD.
Vertebral fractures.
Vertebral fractures are the commonest osteoporotic fractures, are strongly associated with
low bone mineral density and are often considered the hallmark of osteoporosis. They
account for almost half of the 1.5 million osteoporotic fractures which occur annually in
the USA with an incidence almost 3 time that of hip fractures (Riggs and Melton 1995).
Data from Rochester, Minnesota demonstrates that the prevalence of vertebral fractures
increases from 11% in women aged 50-59 to over 54% in those aged over 80 (Melton et
al 1993). The overall prevalence of vertebral fracture was 20-25% for all women aged
over 50. The same study demonstrated that the incidence of vertebral fracture also
increases with age with an incidence of 5.8 and 37.7 per 1000 person years for women
aged 50-54 and 85-89 respectively. Similar changes in the prevalence and incidence of
vertebral fractures with age has been demonstrated in European women (Ismail et al
1999, Felsenberg et al 2002).
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Despite the high prevalence of vertebral fractures it has been reported that only one third
of women with vertebral fractures are aware of their presence (Melton et al 1993). In
addition to this, vertebral fractures are often ignored or missed by medical professionals.
One study looking at the prevalence of fractures on lateral chest X-rays, taken for reasons
other than osteoporosis, demonstrated that only 50% of fractures were noted on the x-ray
report and only 19% of those patients with a fracture received treatment (Gehlbach et al
2000). Finally, even when vertebral fractures are specifically looked for it has been
demonstrated that around 34% of vertebral fractures visible on plain x-ray are not
identified by radiologists (Delmas et al 2005).
Vertebral fractures predict future fracture risk.
It is important to know if a woman has a vertebral fracture, as it is a predictor of future
fracture independent of BMD and thus an indication for treatment. Without bone
protective treatment, the relative risk (RR) of suffering a new vertebral fracture is 2.6 in
the presence of 1 vertebral fracture and this increases further if there is more than 1 (RR
5.1) or more than 2 (RR 7.3) prevalent vertebral fractures (Lindsay et al 2001).
Furthermore, in the same study almost 20% of untreated women who sustained a
vertebral fracture suffered another vertebral fracture in 1 year. It has also been
demonstrated that vertebral fractures predict non-vertebral fractures independent of
BMD. Two large epidemiological studies suggest that a prevalent vertebral fracture
increases the risk of future hip (RR 1.9 and RR 4.5) and non-vertebral fracture (RR1.6 in
each study) (Black et al 1999, Ismail et al 2001). Neither of these studies demonstrated an
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increase in risk of wrist fracture after correcting for BMD. Again, in these studies the risk
of future hip and non-vertebral fracture increased with the number of prevalent vertebral
fractures.
Research topic: Given the implications of a prevalent vertebral fracture on the risk of
future vertebral and non-vertebral fractures and that, despite their high prevalence, most
women with vertebral fractures are unaware of them how should we screen women for
vertebral fractures? This is studied in chapter 4 of this thesis.
Vertebral fractures are associated with considerable mortality.
Population studies suggest that survival is reduced by about 20% over 5 years in patients
presenting for medical attention due to vertebral fractures (relative survival 0.81) (Cooper
et al 1993). An increase in mortality after a clinical vertebral fracture was also
demonstrated when data from the Fracture Intervention Trail was pooled. A clinical
vertebral fracture was associated with a 9-fold increase in the age-adjusted risk of death
(Cauley et al 2000). The mechanism behind the increased mortality associated with
vertebral fractures remains unclear. It may be that vertebral fractures are not
independently linked to an increase risk of death, but instead reflect poor underlying
health status and co-morbidities. Against this is the fact that adjusting for age and several
common co-morbidities did not significantly affect the relative risk of mortality in the
study by Cauley et al (2000).
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Vertebral fractures cause significant morbidity.
The pain from an acute vertebral fracture varies from no or minimal symptoms to severe
pain requiring hospitalisation. Pain from the acute fracture often settles over a period of
weeks however many patients are left with chronic pain. Chronic pain may in part be due
to persistent instability due to non-union of the fracture (Heini 2005). A fracture may also
alter the mechanics of the spine resulting in the abnormal transmission of force through
the vertebral column and abnormal strain on the facet joints and paraspinal
ligaments/muscles, which may contribute further to the development of chronic pain after
a fracture. This morbidity was demonstrated by Nevitt et al (2000) who reported an
increased incidence of severe back pain, limited daily activity and requirement for bed
rest over a 3 year period after a vertebral fracture.
Apart from pain, vertebral fractures have other consequences. Increased thoracic
curvature, the “dowagers hump”, may result in painful crowding of the ribs and a decline
in lung function. A 9% reduction in vital capacity for each thoracic vertebral fracture has
been demonstrated (Harrison et al 2007). Compression of the abdomen can result in
gastro-oesophageal reflux, early satiety and weight loss. There may be psychological
consequences including impaired body image, loss of self-esteem, a fear of future
fracture and depression. Overall, vertebral fractures result in a reduction in the quality of
life and this has been demonstrated in a case control study. Hall et al (1999) reported that
women with vertebral fractures have a reduction in both the physical and mental
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components of the SF36 quality of life assessment when compared to patients without
fracture.
Wrist fractures.
Wrist fractures are predominantly associated with a fall onto an outstretched hand in
women with low bone mineral density who are otherwise relatively healthy and active
and have good neuromuscular function (Kelsey et al 1992). Overall about 17% of women
over 50 in the UK will suffer a wrist fracture during their life (Van Staa et al 2001). The
incidence of wrist fracture increases with age until around age 65 when it plateaus with
an incidence of around 7.5-9 fractures per 1000 person years (Kelsey et al 1992). Wrist
fractures are associated with an increased relative risk for subsequent fracture of the wrist
(RR 3.3), spine (RR 1.7) and hip (RR 1.9) (Klotzbuecher et al 2000). Unlike other
osteoporotic fractures, wrist fractures are not associated with an increase in mortality
(Cooper et al 1993, Van Staa et al 2001). In the short term, wrist fractures are associated
with pain and impaired function and can be complicated by reflex sympathetic dystrophy
which has been reported to occur in up to 10-20% of cases (Zollinger et al 2007,
Zollinger et al 1999). However, in the long term over 80% of patients with a wrist
fracture have a good functional recovery (Rikli et al 1998, Kaukonen et al 1988).
Hip fractures.
Hip fractures are often considered the most devastating consequence of osteoporosis. The
lifetime risk of hip fracture for women aged over 50 is around 11-17% (Kanis 1994, Van
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Staa 2001). In the US it is estimated that 250,000 hip fractures occur per year making hip
fractures more common than either stroke or breast cancer (Riggs and Melton 1995).
Three-quarters of all hip fractures occur in women and the overall incidence of hip
fracture for women in the UK is 1.7 per 1000 person years (Van Staa 2001). The
incidence of hip fracture is low before age 70 after which it increases rapidly and by age
90 the incidence is around 20 per 1000 person years (Van Staa 2001). The increasing
incidence with age is not only due to declining BMD but also due to an increased risk of
falling. 90% of hip fractures are the direct consequence of a fall and around 50% of
women aged over 85 suffer a fall each year (Cummings and Melton 2002). With
increasing age and frailty there is a decline in neuromuscular function, which leads to an
increased risk of falling. Furthermore, such women are more likely to land on their hip
when they do fall as they are less able to use their hands to protect themselves. Therefore
they suffer a hip fracture rather than fracturing their wrist (Nevitt and Cummings 1993).
Finally, hip fractures are associated with future fracture with an increased relative risk for
both subsequent vertebral (RR 2.5) and hip fracture (RR 2.3) (Klotzbuecher et al 2000).
Hip fractures are associated with significant mortality.
Similar to clinical vertebral fractures, hip fractures have been shown to reduce survival
by about 20% over 5 years (relative survival 0.82) (Cooper et al 1993). However, in
contrast to vertebral fractures where survival diverged from normal in a gradual and
increasing manner, the excess mortality due to hip fracture in this study was greatest in
the first 6 months. A high mortality rate early after hip fracture was also reported by
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Center et al (1999) who demonstrated that 20% of women died within 1 year of hip
fracture but over the subsequent 4 years only a further 12% died. Again, the role the hip
fracture plays directly in the mortality rate is debateable as hip fracture may occur in
older more frail women with more co-morbidity who are thus more likely to die
independent of the fracture. However, the high early mortality rate with hip fracture
suggests that hip fracture may contribute more directly to mortality rate than vertebral
fractures. This is again supported by Cauley et al (2000) who demonstrated a 6 fold
increase in death following a hip fracture which persisted even after adjustment for age
and common co-morbidities.
Social and economic consequences of hip fractures.
Hip fractures often have dire consequence, even for those women who survive. By one
year 40% are unable to walk independently, 60% have difficulty with at least one
essential activity of daily living and 27% enter a nursing home for the first time (Cooper
1997). Overall around half of women who were previously independently living in the
community require admission to residential homes or increased help with activities of
daily living after a hip fracture (Cummings and Melton 2002).
Osteoporosis requires significant medical and social resources. It has been estimated that
in 2000 osteoporosis cost the UK around £1.7 billion and hip fractures account for
approximately 80% of the total costs of osteoporotic fracture (Dolan and Torgerson
1998). Over the period of a year, the estimated cost of a hip fracture requiring residential
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care is around £30,000 pounds (Kanis et al 2002). 1 in 5 orthopaedic beds in UK
hospitals are occupied as the result of hip fracture. After a hip fracture visits to medical
outpatient’s departments are increased 3 fold and on average women make an extra 9
visits to their GP in the year after a hip fracture (Dolan and Torgerson 1998).
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Chapter 1.3:
Basic bone physiology and the pathophysiolgy
of postmenopausal osteoporosis.
Normal bone tissue.
Bone is a complex tissue consisting of inorganic mineral, organic matrix and cells. The
majority (90%) of the organic matrix is type 1 collagen with the remaining 10%
comprising of noncollagenous proteins such as Osteocalcin, Osteopontin, Osteonectin
and bone sialoprotein. Type 1 collagen has a triple helical structure but, unlike type 1
collagen in other connective tissues, in bone the collagen fibres have unique covalent
intra and intermolecular cross-links which render the collagen completely insoluble.
Calcium phosphate hydroxyapatite crystals bind to the type one collagen to provide
strength and rigidity. Through its strength and rigidity, bone serves 3 main functions: it
acts as a lever to facilitate mobility; it provides protection for the internal organs and
bone marrow; and it has an important role in the homeostasis and storage of mineral ions,
particularly calcium, magnesium and phosphate.
There are 3 cell types in bone. Osteoclasts are large multinucleated cells of macrophage
origin derived from the haemopoietic stem cells. Osteoblasts and osteocytes are derived
from mesenchymal cell lineage. Osteoclasts remove bone while osteoblasts synthesize
new bone matrix and their actions are coupled to allow the normal turnover of bone.
Osteocytes were originally osteoblasts, which became embedded within lacunae in the
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bone structure. Osteocytes are in contact with each other and the lining cells on the bone
surface via long cellular processes rich in microfilaments, which form a large network of
thin canaliculi throughout the entire bone matrix. Within the osteocyte lacunae and
canaliculi, in between the osteocytes plasma membrane and the bone, there is the
periosteocytic space which contains extracellular fluid. The periosteocytic space provides
a large surface area for ion exchange and, by sensing shear-generated forces applied
across this space, osteocytes are also thought to play a central role in bone’s ability to
respond to mechanical strain (Noble and Reeve 2000).
Normal bone turnover
Bone turnover occurs throughout life by a process known as remodelling. This process
replaces old bone with new bone in order to allow: the repair of microdamage to the
skeleton; the bone to adapt to the mechanical strains it is subjected to; and the
participation of bone in calcium homeostasis (Parfitt 2002). This occurs throughout the
skeleton at around 106 discrete foci called the basic multicellular unit (BMU). The
remodelling process begins with the activation and contraction of the bone lining cells.
Osteoclasts are then recruited from precursors in the bone marrow and the circulation and
bind to the exposed bone tissue. The osteoclasts secrete hydrogen ions and proteolytic
enzymes in order to excavate a resorption cavity over a period of 2-4 weeks after which
they disappear by apoptosis. The boundary of the resorption cavity is marked by a
sclerotic border called the cement line. Osteoblasts then line the resorption cavity and
secrete osteoid, which subsequently undergoes primary mineralization to form bone
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during a process which lasts 4-6 months. Then over a period of several years secondary
mineralization occurs to increase the degree of mineralization from 60% to 90-95% of
maximum (Davison et al 2006). This process is summarised in figure 1.3.1.
Figure 1.3.1: The basic multicellular unit (Riggs and Parfitt 2005).
It has been estimated that around 30% of BMUs form at sites of microdamage while the
remaining 70% are thought to occur in regions of high strain, in response to other
undetermined signals and/or, to some degree, random chance (Burr 2002). The rate at
which bone remodelling occurs varies with the type of bone and the skeletal site. In
general, cortical sites remodel slowly with around 2% of the bone in the radius and 5% of
the bone in the femoral neck being remodelled annually (Noble and Reeve 2000).
Trabecular bone remodels 10 times faster with around 30% being remodelled annually
although the rate can be as high as 50% at certain sites such as the ilium. The rate of
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trabecular remodelling is thought to be related to the degree of surrounding red or yellow
bone marrow with sites with red bone marrow remodelling quicker due to a more
abundant supply of osteoclasts (Noble and Reeve 2000). The differences in bone turnover
rate between cortical/trabecular bone and at sites of red/yellow bone marrow may explain
the results found in chapter 7 and are discussed again later in this thesis.
Constituents of bone strength and the pathogenesis of osteoporosis.
Bone depends on several intrinsic qualities for its strength. Clearly the amount of bone
mass is an important factor but other factors which contribute to overall bone strength
include: the material properties of the bone; bone geometry and bone architecture. As
stated in the definition, osteoporosis is a disease “characterised by low bone mass and
microarchitectural deterioration” resulting in low bone strength and an increased
propensity to fracture.
Bone mass, bone strength and osteoporosis.
The amount of bone is an important determinant of bone strength: the more bone tissue
the skeleton has, the stronger it is and the greater resistance it has to fracture. In clinical
practice BMD is used as an indirect measure of bone mass and overall, in ex-vivo studies,
BMD accounts for around 60-70% of bone strength (Granhed et al 1989). Bone mass
increases throughout the early years of life until peak adult bone mass (PABM) is
achieved during the 3rd decade of life (Teegarden et al 1995). Bone mass then remains
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stable until around the time of the menopause. At this time there is a period of rapid bone
loss over several years followed by a more gradual, but persistent, loss of bone with
ageing. Postmenopausal osteoporosis can result from either the failure to achieve an
adequate PABM premenopause and/or the excessive loss of bone postmenopause.
The PABM is the starting point from which menopausal bone loss commences and as
such women with low PABM are at risk of developing osteoporosis. It has recently been
proposed the bone mass tracks throughout life such that a woman with above average
bone mass at age 30 will remain above average at age 70 (Cooper et al 2006). PABM
reflects various factors which affect the skeleton from in-utero to young adulthood with
puberty being particularly important as around 25% of bone mass is gained around the
time of peak height velocity (Bachrach 2001). Genetic factors play a key role and the
heritability of BMD at the spine and hip has been estimated to lie between 70 and 85%,
with values of 50–60% for wrist BMD (Ralston 2002). There are many potential genes
being studied which are thought to interact and contribute to PABM including the genes
encoding for the vitamin D receptor, oestrogen receptor, type 1 collagen and insulin like
growth factor 1 (Bachrach 2001). Habitual and environmental factors occurring during
childhood and adolescence also influence the achievement of expected PABM. Such
factors include calcium intake, smoking, alcohol consumption and exercise (Javaid and
Cooper 2002). Amenorrhoea due to anorexia or excessive exercise and a variety of
medications and illnesses can also impair PABM. Even factors effecting the foetus while
in-utero, such as maternal smoking, energy intake, weight and vitamin D status, are
associated with reduced neonatal and childhood BMD which potentially may track
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throughout life leading to a reduced peak adult bone mass and potentially lower bone
mass in old age (Cooper et al 2006).
Oestrogen is important for maintaining a healthy skeleton and at the menopause there is a
marked reduction in oestrogen levels. The loss of oestrogen is thought to up-regulate the
formation of osteoclasts and osteoblasts in the bone marrow leading to a significant
increase in the rate of bone remodelling (Manolagas 2000). Furthermore, the loss of
oestrogen results in prolongation of the life of osteoclasts and shortening of the life of
osteoblasts (Manolagas 2000). As a result of this there is failure of the bone formation
phase to completely replace all the bone removed during the resorption phase (negative
remodelling imbalance) which, coupled with the large increase in the rate of remodelling,
results in the rapid loss of bone mass at both trabecular and cortical sites. An early
menopause is associated with an increased risk of developing osteoporosis as it leads to a
shorter period of stable PABM and an earlier onset of bone loss and therefore greater
bone loss over time. After the initial rapid menopausal bone loss, oestrogen also plays a
key role in the rate of continued bone loss as postmenopausal women with low residual
oestrogen levels (<5pg/ml) suffer a more rapid decline in BMD than women with higher
levels (>10pg/ml) (Stone et al 1998). Furthermore, low residual oestrogen levels
(<5pg/ml) have been demonstrated to be associated with an increased risk of hip and
vertebral fracture which persisted even after adjustment for calcaneal BMD (Cummings
et al 1998).
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Other factors are associated with an increased bone loss. Low weight and weight loss
after the age of 50 have both been associated with lower bone mass and a higher rate of
postmenopausal bone loss (Bauer et al 1993). Weight is thought to effect bone mass in 2
ways. Firstly, after the menopause, adipose-derived oestrogen is the primary determinant
of circulating oestrogen levels. Secondly, body weight is an important determinant of the
degree of mechanical loading the skeleton is exposed to during daily life. Smoking has
consistently been demonstrated to be associated with increased bone loss, possibly
though interfering with intestinal calcium absorption due to suppression of the PTH-
calcitriol endocrine axis (Need et al 2002). Excessive alcohol and reduced physical
activity have also been associated with bone loss although less consistently (Bauer et al
1993, Hannan et al 2000). Deficiency in calcium and vitamin D becomes increasingly
common with increasing age and this leads to secondary hyperparathyroidism which
maintains serum calcium levels at the expense of increased bone resorption, thus further
exacerbating postmenopausal bone loss. In addition to these environmental factors,
genetic factors may also play a role in postmenopausal bone loss although the evidence
for this at present is conflicting (Ralston 2002).
Bone architecture, bone strength and osteoporosis.
In postmenopausal osteoporosis, in addition to the loss of bone mass, there is also
deterioration in the architecture of both the cortical and trabecular bone leading to a
further reduction in bone strength. Cortical bone contributes greatly to bone strength,
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particularly at sites such as the radius and hip. There are 3 main determinants of cortical
strength: cortical diameter, cortical thickness and cortical porosity.
With aging, bone is formed on the periosteal surface, which leads to an increase in
cortical diameter. This should increase bone strength as the bending strength of bone is
proportional to the fourth power of its distance from the neutral axis. However, bone is
simultaneously removed from the endocortical surface and this occurs at a greater rate
than the periosteal bone formation leading to thinning of the cortex with age (Kaptoge et
al 2003). By the ninth decade of life cortical thickness has reduced by 42% (Bousson et al
2001). The overall effect on bone strength depends on the relationship between the
increasing cortical diameter and reducing cortical thickness. This can be expressed as the
buckling ratio (radius/cortical thickness) and, when the ratio exceeds 10, bone strength is
lost due to increased propensity to buckling. In women over 65 the mean cortical
buckling ratio at the hip is around 12 and this increases further with age (Kaptoge et al
2003). Therefore, the overall effects of the cortical changes with age result in a reduction
cortical strength.
Cortical porosity also contributes to bone strength. After the menopause there is a great
increase in bone remodelling which, in the cortex, occurs as deep cutting cones, which
remove old bone. Increased porosity of the cortex results in large reduction in bone
strength and higher cortical porosity has been reported in patients who suffer fractures of
the femoral neck (Jordan et al 2000). The overall degree of cortical porosity depends on
both the number of pores and their size. With age in women it has been demonstrated that
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pore size and number both increase up to aged 60 (Bousson et al 2001). After age 60 the
pore size continues to increase although pore number reduces. This is due to pores
coalescing and overall cortical porosity continues to increase with age resulting in further
reductions in cortical strength.
Trabecular bone is also an important determinant of bone strength, particularly at
predominantly trabecular skeletal sites such as the vertebrae. The trabecular bone forms a
honeycomb within the cortical shell. The strength of trabecular bone is related to the
number of trabeculae and their thickness with the strength of any given trabecula being
proportional to the square of its radius. The orientation of the trabeculae is also important
as trabeculae best resist strain inline with their orientation. Finally, there is a high degree
of connectivity between the trabeculae which further contributes to trabecular strength.
Consider the spine where the forces generated by supporting the upper body are
predominantly in the vertical plain. Numerous, thick vertical trabeculae are required to
support this loading however the horizontal trabeculae connect and support the vertical
trabeculae thus increasing their strength further. The strength of a given section of
vertical trabecula is inversely proportional to the square of the distance between
horizontal supporting trabeculae.
After the menopause, bone loss is greater for trabecular bone than cortical bone, most
likely due to the higher rates of bone turnover in trabecular bone. There is a reduction in
trabecular bone volume due to both a reduction in trabecular thickness and number
leading to reduced bone strength (van der Linden et al 2001). However, in
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postmenopausal osteoporosis there seems to be a preferential loss of horizontal trabeculae
leading to a reduction in interconnectivity (Thompson et al 2002). Finite element analysis
modelling predicts that this results in a greater loss of bone strength than losing an equal
amount of bone tissue from all trabeculae. Silver and Gibson (1997) demonstrated that
bone strength was reduced by 70% when horizontal trabeculae were removed to give a
10% reduction in bone volume compared to a 20% reduction in bone strength when an
equivalent bone volume was removed in a more uniform manner.
The increase in bone resorption after the menopause not only leads to a structural
deterioration of the trabecular bone but also directly reduces trabecular strength as the
resorption cavities act as “stress risers”. A stress riser is an area of an object at which
stress tends to be concentrated due to a particular shape or consistency of the material.
The stress transmitted thorough a trabecula is increased in the bone adjacent to a
resorption cavity creating a weak area in the trabecula (van der Linden et al 2001).
Although the amount of bone removed by a resorption cavity is small, its effect on bone
strength is amplified by the stress riser effect. Using finite element modelling van der
Linden et al (2001) demonstrated that removing 20% of the bone volume in the form of
resorption cavities reduced trabecular strength by 50%. Removing the same amount of
bone by uniform trabecular thinning resulted in only a 30% reduction in strength.
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Other factors affecting bone strength.
It is worth discussing the material properties of bone as these also contribute to bone
strength although the role they play in the pathogenesis of osteoporosis is less certain.
Bone is highly mineralised, with the mean degree of mineralization of bone (MDMB)
predominantly reflecting the duration of secondary mineralization and thus being
inversely related to the rate of bone turnover (Boivin and Meunier 2002). In osteomalacia
MDMB is very low and the bone is weak. Conversely over-suppressed or adynamic bone
turnover leads to very high degrees of mineralization, which may make the bone brittle
and weak (Turner 2002). In most postmenopausal women mineralization is in-between
these extremes and the optimum level of mineralization is not known. It has been
observed that bone from osteoporotic women has a lower MDMB than controls
(Roschger et al 2001). This is likely to reflect increased bone turnover and it is uncertain
whether this lower MDMB itself reduces bone strength.
Finally, in addition to the mineral content of bone, the organic component (i.e. type 1
collagen) also has a role in determining bone strength. This is best demonstrated in
osteogenesis imperfecta where a single point mutation in the collagen molecule leads to a
marked reduction in bone strength. Collagen increases the amount of energy a bone can
absorb before it fractures and may have a role in preventing the propagation of micro-
cracks. The strength of type 1 collagen comes from its covalent cross-links. It has been
demonstrated that patients with osteoporosis have a reduction in the number of collagen
cross-links compared to age matched controls (Oxlund et al 1996). This suggests the
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Until recently, antiresorptive therapies were the only treatment available for osteoporosis
and, in the form of bisphosphonates, they remain the mainstay of treatment. There are
several different classes of antiresorptive therapy including HRT, bisphosphonates,
SERMs and calcitonin. These have different mechanisms of action however overall
antiresorptives have 2 main effects on bone tissue. Firstly they reduce the rate of bone
turnover, as measured by the activation frequency. Secondly they improve the balance
between bone resorption and formation at the level of the BMU as measured by the
erosion depth of the resorption cavity and the wall thickness of the osteoid respectively
(Chavassieux et al 1997).
Mechanism of fracture reduction.
Antiresorptives are effective in increasing bone strength and reducing the incidence of
fractures. They achieve this without causing large increases in the absolute amount of
actual bone tissue through several effects, which reverse or prevent the pathogenic
changes of osteoporosis mentioned in chapter 1.3.
Firstly, antiresorptives reduce or prevent the age related loss of bone mass and the
deterioration in microarchitecture which characterises postmenopausal osteoporosis. It
has been demonstrated that placebo treated women suffer reductions in trabecular
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volume, number and connectivity which does not occur in bisphosphonate treated women
(Borah et al 2006, Dufresne et al 2003). Therefore, antiresorptive treated women have a
smaller decline in bone strength with age. Untreated women suffer ongoing reductions in
bone strength which will in part contribute to the higher incidence of fracture observed in
the placebo arm of the various fracture intervention trials using antiresorptives.
By reducing bone turnover, antiresorptives reduce the number and depth of erosion
cavities (Eriksen et al 2005). The amount of bone gained by this contraction of the
remodelling space is relatively small however it results in a significant increase in bone
strength as these erosion cavities act as “stress risers” (van der Linden et al 2001). Stress
risers result in a marked reduction in bone strength, which is reversed with antiresorptive
therapy (Riggs and Parfitt 2005).
By reducing the frequency with which bone undergoes replacement, antiresorptives
permit longer periods of secondary mineralization. After primary mineralization of the
osteoid, secondary mineralization increases the MDMB from 50-60% to 90-95% of the
maximum mineralization (Davidson et al 2006). Treatment with antiresorptives has been
demonstrated to increase the MDMB (Boivin et al 2000, Roschger et al 2001). Increased
mineralization increases the structural rigidity of bone, which will lead to an increase in
bone strength as long as the bone is not over mineralised (Turner 2002). This increase in
mineralization is thought to account for most of the increase in BMD seen with
antiresorptives and may contribute towards their anti-fracture efficacy (Bovin et al 2000).
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Finally, aging is associated with an increase in the porosity of the cortical bone and a
reduction in cortical thickness both of which are associated with a reduction in bone
strength. Antiresorptives have been demonstrated to reduce cortical porosity, which will
also contribute to their anti-fracture efficacy (Roschger et al 2001). Furthermore,
antiresorptives have been demonstrated to prevent age related cortical thinning





In the 1980-90s hormone replacement therapy (HRT) with oestrogen was the mainstay
for the prevention and treatment of postmenopausal osteoporosis. HRT is the original
antiresorptive as it reduces the excessive bone turnover and remodelling imbalance which
occurs as a result of postmenopausal oestrogen deficiency. This is demonstrated with
markers of bone resorption which are increased in peri and postmenopausal women but
reduced to the level of pre-menopausal women by HRT (Lewis et al 2000). Oestrogen
receptors are also found in a variety of other organs including breast, uterus, vascular
endothelium and brain. It was originally hoped that HRT would have overall health
benefits for postmenopausal women with a reduction in menopausal symptoms,
hyperlipidemia, cardiovascular disease and dementia. The benefits on cardiovascular
disease were particularly encouraging as it is the leading cause of death in
postmenopausal women and numerous observational studies had suggested that HRT
caused a 40% reduction in the risk of developing coronary heart disease (Grady et al
1992).
The publication of a large randomised controlled trial, the Women Health Initiative
(WHI) study, in 2002 however failed to confirm these health benefits (Rossouw et al
2002). Not only did the WHI study confirm the known risk of breast cancer, it
demonstrated a 29% increase in cardiovascular disease along with increases in stroke and
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venous thrombosis. It is therefore somewhat ironic that the WHI study also provided the
best evidence to date that HRT has beneficial effects in preventing bone loss and
fractures.
The WHI study was considered by many to be the final word on HRT as it was a very
large rigorously conducted randomised controlled trial with important clinical endpoints,
which therefore provided a “gold standard” evidence base on which to assess the effects
of HRT. However, there are limitations to the WHI study. Randomised controlled trials
only provide data on the population and intervention studied. Therefore the WHI study
only applies to women in their mid 60s, more than 10 years after the menopause, who
take oral conjugated equine oestrogen (CEE) at a dose of 0.625mg per day. The results
cannot be extrapolated to women in their late 40s and early 50s, which is the group of
women most likely to need HRT for menopausal symptoms. This is especially important
with regards to the cardiovascular risks where the age commencing HRT may be an
important determinant of the effects of HRT on cardiovascular events. Furthermore, it is
emerging that HRT at doses lower than those used in the WHI study have positive effects
on bone resorption and the adverse outcomes of the WHI study cannot be extrapolated to
these low dose regimes. Both of these points are discussed in more detail below. Finally,
the WHI studies only followed women for a mean of 5-7 years. As such the benefits in
terms of cardiovascular risk, which could be expected to increase with time (Harman
2006), may be underestimated by the WHI study. This may explain the increase in
cardiovascular events which contradicts the findings reported in the observational studies
which had longer follow up periods (Grady et al 1992).
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The WHI study altered the public opinion of HRT and it has been demonstrated that since
the WHI study HRT use has declined (Main and Robinson 2008). This may in part be due
to the risks of HRT often being expressed as increases in relative risk e.g. “29% increase
in cardiovascular events”. While this would understandably be concerning to a woman
contemplating HRT it is important to put this in the context of the magnitude of absolute
risk which is actually very small, an extra 7 cardiovascular events per 10000 person-
years. Furthermore, the negative risks are often considered in isolation, which distorts the
perception of HRT. For example the 26% increased risk of breast cancer, still only an
extra 8 cases per 10000 person-years, is often quoted without mentioning that overall
cancer rates were not increased due to a reduction in the incidence of colorectal cancer (6
less per 10,000 person-years).
Overall it appears that HRT is judged harshly by ignoring the low absolute risks,
concentrating on the negatives effects of treatment and by the over extrapolation of the
WHI study to different groups of women and HRT preparations. However, despite this it
is still felt that the health risks outweigh the benefits. In the UK the Medicines and
Healthcare products Regulatory Agency (MHRA) has issued guidance recommending
that HRT is only used at the minimum effective dose for the shortest duration of time for
the relief of menopausal symptoms and that HRT is not a first line treatment option for
osteoporosis. Although the WHI study and MHRA recommendation suggest that HRT is
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no longer an appropriate treatment for osteoporosis this may not be the case as there are
still many issues with HRT which are unresolved.
HRT, fractures and bone.
Even prior to the WHI study many studies suggested that HRT reduced the risk of hip
fractures by about 25% (Grady et al 1992). The WHI study confirmed that all types of
fracture were significantly reduced by both oestrogen only HRT (Jackson et al 2006) and
combined oestrogen and progestogen HRT (Cauley et al 2003). Unlike all other studies of
osteoporosis therapy, the WHI study successfully demonstrated fracture reduction in a
population which had not been selected on the basis of BMD. BMD also increased
progressively with both oestrogen only and combined HRT. The BMD and fracture
outcomes of the WHI study are summarised in table 2.1.1.1.
Table 2.1.1.1: The effects of HRT on BMD and fractures.
Oestrogen Combined
only HRT HRT
Baseline age (yrs) 63.6 63.2
Baseline t-score: spine -1.19 -1.30
BMD increase year 3: spine 6.0% 6.10%
BMD increase year 6: spine 7.1% 7.50%
Hip fracture:
Relative risk reduction




























Since the WHI study, HRT is only recommended for short term use around the time of
the menopause. With short term HRT BMD will increase during treatment however upon
discontinuation of the HRT bone loss will occur. Various rates of bone loss after stopping
HRT have been reported but there appears to be a period of rapid bone loss, similar to
early postmenopausal bone loss, followed by persistent but slower normal age related
bone loss (Greenspan et al 2002, Greendale et al 2002, Sornay-Rendu et al 2003). It is
currently uncertain whether this period of rapid bone loss eliminates all the bone mass
gained during the treatment period.
Research topic: Will the short-term use of HRT, as recommended by the MHRA, result in
long term benefits in terms of BMD? This is studied in chapter 5 of this thesis.
One of the limitations of the WHI study is that it studied only one dose of HRT, 0.625mg
CEE with or without progestogens. In more recent years there has been much interest in
the use of low dose HRT, 0.3mg CEE or equivalent, which it is hoped may provide a
treatment for menopausal symptoms and bone loss without the risks associated with
conventional dose HRT. Low dose HRT has been reported to reduce menopausal
symptoms by 65% (Ettinger 2007).
There have been many studies looking at the BMD effects of low dose oestrogen, mainly
using either 0.3mg CEE or 1 mg of oestradiol (E2), with varying progestogen regimes for
women with a uterus. Most of these studies are of relatively short duration, ranging from
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2-4 years, and direct comparison is somewhat difficult due to differences in treatment
regime, sample size and patient age. However, increases in BMD of 1.3-5% at the spine
and up to 3% at the hip over 2-3 years have been reported (van der Weijer et al 2007).
The BMD response to low dose HRT is less than the BMD response achieved in the WHI
study and evidence from bone markers suggest that the antiresorptive effects of HRT is
dose dependant (Ettinger 2007). As such the benefits of low dose HRT in terms of
fracture prevention is uncertain and cannot be extrapolated from the WHI study.
However, neither can the risk of vascular disease and breast cancer observed in the WHI
study be applied to low dose HRT regimes. Furthermore, very low dose oestrogen may be
given to women with a uterus without progestogens potentially providing protective
effects on the bone without the risks associated with progestogens. The potential for low
dose HRT to provide long term prevention of postmenopausal bone loss requires further
research.
HRT and breast cancer.
Breast cancer is probably the most feared complication of HRT even though the average
50 year old woman is ten times more likely to die from coronary heart disease. A 50 year
old woman has a 10% lifetime risk of developing breast cancer and a 3% risk of dying
from breast cancer compared to a 30% risk of dying from coronary heart disease (Grady
et al 1992, Collins et al 2007). The type of HRT is important with regards to breast
cancer. Progestogens are given with oestrogen to women with a uterus. Progestogens
reduce the mitotic rate of the endometrial cells, which prevents an increase in the risk of
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endometrial cancer due to unopposed oestrogen therapy. However, progestogens increase
the mitotic activity of breast tissue, possibly leading to the increased risk of breast cancer.
Consistent with this, the PEPI study demonstrated that breast tissue density on
mammography was increased in women taking combined HRT compared to oestrogen
only HRT (Greendale et al 1999).
Early observational studies revealed mixed results for both oestrogen only HRT and
combined HRT (Grady et al 1992). An early randomised controlled trial, designed to
assess the effects of HRT on secondary cardiovascular disease prevention (HERS study),
demonstrated a non-significant 30% increase in breast cancer incidence in women treated
with combined HRT (Hulley et al 1998). It is likely that this study was too small
(n=2763) and of insufficient duration (mean 4.1 years) to detect a significant increase in
breast cancer. The increased risk of breast cancer associated with combined HRT was
confirmed by both a very large observational study, the Million Women study (MWS),
and the WHI study. The MWS demonstrated that current users of combined HRT had a 2
fold increased risk of developing breast cancer, that the risk increased with duration of
HRT use and that the risk had reduced to baseline within 5 years of discontinuation
(Beral et al 2003). The WHI study demonstrated a 26% increase in breast cancer
incidence, an extra 8 cases per 10000 person-years, in those women taking combined
HRT that separated from the placebo group after 4 years (Rossouw et al 2002).
Oestrogen only HRT appears to have less of an association with breast cancer, if at all.
The MWS study demonstrated a significantly increased risk of breast cancer with
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oestrogen only HRT although the relative risk was smaller than with combined HRT (RR
1.3 versus 2.0 respectively). The WHI study however did not support the findings of the
MWS as there was a trend towards a lower incidence of breast cancer in women taking
oestrogen only HRT compared to placebo (23% reduction, p=0.06) (Anderson et al
2004).
HRT and coronary heart disease (CHD).
For women at age 50, the lifetime risk of dying from coronary heart disease is 30%
(Grady et al 1992, Collins et al 2007). Around the time of the menopause there are
unfavourable metabolic changes in lipid and carbohydrate metabolism and the incidence
of coronary events increases markedly (Collins et al 2007). Numerous studies have
demonstrated that oestrogen has favourable effects on factors associated with
cardiovascular disease including increased HDL cholesterol, reduced LDL cholesterol,
vasodilatation of the coronary arteries, inhibition of platelet aggregation, reduced fasting
insulin levels and reductions in key inflammatory factors (Collins et al 2007, Harman
2006). These effects provide a mechanism by which oestrogen may reduce the
progression of atherosclerosis and this has been demonstrated by a study assessing
carotid artery wall thickness (Hodis et al 2001). Progestogens may negate some of these
positive benefits by reducing vasodilatation and increasing insulin resistance which may
lead to atherosclerotic plaque progression (Collins et al 2007, Harman 2006).
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The majority of the early observational HRT studies suggested that HRT use was
associated with an improvement in risk factors for coronary heart disease and a 40%
reduction in coronary events (Grady et al 1992). There was concern that these
observational studies were subject to “Healthy user” bias by which women who used
HRT were more likely to lead healthier life styles and that this may account for the
reduction in coronary events. The HERS study was the first large randomised controlled
trial to look at the cardiovascular effects of combined HRT on women with existing
coronary heart disease (Hulley et al 1998). Overall there was no difference between HRT
and placebo in terms of coronary events. However, compared to placebo, women
randomised to HRT experienced more coronary events in the first year and fewer in years
4 and 5. The WHI study demonstrated a significant 29% increase in coronary events, an
extra 7 per 10000 person-years, in women receiving combined HRT and no significantly
increased risk in women on oestrogen only HRT (Anderson et al 2004, Rossouw et al
2002).
In the WHI study the risk of coronary heart disease increased soon after initiation of
HRT. However, HRT is usually prescribed during the early menopausal period for the
relief of climacteric symptoms. At this time most women have a low absolute risk for
cardiovascular disease and as such any increase in relative risk would lead to only a small
increase in absolute risk. Furthermore, the “timing hypothesis” suggests that HRT started
at the time of, or soon after, the menopause may lead to a reduction in cardiovascular
events due to the inhibition of atherosclerotic plaque formation and progression (Harman
2006). When HRT is started late after the menopause (mean age in the WHI study was
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63) women may already have mature atherosclerotic plaques which become at increased
risk of causing cardiovascular events due to the increased thrombotic tendency associated
with HRT. Evidence supporting the timing hypothesis includes a recent study which
reported that coronary artery calcification (a marker of atherosclerotic plaque burden)
was reduced in women aged 50-59 who took oestrogen only HRT during the WHI study
(Manson et al 2007). Further evidence comes from a reanalysis of the WHI study which
demonstrated that women who started HRT within 10 years of the menopause had a
lower risk of coronary heart disease than women who started HRT more than 20 years
after the menopause (Rossouw 2007). This appears to be the case for both oestrogen only
HRT (HR 0.48 and 1.12 respectively, significance of trend: p=0.15) and combined HRT
(HR 0.88 and 1.66 respectively, significance of trend: p=0.05).
The timing hypothesis could explain why the observational HRT studies, where HRT was
started for menopausal symptoms, demonstrated a reduction in cardiovascular events.
Similarly, it could explain the HERS study findings of increased early coronary events
and reduced late coronary events. As such HRT started around the time of the menopause
may be safe, or even protective, in terms of cardiovascular disease and allow the
treatment of menopausal symptoms and the prevention of postmenopausal bone loss.
Other associations with HRT.
The WHI study demonstrated an increased risk of stroke in women taking either
combined HRT (41% increase) or oestrogen only HRT (39% increase). Again the
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absolute risk of stroke in women during the early menopausal period is usually low and
as such any increase in relative risk would lead to only a small increase in absolute risk.
The incidence of colorectal cancer was reduced by combined HRT (37% reduction) and
unchanged by oestrogen only HRT. Combined HRT doubled the risk of both deep vein
thrombosis (DVT) and pulmonary embolism (PE). Oestrogen only HRT increased the
risk of DVT by 47% although there was no significant increase in PE.
HRT implications for osteoporosis prevention and treatment.
The WHI study demonstrates that HRT is not the best treatment option for elderly women
with osteoporosis due to the cardiovascular risks and the availability of other effective
treatments for osteoporosis. However, other treatments for osteoporosis are poorly
studied in younger women. For women with menopausal symptoms, an early menopause
or osteoporosis in the early menopausal period HRT may prove to be safe and effective in
the prevention and treatment of osteoporosis. The type of HRT requires consideration as
there are less risks associated with oestrogen only HRT. Furthermore, consideration
needs to be given to the dose of HRT and the route of administration. Low dose HRT
appears to be beneficial in terms of menopausal symptoms and bone protection and may
not have the risks associated with conventional dose HRT. Transdermal oestrogen does
not appear to have the same thrombotic effects as oral oestrogen (Scarabin et al 2003)
and progestogens can be given topically via inter-uterine systems such as the Mirena coil.
Clearly HRT is not suitable for all women as some women may already have significant
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risk factors for, or a history of, breast cancer or cardiovascular disease. However, for low




Bisphosphonates are currently considered by many to be first line agents for the treatment
of osteoporosis. By inhibiting the function of osteoclasts they are potent suppressors of
bone turnover. They have been used in various forms since the 1970s for the treatment of
many bone diseases including Paget’s disease, myeloma, bone metastases and
osteoporosis. The first bisphosphonate used for osteoporosis was etidronate (Didronel).
Etidronate is now infrequently used for osteoporosis due to concerns that continuous
etidronate therapy may induce osteomalacia and lack of evidence for non-vertebral
fracture reduction (Cranney et al 2001). More potent nitrogen containing bisphosphonates
are now used for osteoporosis and are the focus of this chapter.
Structure and function.
Bisphosphonates are metabolically stable analogs of pyrophosphate. They consist of a
carbon atom bound to 2 phosphate groups known as the P-C-P backbone. The phosphate
groups act as a “bone hook” by binding strongly to hydroxyapatite, which accounts for
the high affinity of bisphosphonates for bone. The molecule also has 2 side chains – R1
and R2. The R1 side chain is a hydroxyl group in all bisphosphonates and this further
enhances binding to hydroxyapatite (tridentate binding). The R2 group is specific to each
bisphosphonate although all modern bisphosphonates contain a nitrogen based group at
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this side chain. The molecular structure of modern bisphosphonates is demonstrated in
figure 2.1.2.1.
Figure 2.1.2.1: Molecular structure of bisphosphonates
The bioavailability of oral bisphosphonates is poor. Only around 1-2% of an oral dose of
bisphosphonate is absorbed in the gut. Approximately 50% of the absorbed
bisphosphonate is retained in the bone with the remainder being rapidly cleared from the
plasma by the kidneys within 10 hours of administration (Miller 2005). The
bisphosphonates bind predominantly to the exposed hydroxyapatite at areas of active
bone resorption (Sato et al 1991). During bone resorption, the bisphosphonate is released
from the hydroxyapatite and taken up into the osteoclast. Within the osteoclast
bisphosphonates inhibit farnesyl pyrophosphate synthase (FPS) and, to a lesser extent,
geranylgeranyl diphosphate synthase (GGPPS) which are key enzymes in the mevalonic
acid pathway for cholesterol metabolism (Russell 2007). This inhibits the prenylation of
GTPases which are vital for the regulation of osteoclast morphology, cytoskeletal
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arrangement, membrane ruffling, migration and ultimately cell survival. The mechanism
of action of bisphosphonates is demonstrated in figure 2.1.2.2.
Figure 2.1.2.2: Enzyme inhibition by bisphosphonates.
The different structures of the R2 side chain accounts for the differences between
bisphosphonates in terms of bone binding affinity and potency. Individual
bisphosphonates have different in-vitro binding affinities for hydroxyapatite as
demonstrated in figure 2.1.2.3a. Bisphosphonates with higher binding affinities are
retained longer in the bone, are less likely to be released from the hydroxyapatite by the
osteoclasts and have higher rates of reattachment to the bone after release from
osteoclasts (Russell 2007). The binding affinity is therefore likely to account for the
differences in persistence of action of bisphosphonates after discontinuation, which is
discussed later in this chapter. Furthermore, binding affinity may effect how well
bisphosphonates diffuse through the bone and thus their distribution. The potency of
inhibition of FPS in-vitro also differs between bisphosphonates as demonstrated in figure
GGPP synthase
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2.1.2.3b. The in-vivo effects of bisphosphonates on bone resorption is a complex
interaction between their binding affinity and potency of FPS suppression which is not
fully understood (Russell 2007).
Figure 2.1.2.3: Differences in bisphosphonate binding affinity for hydroxyapatite (a) and
potency if inhibition of FPS (b).
The effect of bisphosphonates on BMD and fractures.
There are 4 nitrogen containing bisphosphonates currently licensed for the treatment of
postmenopausal osteoporosis: alendronate, risedronate, ibandronate and zoledronate.
These drugs have been well studied by good quality randomised controlled trials and are
proven to effectively suppress bone turnover, increase BMD and, most importantly,
prevent fractures. The main clinical outcomes from the fracture prevention trials for these
bisphosphonates are illustrated in table 2.1.2.1.














With the exception of intravenous (iv) zoledronate, all the fracture prevention trials were
performed using daily oral therapy. Bisphosphonate have strict administration
requirements due to their poor absorption, which makes daily therapy inconvenient.
However, the prolonged bone retention of bisphosphonates after an oral dose allows
intermittent therapy. Studies have demonstrated that weekly alendronate (Rizzoli et al
2002), weekly risedronate (Harris et al 2004) and monthly ibandronate (Reginster et al
2006) provide a BMD and bone turnover marker (BTM) response equivalent to that
achieved with daily therapy. As such bisphosphonates are now mostly prescribed as
weekly/monthly therapy. It has been demonstrated that women prefer intermittent therapy
and that this improves persistence with bisphosphonates (Bartl et al 2006).
Differences in the antiresorptive effects of bisphosphonates.
It is becoming apparent that bisphosphonates may have individual characteristics in terms
of antiresorptive properties, onset of fracture reduction and persistence of effect after
discontinuation. The antiresorptive properties of bisphosphonates can be compared
directly in head to head studies using BMD and BTMs. The FACT trial compared weekly
alendronate to weekly risedronate and demonstrated that alendronate is a more potent
antiresorptive. Compared to risedronate, 2 years of alendronate therapy resulted in a
significantly greater suppression of BTMs (CTX -73% vs. -53%, BSAP -40 vs.-29%,
P1NP -62% vs. -46%) and a significantly greater increase in BMD at the spine (5.2 vs.
3.4%) and hip (2.8 vs. 1.0%) (Bonnick et al 2006). A recent, non-inferiority study
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(MOTION) demonstrated that monthly ibandronate therapy was comparable to weekly
alendronate in terms of BMD gain at the spine (5.1% and. 5.8% respectively) and hip
(2.9% and 3.0% respectively) after 1 year of treatment (Miller et al 2007). In a separate
study, 150mg of ibandronate per month reduced serum CTX by 68% which is similar to
the decreases observed with alendronate although this was not a head to head study
(Reginster et al 2006).
Differences in onset of fracture reduction.
Comparison between bisphosphonates in terms of fracture reduction is difficult as the
populations studied in the major fracture prevention trials were too different to allow
direct comparison. A head to head randomised controlled trial to assess for differences in
fracture reduction would require far too large a population to be feasible however this has
recently been investigated by a large observational study. The REAL study is an
observational cohort study using computerised records of health service utilization in the
US. It compared the incidence of clinical fractures during the first year of therapy with
either weekly risedronate (n = 12,215) or alendronate (n = 21,615) (Silverman et al
2007). In this study, compared to women prescribed alendronate, there were significantly
fewer non-vertebral and hip fractures at both 6 and 12 months in women who took
risedronate. This suggests that in the first 12 months of therapy risedronate is more
effective which may be due to a quicker onset of fracture reduction. This is important as
20% of women who suffer a vertebral fracture will fracture again within 1 year (Lindsay
et al 2001). Other studies investigating the speed of onset of fracture reduction
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demonstrate that with risedronate reductions in both clinical vertebral and non-vertebral
fractures are observed 6 months after treatment initiation (Roux et al 2004, Harrington et
al 2004). In contrast, after the initiation of alendronate, vertebral fractures are reduced by
12 months, hip fractures by 18 months and non-vertebral fractures by 24 months (Black
et al 2000). These studies are post-hoc analyses of the FIT and VERT trials, which had
different selection criteria and had very different sample sizes. This makes it difficult to
be certain that the differences observed are genuine however it would explain the greater
reduction in fractures achieved with risedronate during the first year of therapy in the
REAL study.
Differences in offset of the clinical efficacy of bisphosphonates after discontinuation.
After the discontinuation of therapy bisphosphonates remain in the bone for a prolonged
period of time, the duration of which is thought to be related to the affinity of the
bisphosphonate for hydroxyapatite. High affinity bisphosphonates, such as alendronate,
bind more avidly to the bone, have lower rates of uptake by osteoclasts and have higher
reattachment rates after release from the osteoclast (Russell 2007). After discontinuation,
the amount of bisphosphonate in the bone reduces slowly at a rate governed by its
affinity. However the duration of suppression of bone resorption may also depend to
some extent on the potency of the bisphosphonate. The greater the potency of the
bisphosphonate for inhibiting FPS, the longer it will be able to continue to inhibit bone
resorption as the residual amount of bisphosphonate declines.
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Zoledronate, which has both the highest affinity and potency, is able to suppress bone
turnover for 12 months after a single iv infusion (Black et al 2007). Risedronate is also
highly potent but has a lower affinity for hydroxyapatite and as such after discontinuation
bone resorption rapidly returns to normal. This has been demonstrated in an extension to
the VERT-NA trial in which 12 months after the discontinuation of risedronate BSAP
and NTX were no longer different from those women who had not taken risedronate at
all. (Watts et al 2004). Alendronate has a high affinity and 2 studies have demonstrated
that even 5 years after discontinuation there is still suppression of bone turnover, as
assessed by BTMs, and an overall gain in BMD (Bone et al 2004, Black et al 2006). The
prolonged suppression of bone turnover after the discontinuation of bisphosphonates,
especially alendronate, may have consequences if a woman is switched to a different
class of osteoporosis therapy. This is discussed further in chapters 2.2 and 2.3 and is
investigated in chapters 6 and 7.
The effect of this prolonged suppression of bone turnover on fractures however is more
mixed. The FLEX trial demonstrated that, compared to women who continued therapy, 5
years after the discontinuation of alendronate there was a significant increase in clinical
vertebral fractures and a non-significant trend towards an increase in all vertebral
fractures (Black et al 2006). However, there was no increase in the risk of non-vertebral
fractures. It is important to note that women with very low BMD (T<-3.5) and those who
lost BMD during the first 5 years of treatment were not entered into the FLEX trial.
However, the FLEX trial is the best evidence we have regarding the offset of clinical
efficacy of alendronate. It suggests that in clinical practice it is safe to allow low risk
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osteoporotic women to have a treatment holiday from alendronate for up to 5 years. For
women at high risk of fracture it may be more appropriate to either continue life long




Although bisphosphonates are the most frequently prescribed antiresorptive, there are 2
other classes of these drugs: selective oestrogen receptor modulators (SERMs) and
calcitonin. While these treatments are not the focus of any of the studies included in this
thesis they are mentioned in some of the discussions. Therefore, they are briefly reviewed
in this chapter to provide basic background information.
Selective oestrogen receptor modulators (SERM).
To date the only SERM in clinical practice is raloxifene. Raloxifene is a non-steroid
compound which binds to the oestrogen receptor. It has oestrogen agonist effects in some
tissues while having oestrogen antagonist effects in others. In the bone raloxifene is an
oestrogen receptor agonist and thus reduces bone resorption. Compared to
bisphosphonates, raloxifene is a less potent antiresorptive, which is reflected in the BTM
and BMD response. The MORE trial demonstrates that the licensed dose of 60mg/day
reduces osteocalcin (formation marker) by 18% and serum CTX (resorption marker) by
26% compared to placebo (Ettinger et al 1999). BMD increased significantly more than
placebo at the spine (2.6%) and femoral neck (2.1%) over 3 years although the BMD
response is less than that achieved with bisphosphonates. Raloxifene reduced vertebral
fractures by 30% but did not significantly reduce the incidence of non-vertebral fractures.
Unlike bisphosphonates, raloxifene does not bind to the bone so it has a rapid offset of
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action with reductions in BMD being observed within 1 year of discontinuation (Neele et
al 2002).
As raloxifene stimulates the oestrogen receptor it is important to consider some of the
health issues around HRT. Raloxifene has anti-oestrogen effects on breast tissue and
blocks oestrogen induced DNA transcription. Two large randomised controlled trials
have demonstrated that long term raloxifene reduces the risk of invasive oestrogen
receptor positive breast cancer by 55-76% with no significant effect on oestrogen
receptor negative breast cancer (Barrett-connor et al 2006, Martino et al 2004).
Raloxifene has no effect on the incidence of gynaecological cancers although uterine
polyps are more frequent (Martino et al 2005). Raloxifene does not cause an increased
risk of coronary events, even in women at high risk of CHD (Barrett-connor et al 2006).
In osteoporotic women in general raloxifene does not increase the risk of stroke (Martino
et al 2005) however a 49% increase in risk of fatal stroke has been reported in women
with an increased risk of CHD (Barrett-connor et al 2006). Raloxifene causes a 40-70%
increase in the risk of DVT and PE (Martino et al 2005, Barrett-connor et al 2006). Other
adverse effects of raloxifene include hot flushes, oedema and leg cramps.
Calcitonin.
Physiological calcitonin is released from the C-cells in the thyroid gland. Calcitonin
reduces bone resorption by decreasing osteoclast formation and attachment. For
osteoporosis salmon calcitonin is usually used via either a subcutaneous injection or a
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nasal spray. It is a weak antiresorptive. The PROOF study demonstrated that the licensed
dose of 200 iu/day of nasal calcitonin resulted in only a 1.0% increase in BMD and a
12% reduction in serum CTX compared to placebo (Chestnut et al 2000). The PROOF
study demonstrated a 33% reduction in vertebral fractures with 200 iu/day but no
significant non-vertebral fracture reduction. Calcitonin is a well tolerated drug with the
only common side effect being an increased incidence of nasal symptoms. One advantage
of calcitonin is that it appears to have analgesic benefits. It has been demonstrated in
randomised controlled trials that calcitonin significantly reduces pain and the number of
days of bed rest required after an acute vertebral fracture compared to placebo (Lyritis
and Trovas 2002). However, the only rescue analgesia permitted in the trial was
paracetamol. Whether such a benefit would have been observed if stronger conventional




Anabolic therapies are an exciting and important development in the treatment of
osteoporosis. Unlike antiresorptives, which preserve and strengthen existing bone,
anabolic therapy leads to new bone formation. This leads to an increase in bone mass and
improvements in bone microarchitecture thus reversing the pathological changes
characteristic of osteoporosis. Historically, the first anabolic drug used for the treatment
of osteoporosis was fluoride. Fluoride is incorporated into the hydroxyapetite crystal
leading to an increase in osteoblast cell attachment, proliferation and differentiation (Qu
and Wei 2006), which stimulates bone formation leading to increases in trabecular bone
volume and connectivity (Eriksen et al 1981, Vesterby et al 1991). However, it was also
observed that fluoride lead to incomplete mineralisation of the osteoid with woven bone
formation (Eriksen et al 1981) and biomechanical testing of bone biopsies demonstrated a
reduction in bone strength (Sogaard et al 1994). Finally, in 2000 a large meta-analysis
demonstrated that treatment with fluoride did not reduce vertebral fractures and non-
vertebral fracture incidence actually increased after 4 years of therapy (Haguenauer et al
2000).
With fluoride no longer considered as an effective treatment for osteoporosis the only
licensed anabolic therapy to date is recombinant human parathyroid hormone (PTH).
Endogenous PTH is an 84 amino acid protein. The N-terminal is responsible for the
actions of PTH and only the first 34 amino acids are required for receptor activation and
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biological effect. Studies investigating the anabolic actions of PTH date back almost 30
years (Reeve et al 1980) and there are currently 2 forms of PTH licensed for
osteoporosis: teriparatide, comprising of the first 34 amino acids of PTH (PTH 1-34); and
full length PTH (PTH1-84) (Figure 2.2.1).
Figure 2.2.1: The structure of PTH and teriparatide (PTH 1-34).
Cellular effects of PTH.
The physiological role of PTH is to maintain adequate serum calcium levels. In response
to hypocalcaemia, PTH increases serum calcium levels by reducing the renal excretion of
calcium and increasing the formation of 1,25 dihydroxyvitamin D, which leads to
increased calcium absorption from the intestine. However, most relevant to osteoporosis
is PTH’s effect on bone where osteoclast mediated bone resorption is increased in order
to release calcium into the circulation. It is therefore somewhat counter-intuitive that
PTH therapy can lead to bone formation.
67
The effect of PTH on bone depends on its mode of administration. Continuous infusion,
which maintains a persistently elevated serum PTH level, as seen in primary
hyperparathyroidism, stimulates osteoclast mediated bone resorption. However, when
given as daily subcutaneous injections the PTH concentration peaks at approximately 4-5
times the upper limit of normal after 30 minutes and returns to basal level within 3 hours.
These brief peaks in serum PTH result in bone formation rather than resorption.
The effects of PTH are induced by the binding of the N-terminal of PTH to the PTH
receptor on the surface of the osteoblast. The effect of PTH on osteoclasts is indirect as
the osteoclast does not have a PTH receptor. Within the osteoblast, activation of the PTH
receptor results in the rapid (within minutes) activation of several intracellular pathways,
including the cyclic AMP-dependant protein kinase A and the calcium-dependant protein
kinase C signalling pathways, which ultimately regulate gene expression and osteoblast
function (Canalis et al 2007). The alterations in osteoblast gene expression depend on the
exposure to PTH. In one study, continuous PTH exposure resulted in the activation of
195 genes while intermittent PTH activated 41 genes (Onyia et al 2005). The exact
mechanism for PTH’s anabolic effects is unknown but ultimately intermittent PTH
therapy increases osteoblast differentiation and survival leading to an increase in
osteoblast number and bone formation (Canalis et al 2007). Furthermore, in response to
PTH the osteoblasts also regulate the activity of the osteoclasts via alterations in the
RANKL/OPG pathway (Ma et al 2001).
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The effects on intermittent PTH on bone structure.
Intermittent PTH therapy results in the formation of both trabecular and cortical bone.
Bone biopsy studies using 2D histomorphometry and 3D microCT demonstrate that daily
teriparatide increases the volume of trabecular bone. Other improvements in
microarchitecture include increased connectivity between the trabeculae and changing of
the trabeculae from a rod-like structure to a more plate-like structure (Jiang et al 2003).
Teriparatide also improves cortical bone with increases in cortical thickness associated
with an overall increase in the diameter of the bone (periosteal circumference) (Jiang et al
2003, Zanchetta et al 2003). At the hip, these cortical changes have been shown to
improve bone geometric strength as demonstrated by an increase in the bending strength
and a decrease in the buckling ratio (Uusi-Rasi et al 2005). The changes in bone structure
are illustrated in figure 2.2.2.
Teriparatide reverses the postmenopausal decline in bone mass and the deterioration in
microarchitecture which characterises osteoporosis although there is one exception –
cortical porosity is increased (Jiang et al 2003). An increase in cortical porosity would, to
some extent, counter the beneficial effects, which the other structural changes have on
cortical strength. However, the effect of the increase in cortical porosity is limited as it
predominantly occurs at the endocortical bone surface, which contributes less to overall
cortical strength than the periosteal bone surface (Jiang et al 2003).
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Figure 2.2.2: The effects of 20µg/day of teriparatide for 21 months on trabecular and
cortical bone structures at the iliac crest as measured using microCT (Jiang et al 2007).
The clinical effects of intermittent PTH on BTM’s, BMD and fractures.
Compared to antiresorptives, PTH has the opposite effect on bone turnover with increases
of bone formation and resorption markers. Bone formation markers demonstrate a
significant increase 1 month after the initiation of PTH therapy, peak at 6 months, plateau
for a time before gradually declining back towards baseline (Chen et al 2005, Ettinger et
al 2004, Greenspan 2007). Bone resorption markers increase at a slower rate and peak
later. Therefore there is a time period when bone formation is believed to greatly exceed
bone resorption and PTH is thought to have the majority of its anabolic effects – this
period is known as the “anabolic window” (figure 2.2.3) (Girotra et al 2006). This
concept is supported by evidence from bone histomorphometry, which demonstrates that
b):Post-treatmenta): Pre-treatment
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bone formation indices are increased after 1 month of teriparatide but not after 18 months
of treatment (Jiang et al 2003).
Figure 2.2.3: The different profiles of bone formation and resorption markers in response
to PTH therapy and the anabolic window (Girotra et al 2006).
The original fracture prevention trial was prematurely terminated by the sponsor after a
mean of 18 months because of a reported increase in the incidence of osteosarcoma in
rats treated with long term teriparatide (Neer et al 2001). The risk of osteosarcoma has
never been demonstrated in humans however because of the increased incidence in rats,
and the lack of long term human data, PTH therapy is usually limited to 18 months. This
may not actually be a disadvantage as the “anabolic window” suggests that it is the early
period of treatment, which may be most important in terms of gains in bone mass.
The main fracture prevention trials with PTH demonstrated that after 18 months of
therapy BMD had increased at the spine by 6.9% (full length PTH) and 8.7%
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(teriparatide) compared to placebo (Greenspan 2007, Neer et al 2001). After 18 months
femoral neck BMD had increased by 2.5% (full length PTH) and 3.5% (teriparatide)
compared to placebo. During the first 6 months of treatment with PTH it has been
observed that BMD at the hip declines slightly (Greenspan 2007). This occurs as the hip
is a predominantly cortical site and there is an increase in cortical porosity. Furthermore,
even though new bone is being formed it will take 4-6 months to complete primary
mineralization and thus have maximum effect on BMD. This was demonstrated by Black
et al (2003) who used quantitative CT to investigate the effects of 12 months of therapy
with full length PTH. In this study cortical BMD at the hip was reduced even though
cortical volume was increased suggesting new bone formation. In the same study,
trabecular BMD at the spine increased by 25.5% in response to full length PTH reflecting
the effects of PTH therapy on trabecular bone.
As with any therapy for osteoporosis, ultimately it is vital that intermittent PTH reduces
the incidence of fractures. The main fracture prevention trial with teriparatide
demonstrated that after a mean of 18 months of therapy with 20µg/day vertebral fractures
were reduced by 65% (9% absolute risk reduction (ARR)), all non-vertebral fractures
were reduced by 35% (4% ARR) and non-vertebral fragility fractures were reduced by
53% (3% ARR) (Neer et al 2001). The study was not powered to look for site specific
fracture reduction (i.e. hip). Furthermore, follow up studies have demonstrated that
teriparatide therapy provides long term reductions in vertebral fracture incidence. During
an 18 month follow up period women who had received teriparatide during the fracture
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prevention trial had a 41% (7.7%ARR) reduction in the incidence of new vertebral
fractures compared to women who received placebo during the trial (Lindsay et al 2004).
Full length PTH also reduces vertebral fractures by 58% (2% ARR) at the dose of
100µg/day (Greenspan et al 2007). However, in this study full length PTH did not
demonstrate significant non-vertebral fracture reduction, which is likely to be due to the
women having a lower baseline fracture risk. This is illustrated by the 5.9% non-vertebral
fracture rate in the placebo group which is lower than the 9.7% reported in the placebo
arm of the teriparatide study (Neer et al 2001).
Interactions between anabolic and antiresorptive therapies.
1): Antiresorptives after PTH.
PTH is usually prescribed for 18 months. Therefore it is important to consider how to
treat women after the completion of PTH therapy. PTH therapy results in bone formation
however once therapy is discontinued, postmenopausal bone loss resumes. This is
illustrated by the observation that BMD at the spine declines after the discontinuation of
both teriparatide (Lindsay et al 2004) and full length PTH (Black et al 2005).
Antiresorptives would be expected to reduce bone loss and protect the bone mass gained
during PTH therapy. Furthermore, antiresorptives would cause contraction of the
remodelling space and allow prolonged secondary mineralization of the newly formed
bone. This is supported by evidence that BMD increases further when bisphosphonates
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are commenced after PTH therapy (Lindsay et al 2004, Black et al 2005, Prince et al
2005). Cosman et al (2001) also reported that BMD was maintained in women who took
HRT after teriparatide therapy although in this study there was no control group which
did not receive HRT for comparison. If raloxifene is commenced after teriparatide there
is a significant reduction in BMD at the spine however there is a greater reduction if no
therapy is commenced (Adami et al 2007). None of these studies had sufficient power to
detect a significant reduction in vertebral and non-vertebral fracture incidence if
antiresorptive therapy was commenced after PTH. Despite the lack of fracture data, it is
recommended that bisphosphonates are prescribed to women completing PTH therapy.
2): Antiresorptives combined with PTH.
The observation that bone resorption markers increase with PTH therapy has lead to
interest into combining PTH and antiresorptive therapy. It was hoped that this approach
would increase the amount of bone mass gained by inhibiting bone loss while allowing
new bone formation. Early studies were encouraging with reports that HRT combined
with teriparatide resulted in fewer vertebral fractures and better BMD gains than HRT
alone (Lindsay et al 1997, Cosman et al 2001). However in these studies HRT was unable
to prevent the increase in bone resorption markers and the overall changes in resorption
markers were similar to those reported with teriparatide therapy alone. Furthermore, it is
not known whether HRT-teriparatide combination therapy results in a greater, similar or
smaller BMD response than teriparatide monotherapy as there was no such group
included in these studies for comparison.
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2 studies were performed looking at the combination of alendronate and PTH therapy.
Finkelstein et al (2003) reported that, compared to teriparatide monotherapy, the
combination of teriparatide and alendronate in men resulted in smaller gains in BMD
after 30 months. In a 1 year study of postmenopausal women, Black et al (2003) reported
that alendronate and full length PTH combined did not result in a significantly greater
increase in BMD at the spine or neck of femur than full length PTH alone. As both
treatments were started simultaneously in these studies it is uncertain to what degree the
increase in BMD observed was due to new bone formation and how much was due to the
antiresorptive effects of alendronate. The bone formation marker response was severely
suppressed by combination therapy in both of these studies suggesting that alendronate
was suppressing the anabolic effects of PTH. Therefore a large proportion of the BMD
increase may reflect the actions of alendronate. In these studies quantitative CT
demonstrated that, compared to PTH monotherapy, combination therapy significantly
inhibited the increase in trabecular bone density at the spine and the increase in cortical
volume at the hip. These observations suggest that alendronate impairs the ability of PTH
therapy to stimulate new bone formation.
Interestingly, the SERM raloxifene does appear to be able to suppress the bone resorption
response to PTH therapy without inhibiting the bone formation response. In one study of
postmenopausal women combining raloxifene with teriparatide delayed the increase in
bone resorption markers and resulted in a significantly lower level at 6 months compared
to teriparatide monotherapy (Deal et al 2005). The changes in bone formation markers
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were identical between the 2 groups. BMD at 6 months increased to a greater extent in
the combination group although the difference was only significant at the hip. It therefore
appears that raloxifene, by selectively reducing the bone resorption response, may be able
to increase the size of the “anabolic window” leading to increased amounts of new bone
formation although a longer term study would be needed to properly assess the BMD
benefits. The differences between combination PTH therapy with alendronate and
raloxifene may be due to differences in the mode of action or antiresorptive potency.
3): Antiresorptive therapy before PTH.
As PTH therapy is expensive, in the UK it is only prescribed to women who have had an
inadequate response to antiresorptive therapy. Bisphosphonates are the most commonly
prescribed antiresorptive. After discontinuation bisphosphonates remain detectable in the
body for many months (Russell 2007) and alendronate has been demonstrated to suppress
bone turnover for up to 5 years after discontinuation (Black et al 2006). As already
discussed, concurrent bisphosphonate therapy blunts the anabolic effects of PTH. There
is therefore concern that the residual effects of prior bisphosphonate therapy may cause
long term bone suppression leading to a blunting of the effects of PTH. To date there is
only one study looking at this. Ettinger et al (2004) studied postmenopausal women who
had previously been treated with either alendronate or raloxifene for a mean of 29
months. Women with prior raloxifene exposure achieved the expected BTM and BMD
response. In contrast, prior alendronate use led to a general reduction in the BTM
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response and a significant reduction in the BMD gain at the spine and hip. This suggests
that prior bisphosphonate use may blunt the anabolic effects of PTH.
Research topic: In the UK, the National Institute for Health and Clinical Excellence
restricts the prescribing of teriparatide to women who have had previous bisphosphonate
therapy. The study by Ettinger et al (2004) suggests that this policy will blunt the





Strontium ranelate is the first of a new class of osteoporosis therapy, the dual action bone
agent (DABA). Strontium was originally discovered in 1808 by Sir Humphry Davy in the
village of Strontian in Scotland from which its name is derived. Strontium is a bone
seeking element which belongs to the same chemical family as calcium. To the general
public it is commonly thought of as the radioactive isotope strontium 90, which was
produced by nuclear weapons testing and the Chernobyl disaster and is associated with
bone cancer and leukaemia. Fortunately, natural strontium 38 is nonradioactive and
nontoxic. Strontium ranelate is comprised of 2 strontium atoms, the bone active
component, bound to ranelic acid, which increases its bioavailability (figure 2.3.1).
Strontium makes up 34% of the molecular weight of strontium ranelate so the licensed
dose of 2g/day delivers 680mg of strontium to the intestine of which 25% is absorbed.
Strontium ranelate has unique effects on bone although its exact effects and mechanisms
of action are still being determined. Unlike antiresorptive and anabolic therapies,
strontium ranelate appears to have little effect on the overall rate of bone turnover as
measured by the activation frequency (Arlot 2005). Instead it seems to predominantly
affect the remodelling balance at the level of the BMU by uncoupling bone formation and
resorption. By increasing bone formation while reducing bone resorption strontium
ranelate is thought to cause a positive remodelling balance and an overall gain in bone
mass with each remodelling cycle. In theory this suggests that strontium ranelate has
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anabolic properties although this will be questioned by the results of chapter 7 in this
thesis.
Figure 2.3.1 Chemical structure of strontium ranelate.
Cellular mechanisms of strontium ranelate.
How strontium ranelate affects bone remodelling is uncertain. Strontium ranelate
increases osteoblast proliferation and differentiation (Bonnelye et al 2007) which is likely
to be important in strontium ranelate’s effects on bone formation. This is in part due to
strontium’s ability to activate the calcium sensing receptor (CSR) on the osteoblasts
although other pathways are also likely to be involved as osteoblast replication can still
be induced by strontium in the absence of the CSR (Chattopadhyay et al 2007, Bonnelye
et al 2007). Another potential mechanism of action for strontium is through the induction
of cyclooxygenase 2 in osteoblasts, which leads to increased prostaglandin E2 synthesis
(Choudhary et al 2007). Prostaglandin E2 has autocrine effects on the osteoblast leading
to increased differentiation and has been demonstrated to increase bone formation
(Choudhary et al 2007).
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Strontium ranelate has also been demonstrated to inhibit osteoclast differentiation,
increase osteoclast apoptosis and inhibit osteoclast mediated bone resorption by
disrupting the ruffle border between the osteoclast and the bone (Bonnelye et al 2007).
The mechanism by which osteoclasts are inhibited by strontium is again uncertain
although recent data suggests the RANKL/OPG pathway is involved. It has been
demonstrated that strontium ranelate can down regulate RANKL expression on
osteoblasts while increasing osteoblast OPG expression (Breenan et al 2007). Therefore,
the RANKL/OPG ratio is reduced resulting in decreased activation of RANK on
osteoclasts which in turn leads to reduced osteoclastogenesis and bone resorption.
The effects on strontium ranelate on bone remodelling.
These cellular effects provide a mechanism by which strontium ranelate may increase
bone formation and reduce resorption. Evidence supporting this was originally provided
by animal studies. In ovariectomized rat models of postmenopausal osteoporosis,
strontium ranelate was demonstrated to reduce histomorphometric measures of bone
resorption (osteoclast surface and osteoclast number) while maintaining elevated bone
formation indices (bone formation rate and osteoblast surface) (Marie et al 1993). Similar
histomorphometric effects have been reported in monkeys (Buehler et al 2001) further
supporting the “dual action” of strontium ranelate.
More recently the histomorphometry findings from animal studies have been confirmed
using human bone biopsies. Arlot et al (2005) demonstrated that strontium ranelate
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increased osteoblast surface and mineral apposition rate (bone formation indices)
associated with a trend towards a reduction in eroded surfaces, osteoclast surface and
osteoclast number (resorption indices). The same study demonstrated no change in
activation frequency (rate of bone turnover) or impairment of mineralization.
The effects on strontium ranelate on bone structure.
By increasing bone formation and reducing bone resorption, strontium ranelate should
cause an overall increase in bone mass and improvements in microarchitecture. In rats 2
years treatment with strontium ranelate has been demonstrated to increase bone volume,
trabecular thickness, trabecular number and cortical area (Ammann et al 2004).
Furthermore, no increase in cortical porosity was evident (Ammann et al 2004). In this
study compression testing demonstrated that the mechanical properties of the bone were
improved leading to an overall increase in bone strength with strontium ranelate therapy.
These findings have again been confirmed with human bone biopsies. Jiang et al (2006)
used microCT to demonstrate that, compared to placebo, women treated with strontium
ranelate had an increased trabecular number (+14%), a reduced trabecular separation (-
16%) and an increased cortical thickness (+18%). The trabecular structural model index
also improved suggesting a shift from rod-like trabeculae to a more plate-like pattern. In
contrast to PTH therapy there was no increase in cortical porosity. This suggests that,
compared to no treatment, strontium ranelate reverses the postmenopausal
microarchitectural deterioration discussed in chapter 1.3, thus leading to an increase in
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bone strength. However, there were no baseline biopsies in either group for comparison
and therefore this does not prove that strontium has anabolic properties. Similar
differences in microarchitecture could arise from a purely antiresorptive effect by
preventing the deterioration in microarchitecture which would occur in placebo treated
group.
To prove strontium ranelate has anabolic properties biopsies before and after treatment
would be required. To date there is only one small report on paired bone biopsies in
postmenopausal women. Busse et al (2007) demonstrated that, compared to baseline, 12
months treatment with strontium ranelate resulted in an increase in markers of active
bone formation (osteoid volume and osteoid surface) as well as an increase in structural
indicies (bone volume, trabecular interconnectivity and trabecular thickness). This
suggests that strontium ranelate does increase bone formation, which leads to an increase
in the amount of bone and improved microarchitecture. Therefore strontium may indeed
have anabolic effects in postmenopausal women although evidence from chapter 7 in this
thesis will cast some doubt on this.
The effects of strontium ranelate on BTM’s.
Much of the data suggesting that strontium ranelate has a dual mode of action is derived
from animal and in-vitro studies. It is therefore important that evidence from BTMs in
postmenopausal women also supports strontium ranelate’s dual effects. The first study to
show this was the phase 2 dose ranging study (STRATOS) (Meunier et al 2002). Even in
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this small study, 2g/day of strontium ranelate for 2 years increased BSAP (formation
marker) by 11% while reducing urinary NTX (resorption marker) by 10%. Subsequently
a large phase 3 study (SOTI) confirmed strontium ranelate’s differential effects on
formation and resorption markers. In this study strontium ranelate again increase BSAP
by 8% and reduced serum CTX (resorption marker) by 12% (Meunier et al 2004).
Therefore the BTM response to strontium ranelate supports the preclinical data and
suggests that in postmenopausal women strontium ranelate does increase bone formation
while reducing bone resorption.
The clinical effects of strontium ranelate on BMD.
Strontium ranelate induces large increases in BMD as measured by DXA. The phase 3
clinical studies demonstrated that after 3 years of treatment BMD had increased by 14%
at the spine and 8% at the hip compared to placebo (Meunier et al 2004, Reginster 2005).
These BMD increases are far greater than those observed with 3 years treatment with
antiresorptives. Unfortunately a large part of this increase in BMD is an artefact rather
that a true increase in bone mass. Strontium has a higher mass than calcium (atomic
number 38 and 20 respectively) which leads to a greater attenuation of x-rays. DXA
scanners calculate BMD by measuring the attenuation of x-rays as they pass through
bone. As such, the incorporation of strontium into bone results in a greater x-ray
attenuation, which is incorrectly interpreted as an increase in calcium content, artificially
increasing BMD. It has been estimated that approximately 50% of the measured BMD is
an artefact and, after correction for this, the increase in “true” BMD at the spine from
83
baseline in the SOTI study was estimated at 6.8% (Meunier et al 2004). This adjustment
was based on the bone strontium content (BSC) of a small number of women (n=14),
who had an iliac crest bone biopsy as part of the SOTI study, and the ratio of BSC in the
spine compared to the iliac crest of female cynomolgus monkeys (ratio = 0.61). However,
other animal models give different spine to pelvis BSC ratios and it is surprising that the
ratio is not closer to, or greater than, 1.0 given that the spine has a higher rate of bone
turnover and therefore could be expected to have a higher BSC (Blake et al 2007). If a
ratio of 1.0 is used for the adjustment calculation then the percentage increase in “true”
BMD from baseline in the SOTI study changes from 6.8% to around 3% (Blake and
Fogelman 2005). Until data from humans is available any attempts at correction are
potentially flawed and therefore unreliable.
If this artefact accounts for a proportion, but not all, of the BMD response to strontium
ranelate, the remaining portion must reflect the effects of strontium ranelate on the bone.
If strontium does have anabolic properties then the increasing bone mass and
improvements in microarchitecture will lead to an increase in BMD. Likewise if
strontium has significant antiresorptive properties then part of the increase in BMD
observed may be due to contraction of the remodelling space and prolonged secondary
mineralization. The majority of the BMD increase due to bisphosphonates occurs in the
first few years of treatment with a plateauing of the BMD response at the hip and a
slower rate of increase at the spine after 3 years of treatment (Black et al 2006, Bone et al
2004). In contrast long term data from the SOTI study demonstrates that BMD continues
to rise in a uniform manner over 5 years at both the spine and hip (Blake et al 2007). This
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suggests that either strontium continues to be incorporated into the skeleton over 5 years
or there is continued increases in bone mass or a combination of both. Data from bone
biopsies demonstrate that BSC does not increase further after 2 years of treatment with
2g/day of strontium ranelate (Boivin et al 2006). The number of biopsies studied was
small but if this is the case then it suggests that the increase in BMD observed beyond 2
years is due to an actual increase in bone mass.
Although the BMD artefact prevents direct comparison between strontium ranelate and
other osteoporosis therapies it does make BMD a very useful way to monitor the response
to treatment. The increase in BMD with strontium ranelate exceeds the least significant
change of a DXA scanner within 6-12 months, which is earlier than many other
osteoporosis treatments (Blake et al 2007). This allows an earlier follow up DXA scan to
assess the treatment response, thus enabling early reassurance to both the physician and
the woman that the treatment is clinically effective. If no improvement is apparent
enquires should be made regarding compliance and whether the woman is taking the
strontium ranelate in the correct manner. A lack of a BMD response in a woman who is
taking strontium ranelate regularly and correctly for 1-2 years would be unusual and
therefore should prompt consideration of medical conditions associated with
malabsorption (e.g. coeliac disease) or ongoing bone loss.
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The clinical effects of strontium ranelate on fractures.
The phase 3 studies confirmed that the effects of Strontium ranelate on bone leads to a
reduction in the incidence of osteoporotic fracture. Vertebral fracture reduction was
investigated by the SOTI study (Meunier et al 2004), which included 1649
postmenopausal women with a prevalent vertebral fracture who received strontium
ranelate or placebo for 3 years. The risk of a new vertebral fracture was 49% lower (ARR
5.8%) in the strontium ranelate group after 1 year and 41% lower (ARR 11.9%) after 3
years. Clinical vertebral fractures were reduced by 38% (ARR 6.1%) over 3 years.
Non-vertebral fracture reduction was assessed in the TROPOS study. Reginster et al
(2005) investigated 5091 postmenopausal women with osteoporosis at the femoral neck
who were either aged over 74 or over 70 if they also had an additional risk factor for
fracture. After 3 years there was a significant 16% reduction (ARR1.7%) in all non-
vertebral fractures and a 19% reduction (ARR1.7%) in the risk of suffering a major non-
vertebral fracture. Hip fractures were reduced by 15% in the population as a whole but
this was not significant as the study was not powered to investigate hip fractures. In a
subset of high risk women (over 75, T<-3.0) there was a significant 36% reduction (ARR
2.1%) in the incidence of hip fractures. The TROPOS study also confirmed the
reductions in vertebral fracture observed in the SOTI study. 3640 women in TROPOS
underwent yearly spinal x-rays and in these women vertebral fractures were reduced by
45% over the first year and 39% over 3 years (ARR 6.3%). This study also demonstrated
that strontium ranelate significantly reduced the incidence of vertebral fractures in
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women with or without prevalent vertebral fractures at baseline (32% and 45% RRR
respectively).
Both the SOTI study and the TROPOS study have been continued for 5 years although in
the last year of the SOTI study women in the strontium group were randomly assigned to
either continuing strontium ranelate or to switch to placebo. These studies confirm that
strontium ranelate continues to reduce fractures beyond 3 years. The TROPOS study
demonstrated that, after 5 years, strontium ranelate reduced vertebral fractures by 24%
(ARR 4.1%) and non-vertebral by 15% (ARR 2.3%) (Reginster et al 2007). Again in the
high risk subgroup over the 5 years hip fractures were reduced by 43%. Years 4-5 of the
SOTI study also demonstrated a 33% (ARR 9.4%) reduction in vertebral fractures over 4
years (Blake et al 2007).
Strontium ranelate in women over 80.
Of all the treatments for osteoporosis, strontium ranelate has the best evidence for
fracture reduction in the over 80s. This is a particularly important group of women as it is
the fastest growing population age group and contributes to over 30% of all fractures and
60% of all hip fractures (Seeman et al 2006). Both the SOTI and TROPOS studies had no
upper age limit on recruitment and therefore 1556 women over 80 were recruited.
Seeman et al (2006) performed a pooled analysis of these older women and found that
strontium ranelate significantly reduced the incidence of vertebral fractures by 59%
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(ARR 4.8%) at 1 year and 32% (ARR 7.4%) at 3 years. Non-vertebral fractures were also
significantly reduced by 41% (ARR 1.6%) at 1 year and 31% (ARR 5.5%) at 3 years.
Other therapies are poorly studied in women over 80. The FIT trials (alendronate) and
MORE trial (raloxifene) excluded women over 80. The VERT-NA and VERT-MN trials
(risedronate) only included 180 and 137 women respectively over 80. The HIP study
(risedronate) specifically included women over 80 with at least one risk factor for
fracture or low BMD at the hip. However, the HIP study failed to demonstrate a
significant reduction in hip or non-vertebral fractures. A subsequent pooled analysis of all
women over 80 with osteoporosis at the hip who had participated in the VERT and HIP
studies demonstrated that there was again no significant reduction in non-vertebral
fractures although vertebral fractures were reduced (Boonen et al 2004). The HORIZON
trial (zoledronate) included women up to 89 years of age but provided no data
specifically for women over 80. The teriparatide fracture prevention trial was reanalysed
to assess the effects of teriparatide on women over 75 although the number of women
was small and only 48 were over 80 (Boonen et al 2006). This study suggested that
increasing age did not reduce the efficacy of teriparatide and vertebral fractures were
significantly reduced in those women over 75. However, the number of women was too
small so show a significant reduction in non-vertebral fractures.
The reason why strontium ranelate reduces non-vertebral fractures in women over 80
while risedronate, the only other treatment specifically studied in this age group, fails to
do so is uncertain. It was suggested that risedronate’s failure to reduce non-vertebral
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fractures was due to non-skeletal risk factors, such as falling, which increase with age
(Boonen et al 2004). However, similar factors were likely to exist in those women over
80 in the strontium ranelate studies. This suggests that these factors are not solely
responsible for the lack of efficacy of risedronate unless strontium ranelate somehow
addresses these factors. One explanation maybe that by age 80 bone mass and
microarchitecture have deteriorated to such a degree that simply reducing the rate of bone
resorption is inadequate to sufficiently reduce the risk of non-vertebral fractures. In this
case strontium ranelate, which is thought to have anabolic properties, may improve bone
mass and microarchitecture leading to a reduction in non-vertebral fractures.
Interactions with other osteoporotic therapies.
There is very little data regarding the interactions of strontium ranelate with other
therapies for osteoporosis. When strontium ranelate is discontinued BMD declines as
strontium is released from the bone and/or bone mass is lost (Ortolani and Diaz-curiel
2007). Bisphosphonates after strontium ranelate may theoretically reduce or prevent this
decline in BMD but there are no studies assessing this yet. Combining strontium ranelate
with bisphosphonates may increase its antiresorptive effects but may also blunt its
anabolic actions, as occurs with teriparatide, but again this has not been studied.
The effect of prior bisphosphonate therapy on the subsequent response to strontium
ranelate is a particularly important interaction to consider, as in the UK bisphosphonates
are usually prescribed as first line therapy. If strontium ranelate does have anabolic
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properties then prior bisphosphonate use may blunt these effects as has been reported
with teriparatide (Ettinger et al 2004). Furthermore, the prolonged suppression of bone
turnover by prior bisphosphonate therapy may reduce the uptake of strontium into the
bone as strontium is predominantly deposited in newly formed bone (Boivin et al 2006,
Boivin et al 2007).
Research Topic: The long term suppression of bone turnover by prior bisphosphonate
therapy could be expected to reduce the BMD response to strontium ranelate due to
blunting of the possible anabolic actions of strontium and/or the reduced uptake of
strontium into the bone. This is investigated in chapter 7.
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Chapter 2.4:
Percutaneous vertebroplasty for painful vertebral fractures.
As discussed in chapter 1.2, vertebral fractures are the commonest osteoporotic fracture
and are associated with significant morbidity. The pain associated with an acute vertebral
fracture can vary from a mild transient pain for which no medical help is sought to
debilitating back pain requiring hospitalisation. In most women the back pain settles with
conservative treatment over a period of weeks to months but a significant number of
women are left with persistent, chronic pain (Heini 2005, Nevitt et al 2000). This chronic
pain can arise due to persistent instability associated with micromotion of the vertebra
causing pain during spinal loading and movement (Heini 2005). This is illustrated in
figure 2.4.1. Other causes of chronic pain after a vertebral fracture include radiculopathy
due to foraminal narrowing and, with sufficient kyphosis, impingement of the ribs on the
iliac crests. Increased kyphosis also results in spinal imbalance leading to increased
mechanical strain on the facet joints and paraspinal ligaments/muscles. Traditionally, the
treatment of painful vertebral fractures was based on bed rest, potent analgesia and, if
necessary, external bracing.
Vertebroplasty was first used for painful vertebral lesions by Galibert and Deramond in
France in the mid-1980s for the treatment of vertebral haemangiomas. Soon after,
vertebroplasty was applied as a minimally invasive technique for the treatment of other
painful vertebral lesions or fractures. This technique involves the insertion of cement into
the vertebral lesion/fracture in order to stabilise and strengthen the vertebra. Although
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indications for vertebroplasty include haemangiomas, spinal metastases and multiple
myeloma, this chapter of the thesis will concentrate on its use for the treatment of
osteoporotic vertebral fractures. Vertebroplasty is currently a relatively new treatment
option and at present the majority of women who suffer painful osteoporotic vertebral
fractures do not undergo a vertebroplasty. This is in part due to limitations in the
availability of vertebroplasty services which are often only available at larger bone
centres. There are also issues regarding patient selection and the timing of the
vertebroplasty relative to the occurrence of the fracture, which further limit the number of
women deemed eligible for vertebroplasty. These are discussed in more detail below.
Figure 2.4.1. A severe wedge fracture of T11 on erect x-ray (a) with a degree of
spontaneous correction on lying down for MRI (b) suggesting instability of the fracture.
(Heini 2005).
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Vertebroplasty: patient selection and assessment.
As vertebroplasty is not without risks, careful patient selection is required to target
patients who will benefit from the procedure. Vertebroplasty is performed for pain relief
so should only be offered to patients with painful vertebral fractures. The location of the
pain should be in the midline of the spine over the site of the fracture and there is usually
tenderness on palpation/percussion of the affected vertebra. Other causes of back pain,
such as spondylosis and radiculopathy, which would not be expected to respond to
vertebroplasty, should be considered. Full medical history and examination should be
performed to look for other potential causes of the vertebral fracture, neurological deficit
and medical conditions, which may complicate vertebroplasty.
Potential contraindications for vertebroplasty include overlying infection, uncorrectable
coagulopathy, fractures associated with neurological deficit, and significant respiratory
disease. Vertebral plana fractures are technically more difficult to vertebroplasty. A
fracture of the posterior wall of the vertebra or retropulsed bone fragments also needs to
be looked for on imaging as this would increase the risk of spinal cord compression when
the cement is injected.
Imaging of the spine is vital prior to vertebroplasty. Imaging allows assessment of the
location and extent of vertebral collapse and identifies other pathological causes for
fracture, such as malignancy. It also permits assessment of the pedicles, the extent of
cortical disruption and whether there is complicating spine or nerve root compression.
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Finally, imaging can assess whether the fracture is acute or “active”. Plain x-rays are
usually performed to confirm the presence of a vertebral fracture and provide basic
information on the number and severity of fractures. Comparison with previous x-rays
can help gauge the age of the fracture. However, more accurate imaging is usually
required.
An MRI scan is usually the imaging modality of choice. This allows accurate assessment
of the fracture and the whole spine anatomy including assessing for spinal cord and nerve
root involvement. MRI also helps distinguish acute/active fractures from chronic stable
fractures. Acute or “active” fractures are indicated by the presence of bone oedema,
which is demonstrated as a decreased signal in T1 images and an increase in signal in
short-tau inversion recovery (STIR) sequence (Figure 2.4.2). This is particularly useful in
patients with multiple vertebral fractures of varying age in order to determine which
fracture(s) is most likely to be responsible for the pain. Although bone oedema is often
sought to identify acute fractures, the absence of bone oedema is not an absolute
contraindication to vertebroplasty. Brown et al (2005) demonstrated that 100% of patients
with bone oedema on MRI (n=30) reported an improvement in pain after vertebroplasty.
However, an improvement in pain was still reported in 80% of patients (n=15)
undergoing vertebroplasty for severe focal fracture pain with no corresponding bone
oedema. Even though the response rate was almost significantly lower (p=0.07) for those
with no bone oedema, this study demonstrates that vertebroplasty is still capable of
reducing pain in the majority of patients with non active fractures. This is in agreement
with the observation that studies which selected patients for vertebroplasty on the basis of
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bone oedema (Diamond et al 2006, Kobayashi et al 2005) yielded comparable results to
those which included patients regardless of MRI findings (Do et al 2005, Evans et al
2003, Anselmetti et al 2007).
In patients unable to undergo an MRI, a CT scan can be performed to assess the vertebral
architecture however CT poorly differentiates acute and chronic fractures. In these cases
an isotope bone scan can be performed on which acute fractures demonstrate an increased
uptake of radioisotope. Maynard et al (2000) demonstrated that 93% of patients with an
increased uptake on a bone scan reported an improvement in pain after a vertebroplasty.
Unfortunately, the lack of a control group in this study means it is not known if patients
with fractures which do not have increased uptake on bone scan respond more poorly to
vertebroplasty.
Figure 2.4.2: a T2 weighted sagittal STIR
MRI scan demonstrating high signal in
the L3 vertebrae indicating bone oedema
(Ansemetti et al 2007)
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Vertebroplasty: when to perform.
There is no agreement on the optimum time at which to perform a vertebroplasty. When
performed acutely (days – weeks) after a vertebral fracture, vertebroplasty is highly
effective at rapidly reducing pain and permitting an early return to activity. Diamond et al
(2006) reported the only large study (n=126), which included a control group and
assessed the efficacy of vertebroplasty in the acute setting (range 1-6 weeks). Those who
underwent an acute vertebroplasty had a 60% reduction in pain and a 29% improvement
in physical function after 24 hours compared to no improvement in the control group.
However, by 6 weeks there was no significant difference in terms of physical function
and only a small benefit for the vertebroplasty group in terms of pain reduction (-75% vs.
-65%, p=0.002). By 6 months the pain had reduced by the same amount in each group
(85% vs. 80%, p=0.36). This is because most painful fractures will improve with time
and suggests that vertebroplasty should not be used routinely for all acute vertebral
fractures. Instead a period of months of conservative treatment should be allowed before
considering vertebroplasty. The possible exception to this is severely painful fractures
which require hospitalisation and bed rest despite adequate analgesia. In these patients an
acute vertebroplasty may aid mobilisation and avoid the complications associated with
prolonged bed rest. Acute vertebroplasty has been demonstrated to reduce mean hospital
stay from 17.5 to 10.4 days (Diamond et al 2006).
In most cases vertebroplasty is performed at least a few months after the acute fracture in
patients whose pain persists despite analgesia. However, there is no evidence to support
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an upper time limit from fracture to vertebroplasty. Evans et al (2003) reported outcomes
of vertebroplasty depending on the age of the fracture. This study demonstrated that pain,
ambulation and ability to perform activities of daily living improved equally in patients
with acute (< 3 months) and chronic (>1 year) fractures. Brown et al (2005) also reported
a high rate (80%) of symptomatic improvement in patients undergoing vertebroplasty
more than 1 year after the fracture occurred. Therefore it appears that while
vertebroplasty should not be routinely offered for acute fractures, women with ongoing
pain from a vertebral fracture should not be excluded from vertebroplasty on the basis of
chronicity.
Vertebroplasty: the procedure.
The patient is positioned prone on a radiolucent table. In most cases local anaesthetic is
used in combination with intravenous sedation although general anaesthetic is used in
some cases. The relevant area of skin is sterilised and patients often receive antibiotic
prophylaxis. Radiographic guidance is used, usually in the form of C-arm fluoroscopy
although CT guidance can be used. A small paramedian skin incision is made over the
appropriate pedicle and an 11 gauge bone biopsy needle is advanced into the vertebral
body via a transpedicular (Figure 2.4.3a) or peripedicular route. The transpedicular route
is most commonly used as this maximises the distance between the entry point of the
needle and the site of cement injection thus reducing the risk of cement leakage back
through the entry point. A unilateral vertebroplasty usually provides adequate filling of
the whole vertebral body although a bilateral approach can be used if a uniform
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distribution of cement is not achieved with a unilateral approach. Once the needle is in
the vertebral body it is advanced into the anterior third of the vertebra. At this point some
operators chose to inject contrast medium in order to ensure there is no leakage either
into the venous system or out of the vertebral body via defects in the cortex. Once the
needle is in the correct position, bone cement is injected under fluoroscopic guidance
until the cement reaches the posterior third of the vertebra. Typically 2-3ml of cement is
required for thoracic vertebrae and 3-5mls for lumbar vertebrae (Figure 2.4.3b). The
cement sets within minutes of injection and patients are able to mobilise once they have
recovered from the sedation. Although patients are often kept in overnight after a
vertebroplasty it is possible to perform vertebroplasty as a day case procedure.
Figure 2.4.3: a): An 11 gauge bone biopsy needle is advanced down the right pedicle into




Polymethylmethacrylate (PMMA) has been used as bone cement for orthopaedic
procedures for decades. PMMA is used in the vast majority of vertebroplasty reports in
the literature. For vertebroplasty PMMA is often modified to improve its performance.
To increase its visibility on x-ray compounds containing tungsten or barium are added.
Extra monomer can also be added to extend its working time. In the early days of
vertebroplasty this mixing was originally performed by the operator at the time of the
procedure. More recently specifically designed pre-mixed PMMA is now available for
vertebroplasty.
In recent years there has been interest in developing other, non-PMMA, cements for
vertebroplasty with improved performance. Cortoss™ (Orthovita, Malvern, Pa) is a
modified bisphenol-a-glycidyl dimethactylate (bis-GMA) resin, which has been
specifically developed for vertebroplasty. Cortoss is inherently radiopaque making it
easier to visualise on fluoroscopy and it is easier to handle as it requires no premixing or
modification and hardens in 5-8minutes. It is less exothermic during polymerisation than
PMMA (63 oC vs. 84oC) reducing the risk of thermal damage to the bone. Cortoss has a
modulus of elasticity, which is close to that of bone and binds more strongly to bone than
PMMA which is often separated from the bone by a layer of fibrous tissue (Erbe et al
2001). There is very little clinical data on Cortoss vertebroplasty in general. Whether the
potential advantages of Cortoss result in a better clinical outcome is not known as there
are no head to head studies comparing PMMA and Cortoss.
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Research Topic: At our centre all vertebroplasties are performed using Cortoss cement.
In chapter 8 of this thesis the clinical outcomes of our Cortoss vertebroplasty service are
studied and compared to the reported outcomes from PMMA vertebroplasty.
The clinical benefits of vertebroplasty.
There are many reports of vertebroplasty in the literature. Comparing the results is
difficult as the studies are a mix of small and large retrospective or prospective
observational studies, which are almost invariably uncontrolled. Furthermore some
studies include a variety of vertebral lesions while others are restricted to osteoporotic
fractures, which seem to achieve better pain relief with vertebroplasty than malignant
lesions (Martin et al 1999, Barr et al 2000). The duration of the lesion undergoing
vertebroplasty varies from days to years in different studies while some, but not all,
studies only performed a vertebroplasty after an MRI had confirmed an “active” fracture.
Almost all the studies to date involve PMMA cement although some studies used specific
makes of PMMA while others either added extra compounds to improve the cement’s
performance or do not specify the type of PMMA. The results from the largest
vertebroplasty reports to date are summarised in table 2.4.1.
Despite the differences between the studies, on the whole, the majority of patients (76-
100%) reported an improvement in pain post vertebroplasty. The visual analogue scales
(VAS), a validated measurement of pain, demonstrated dramatic reductions in the mean
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level of pain after a vertebroplasty. Most patients were able to reduce their analgesia
requirements post procedure while many discontinued analgesia altogether.
Improvements in quality of life (measured by SF36), physical function (Barthel index)
and mobility have also been reported (Table 2.4.1). However, it is important to remember
that most studies lack a control group and Diamond et al (2006) demonstrated that
vertebroplasty resulted in no benefit over conservative management 6 months after an
acute fracture. Whether or not vertebroplasty has benefits over conservative management
in non-acute persistently painful vertebral fractures remains to be proven.
The potential complications of vertebroplasty.
Vertebroplasty is largely a safe procedure. The complications encountered in the large
vertebroplasty studies are summarised in table 2.4.2. The commonest complication is
leakage of the cement into the surrounding tissue, disc space or vein. This has been
reported in up to 75% of vertebroplasties although it is usually asymptomatic and of no
clinical relevance. In some cases the cement leakage can embolise to the lungs or cause
compression of the spinal cord or nerve roots although this is rare. Up to 4 % of patients
have been reported to have transient nerve root symptoms despite no evidence of cement
compressing the nerve root on CT. Rib fractures occur in 1-2% of patients, probably a
consequence of lying patients with osteoporosis prone for the procedure. Haematomas




Kyphoplasty is a more recently developed technique for the treatment of painful vertebral
fractures. This technique is similar to vertebroplasty however a balloon is inflated within
the vertebra before the cement is injected. The balloon reduces the fracture prior to
fixation. This procedure has several potential advantages over vertebroplasty as it reduces
the kyphotic angle of the spine as well as stabilising the fracture. This may lead to better
pain relief in patients with a significant kyphosis as it will correct the mechanical factors
discussed above which contribute to the chronic pain associated with vertebral fractures.
Whether this leads to significantly better clinical outcomes compared to vertebroplasty is
yet to be proven and the role of kyphoplasty remains to be established. However,




Methods of assessing treatment response.
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Chapter 3:
Methods of assessing treatment response.
Osteoporosis is a chronic disease, which requires long term treatment. After initiating
therapy it is important to monitor the treatment response as, unless a fracture occurs,
osteoporosis is a silent disease in which therapy provides no symptomatic relief.
Monitoring treatment with surrogate markers, such as BMD and BTMs, provides
reassurance that the treatment is working and acts as a means of reinforcing the need for
adherence to long term therapy. Treatment monitoring also enables the detection of poor
responders to treatment. Potential causes for a poor treatment response are poor
compliance, incorrect treatment administration, malabsorption of the drug, and other
conditions affecting bone metabolism. Treatment monitoring during research studies
provides insight into the effects of certain drugs on bone. In clinical trials monitoring
surrogate markers also provides a means of assessing and comparing the efficacy of
different treatments with smaller numbers of subjects than would be required if fracture
incidence was used as the primary endpoint. However, it is important to remember that
surrogate markers are a poor substitute for hard clinical outcomes such as fractures. This
is best illustrated with fluoride, which causes large increases in BMD but does not reduce
the incidence of fractures. There are several potential tools for monitoring treatment
however in clinical practice, and in the studies in this thesis, axial BMD and BTMs are
used predominantly and are therefore discussed in detail in this chapter.
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Treatment monitoring and the least significant change.
Whether using BMD or BTMs to monitor an individual patient it is important to
understand the concept of the least significant change (LSC). Whenever a measure is
repeated the change observed depends on 2 factors: the true change in the measure (e.g.
the treatment effect) and the repeatability of the measure (test-retest precision). Various
factors can affect the precision of a measurement including device errors, operator
variability, differences in patient positioning (BMD), time of day (BTMs) and fasting
(BTMs). The precision error is expressed as the coefficient of variation (CV). For BMD
the CV ranges from 0.9-1.9% at the spine and 0.9-2.5% at the hip (Delmas 2000). The
CV for BTMs varies from around 4-14% depending on the population studied and the
exact marker used.
The LSC is defined as the least amount of change between 2 measurements over time that
must be exceeded before one can be 95% confident that a true change in the measure has
occurred. The LSC is usually calculated as 2.77 x CV (Sheperd and Lu 2007) although
other definitions have been proposed (Delmas 2000). For example, an individual must
have an increase in BMD of more than 2.5- 5.2% at the spine in order to be confident that
they have had a true increase in BMD in response to therapy.
While the LSC is important for monitoring individual patients, the LSC is less important
for clinical trials where the treatment response from a group of women is averaged. This
effectively cancels out the effect of the precision error meaning that a small increase in
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the measure can be considered significant even if it is less that the LSC. The difference
between treatment monitoring in clinical trials and individual patients can be illustrated
with raloxifene. The MORE trial demonstrated that raloxifene induced a modest 2.6%
increase in BMD at the spine over 3 years (Ettinger et al 1999). However, if an individual
woman achieved a 2.6% increase in BMD then one could not be entirely confident that
her BMD had truly increased as it barely exceeds the most optimistic LSC for spinal
BMD.
Using bone mineral density to monitoring therapy.
BMD is a logical means of monitoring the treatment response. The spine is usually the
preferred site as the lumbar vertebrae demonstrate the quickest and greatest response to
therapy due to the high proportion of trabecular bone. Low BMD defines osteoporosis
and, whether treated with antiresorptives, anabolic agents or strontium ranelate, BMD
increases to varying degrees demonstrating a beneficial response to therapy which is
easily understood by physicians and patients alike. Furthermore, the majority of women
undergo a DXA prior to starting therapy and therefore have a baseline BMD
measurement for comparison. However, BMD increases slowly with treatment and
depending on the therapy used a period of 12-24 months between DXA scans is required
for BMD to increase by more than the LSC. Furthermore, the increase observed in BMD
represents different changes in the bone tissue with different therapies. Degenerative
changes and vertebral fractures can also falsely elevate spinal BMD. Finally, the increase
in BMD with treatment only accounts for a small proportion of the observed reduction in
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fracture risk. Therefore, although BMD is used as a surrogate marker of treatment
efficacy in clinical trials, the use of BMD as a means of monitoring individual patients
has limitations.
Bone mineral density changes and the reduction in fracture risk with treatment.
The extent to which increases in BMD correlate with reductions in fracture risk is
controversial. All antiresorptives reduce the risk of vertebral fracture by 30-50% even
though bisphosphonates, raloxifene, calcitonin and HRT all result in different increases in
BMD (Figure 3.1). Changes in BMD only explain 4-28% of the vertebral fracture
reduction observed with antiresorptive therapy suggesting that a large proportion of the
increase in bone strength with antiresorptives is due to factors, which have little effect on
BMD (Eastell et al 2003). The likely explanation for this large discrepancy between
fracture reduction and BMD change is the effect of antiresorptives on the erosion
cavities. By reducing the number and depth of these cavities antiresorptives greatly
increase bone strength by reducing the “stress riser” effect, as discussed in chapter 1.3,
however the effect of this on BMD is minimal as the absolute amount of bone gained is
small. Instead the increase in BMD is more likely to reflect the increased MDMB due to
prolonged secondary mineralisation, which has less certain effects on bone strength.
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Figure 3.1: Data from the principal antiresorptive fracture prevention trials demonstrating
consistent reductions in vertebral fracture risk despite variable effects on BMD.
Overall, there does appear to be a relationship between change in BMD with
antiresorptive therapy and reduction in fracture risk. Meta-analyses of antiresorptive trials
demonstrate that greater increases in BMD are associated with greater reductions in
vertebral (Wasnich and Miller 2000, Cummings et al 2002) and non-vertebral fracture
risk (Hochberg et al 2002). However, the magnitude of the reduction in risk that is
attributable to change in BMD is uncertain. Cummings et al (2002) reported that
increases in spine BMD explained only 16% of the reduction in vertebral fracture risk
compared to over 50% reported by Wasnich and Miller (2000). Chapurlat et al (2005)
reported that women who complied with alendronate and yet had a 0 to 4% decline in
BMD still obtained a reduction in vertebral fracture risk that was equal to those women
who gained BMD with treatment. Only those women who lost more than 4% of their
spine BMD despite complying with alendronate did not achieve a significant reduction in
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vertebral fracture risk. The 4% cut off in this study was equivalent to the LSC suggesting
that effective fracture reduction is achieved with alendronate even if there is no
significant change in BMD. Wasnich and Miller (2000) and Cummings et al (2002) also
reported reductions in vertebral fracture risk in women who did not experience an
increase in BMD although this was not found to be the case with non-vertebral fractures
by Hochberg et al (2002). It is generally agreed that with antiresorptive therapy BMD
should not reduce by more that the LSC. Therefore the aim of monitoring antiresorptive
therapy with BMD is to ensure BMD remains stable or increases.
With strontium ranelate BMD provides a convenient means of monitoring therapy as
BMD increases greatly with treatment resulting in a change of more than the LSC after
only 6-12 months. Changes in BMD correlate well with vertebral fracture reduction as
each percentage increase in BMD at the hip is associated with a 2-3% reduction in the
absolute risk of vertebral fracture (Bruyere et al 2007). In this study the change in BMD
after three years explained around 75% of the reduction in vertebral fracture risk
observed with treatment. Furthermore, a non-significant trend was found between the
incidence of new non-vertebral fractures and the 3 year change in femoral neck BMD (P
= 0.09) and total hip BMD (P = 0.07). In a subgroup analysis of 465 women aged over 74
years with a hip T score <-2.4 Bruyere et al (2007) found that, after 3 years treatment, for
each percentage increase in hip BMD the risk of hip fracture was decreased by 7% (p =
0.04).
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BMD changes with teriparatide are also associated with vertebral fracture reduction
although the magnitude is smaller. Chen et al (2006) reported that changes in spine BMD
accounted for 30-41% of the reduction in vertebral fracture risk. There is no data on the
association between BMD changes with teriparatide and non-vertebral fracture reduction.
Bone turnover markers (BTMs).
BTMs are products of bone turnover, which are either released from the activated bone
cells or from the breakdown or formation of type 1 collagen. Monitoring for changes in
BTMs provides an indirect in-vivo assessment of alterations in bone turnover in response
to therapy. There are 2 groups of BTMs. Bone formation markers are all measured in the
serum and include bone specific alkaline phosphatase (BSAP), osteocalcin, procollagen,
type 1 amino terminal propeptide (P1NP) and procollagen type 1 carboxy terminal
propeptide (P1CP). Bone resorption markers are mostly products of collagen degradation,
which are measured in the serum or urine. They include hydroxyproline, pyridinoline,
deoxypyridinoline (DPD), carboxy-terminal crosslinking telopeptide of type 1 collagen
(CTX), amino-terminal crosslinking telopeptide of type 1 collagen (NTX). BSAP, P1NP
and CTX are the markers used in this thesis so they are discussed in detail.
Alkaline phosphatase(AP) is produced by various tissues, including bone, liver, intestine,
kidney and placenta. Using techniques such as heat denaturation or electrophoresis it is
possible to identify and quantify the bone isoform of AP although there is up to 20%
cross-reactivity with liver AP making interpretation difficult in patients with liver
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disease. BSAP is a membrane bound enzyme expressed on the cell membrane of
activated osteoblasts, which is produced during bone formation. The precise function of
BSAP is not known although it is thought to be involved in osteoid formation and
mineralization (Seibel 2005). Serum BSAP can be measured by a variety of techniques
but for the studies contained in this thesis enzyme-linked immunosorbent assay (ELISA)
was used (Metra BAP, Quidel Corp, CA, USA). Using this method the normal range for
postmenopausal women is 14.2-42.7U/L with a CV of 8%.
P1NP is produced during the synthesis of type 1 collagen which makes up 90% of the
organic matrix of bone. Osteoblasts synthesize procollagen which is secreted into the
extracellular space where propeptidases cleave the terminal extension propeptides from
the amino and carboxy terminals of the procollagen molecule to produce the type 1
collagen molecule. The cleaved propeptides are released into the circulation as P1NP and
P1CP which are subsequently removed by the liver. This is illustrated in figure 3.2.
Although other tissues such as skin, fibrocartilage and tendons also contain type 1
collagen, P1NP is thought to provide a quantitative measure of type 1 collagen formation
in bone, as these other tissues are metabolically much less active than bone (Seibel 2005).
For the studies contained in this thesis electrochemiluminescence immunoassay was used
to measure P1NP (total P1NP, Roche diagnostics, IN, USA). P1NP undergoes rapid
thermodegradation in the blood from a trimeric to a monomeric structure. This technique
uses a monoclonal antibody to detect both fractions of P1NP and the normal range for
postmenopausal women is 30-78 μg/L with a CV of 4.5%.
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Figure 3.2: An illustration of the procollagen molecule demonstrating the terminal
extension propeptides prior to cleavage by propeptidases (Seibel 2005).
During the breakdown of type 1 collagen crosslinked telopeptides are released from the
carboxy (CTX) and amino (NTX) terminals of the collagen molecules. These molecules
can be detected in the serum or urine by a variety of methods and provide a measure of
bone resorption. For the studies contained in this thesis electrochemiluminescence
immunoassay was used to measure CTX in the serum (β-crosslaps, Roche diagnostics,
IN, USA). This method is specific for crosslinked isomerised telopeptides which include
a specific octapeptide containing beta-asparic acid (Asp(β)) (figure 3.3). Asparic acid
converts from its α form to its β form as bone ages thus the telopeptides identified using
this technique are specific for the degradation of the type 1 collagen dominant in bone.
This technique uses monoclonal antibodies, which recognise collagen telopeptides which
contain this octapeptide regardless of the nature of the crosslink. Using this method the
normal range for postmenopausal women is 0.10-1.01 µg/l with a CV of 7.6%.
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Figure 3.3: An illustration of the type 1 collagen molecule demonstrating the carboxy and
amino terminal telopeptides
Using bone turnover markers to monitoring therapy.
BTMs have two major advantages over BMD for monitoring therapy. Firstly there are
significant and detectable changes in BTMs within 3-6 months of treatment initiation
compared to BMD where 1-2 years are required for an increase greater than the LSC
(Delmas et al 2000). This allows a more rapid detection of poor responders and thus rapid
intervention to improve response. Secondly BMD measures changes in bone mass and
mineral density and therefore increases whether treatment is with an antiresorptive, an
anabolic agent or strontium ranelate. While this is useful to assess the treatment response
in clinical practice it provides the researcher with little information about the actual effect
the drug has on bone turnover. BTMs provide an in-vivo method of assessing the effect
of treatment on the rate of bone turnover as well as the relative changes in bone formation
and resorption (Meunier et al 2004).
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BTMs require careful consideration when used to monitor an individual patient’s
treatment response. It is useful, if not essential, to have a pre-treatment level of the BTM
to which a follow up measurement can be compared. It is also important to understand
the mechanism of action of the prescribed therapy in order to interpret the BTM changes
correctly. With bisphosphonates a reduction in BTM, which is greater than the LSC
demonstrates that bone resorption is being inhibited and treatment is having an effect on
bone turnover. The opposite is true of PTH therapy where an increase in BTMs of more
that the LSC suggests that bone is being formed and treatment effective. In general it is
preferable to measure an antiresorptive therapy with bone resorption markers (CTX)
while PTH therapy is best monitored with bone formation markers (P1NP) as these show
the earliest response to the respective therapy (Bonnick et al 2006, Girotra et al 2006).
This however is not essential as usually bone formation and resorption are coupled
leading to similar overall changes in both formation and resorption markers with therapy
(Seibel 2005).
With strontium ranelate, raloxifene and calcitonin the mean change in BTMs observed is
less than the LSC making it difficult to meaningfully assess an individual patient’s
treatment response with BTMs (Delmas 2000). However, BTMs are useful in clinical
trials of these therapies in order to assess the effects of these drugs on bone turnover
(Meunier et al 2004).
When using repeated BTM measurements to monitor therapy it is important to consider,
and where possible control for, several factors which influence the level of BTMs leading
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to an increase in CV. Careful handling of the samples with rapid transfer to the laboratory
for storage is necessary as BTMs are sensitive to thermodegradation and photolysis
(Delmas et al 2000). Furthermore, it is important to standardise the timing of sample
collection as BTMs demonstrate significant diurnal variation with high levels in the early
hours of the morning and low values during the afternoon/evening. Diurnal variation for
most markers is around 15-30% although diurnal variability is high for CTX (up to 66%)
and low for P1NP (6%) (Seibel 2005). Some BTMs, including serum CTX, are affected
by food intake therefore necessitating fasting blood samples while P1NP is not affected
by diet (Seibel 2005). Vigorous exercise can induce a short term increase in BTMs and as
such should be avoided prior to BTM measurement. BTMs are also affected by other
bone diseases such as Paget’s disease and malignancy. Most importantly for osteoporosis,
fractures are associated with an increase in BTMs, which may persist for 6 to 12 months
(Veitch et al 2006). Therefore BTMs are not reliable in women with a recent fracture and
a sudden unexpected increase in BTMs may reflect a subclinical vertebral fracture.
Do baseline bone turnover markers predict the response to treatment?
As BTMs reflect the rate of bone turnover it can be hypothesised that the level of pre-
treatment BTMs can be used to predict treatment response. The most logical case for this
is with antiresorptives. Women with high baseline bone turnover are likely to have a
greater remodelling space and therefore gain more bone mass when the remodelling
space is filled. This is consistent with reports that women with high BTMs have a greater
BMD response to calcitonin, HRT and bisphosphonates (Delmas 2000). Similar findings
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have been reported with anabolic agents. Chen et al (2005) demonstrated a significant
positive correlation between baseline P1NP or NTX and the change in lumbar spine
BMD at 18 months (r=0.41 and 0.40 respectively, p<0.05). Therefore baseline BTM level
does appear to be associated with the BMD response to these therapies.
Although baseline BTMs are associated with the BMD response to treatment, the
association with vertebral fracture risk reduction is less clear. With risedronate Seibel et
al (2004) reported that women with a high pre-treatment level of bone resorption, as
assessed by urinary deoxypyridinoline (DPD), experienced a similar reduction in risk of
vertebral fracture compared to those with a low baseline DPD after 1 (RR 0.28 vs. 0.33)
and 3 years (RR=0.52 vs. 0.54). However those women with high baseline DPD had a
greater incidence of vertebral fracture than those with low DPD. Therefore high baseline
DPD resulted in a greater reduction in absolute risk of fracture despite the similar
reduction in relative risk. This effect was more pronounced after the first year (absolute
risk reduction 7.1% vs. 4%) than after 3 years (absolute risk reduction 8.3% vs. 7.1%).
Eastell et al (2003) also studied risedronate and reported that the relationship between
baseline CTX or NTX level and vertebral fracture incidence was not significant after
correcting for BMD. More recently Bauer et al (2006) have reported that with
alendronate there was no significant association between baseline P1NP and relative risk
of vertebral fracture.
In contrast to the data for vertebral fractures, Bauer et al (2006) reported that women in
the highest tertile of baseline P1NP experience a significantly greater reduction in non-
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vertebral fracture risk with alendronate therapy than women in the lowest tertile (RR 0.54
vs. 0.88 respectively, p=0.03). A similar trend for non-vertebral fractures was also
observed with BSAP although it was not significant (RR 0.61 vs. 0.83 respectively,
p=0.17).
For anabolic therapy, Delmas et al (2006) reported that the reduction in the relative risk
of vertebral fracture achieved with teriparatide was independent of baseline BTM level.
However, again a greater reduction in absolute risk was observed in those with high pre-
treatment bone turnover. Overall it is currently uncertain whether baseline bone turnover
should influence either the choice of treatment or the subsequent response to therapy.
Short term changes in BTMs as a means of monitoring treatment efficacy.
As BTM changes occur soon after the initiation of therapy, there has been much interest
in whether short term changes in BTMs can predict the long term efficacy of therapy.
With antiresorptives a greater reduction in BTMs suggests a greater closure of the
remodelling space and therefore a better response to therapy. This is consistent with
reports that women with the greatest reduction in BTMs in response to HRT or
bisphosphonates experience the greatest gain in BMD after 2 years (Delmas 2000).
Likewise with anabolic agents a greater increase in BTMs suggests more bone formation
and better treatment efficacy. Chen et al (2005) reported significant positive correlations
between the change in PICP at 1 month / PINP at 3 months and the change in spine BMD
at 18 months (r=0.65 and 0.61 respectively; p< 0.05). Given the relationship between
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BTM and BMD changes it is possible to define a minimum change in BTM which
predicts that an individual woman will have a significant increase in her BMD. For
antiresorptives using cut-offs of a 40-55% reduction in serum CTX or a 30-40%
reduction in BSAP predicts a significant (>3%) increase in BMD with 90% specificity
(Delmas 2000). For teriparatide if a woman has an increase in P1NP at 3 months of
17.2ng/ml or more then she has a 88% probability of achieving a >3% increase in spinal
BMD at 18 months (Chen et al 2005).
As well as predicting the BMD response, it is also important that short term BTM
changes are associated with a significant reduction in fracture risk with therapy. Eastell et
al (2003) reported a significant non-linear relationship between 3-6 month change in
CTX and the incidence of vertebral and non-vertebral fractures over 1 and 3 years. Up to
a point, the greater the percentage reduction in CTX at 3-6 months the lower the risk of
incident fracture. However, reducing CTX by more than 55-60% from baseline did not
result in further reduction in fracture incidence. Similar findings were also reported with
alendronate by Bauer et al (2004). In this study those alendronate treated women who
achieved the greatest percentage reduction in BSAP at 1 year had the lowest risk of
fracture. For each standard deviation reduction in BSAP the incidence of spine, non-
vertebral and hip fracture was reduced by 26%, 11% and 39% respectively. In contrast to
Eastell et al (2003) the relationship was linear with no plateauing of effect. Change in
P1NP and serum CTX was also associated with reductions in vertebral fracture incidence
although the trend was not significant for non-vertebral or hip fracture (Bauer et al 2004).
Therefore it does appear that for bisphosphonates short term changes in BTMs can be
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used to assess the anti-fracture efficacy of therapy although the optimum level of
suppression has not yet been determined. There is no data to date regarding the
relationship between BTM changes and fracture incidence for anabolic agents.
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Introduction summary, the treatment of postmenopausal osteoporosis.
Women identified as being at risk according to the Royal College of Physicians guidelines on
osteoporosis case finding because of: history of low trauma fracture, vertebral fracture on x-ray,
height loss, current steroid use, family history of osteoporosis in a first degree relative or a medical
condition predisposing to osteoporosis (e.g coeliac disease, thyroid disease).
BMD measured at spine and hip. Patient fracture risk assessed based on BMD and, if
present, BMD independent risk factors (age, history of fracture, current steroid use,
current smoking and alcohol more than 2 units per day).
Low risk / normal
BMD, reassure.
Intermediate risk / osteopenia, life
style advice, consider calcium and
vitamin D supplementation.
High risk / osteoporosis, life
style advice, calcium and
vitamin D supplements
1st line treatment: Bisphosphonates
Intolerant
Fracture
2nd line treatments: Strontium


















Routine versus targeted vertebral fracture assessment
for the detection of vertebral fractures
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Introduction.
Vertebral fractures are the commonest osteoporotic fractures and are often considered the
hallmark of osteoporosis. As discussed in chapter 1.2, vertebral fractures predict future
vertebral, non-vertebral and hip fractures independent of BMD (Lindsey et al 2001,
Ismail et al 2001) making the knowledge of vertebral fracture status important when
assessing fracture risk. Two thirds of women with vertebral fractures are unaware of them
(Melton et al 1993) and in these women their future fracture risk will be substantially
underestimated which may lead to the inappropriate withholding of treatment.
The only way to detect these asymptomatic vertebral fractures is radiologically. Modern
DXA scanners are able to perform a Vertebral Fracture Assessment (VFA) of the spine
which can detect vertebral fractures with a high degree of sensitivity and specificity (Rea
et al 2000b, Binkley et al 2005, Chapurlat et al 2006). Compared to spinal x-rays, VFA
has the advantages of being less expensive, having a lower radiation dose and being
performed at the same time as DXA (Rea et al 2000). This makes VFA a potential
screening tool which can be performed on women attending for DXA.
This study compares two different VFA screening strategies used at our centre: screening
all women (routine VFA screening) and screening only those women with reasons to
suspect a prevalent vertebral fracture (targeted VFA screening). We hypothesize that
attempting to target VFA results in large numbers of women with fractures being
excluded from the screening program. We also examine the merits of routinely screening
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Since 2001 all patients attending for bone densitometry at the Centre for Metabolic Bone
Disease in Hull have had spine and hip BMD measured using a Lunar Prodigy bone
densitometer (GE Lunar, Madison, WI) which has VFA capability. Vertebral fracture
screening using VFA was initially targeted only at women with reasons to suspect a
possible fracture. Indications for a targeted VFA were reported height loss (>2.5cm, 1
inch), Dowager hump, suspected fracture on anterior-posterior spine DXA and known
vertebral fracture. In August 2005 our Centre changed to a routine screening program
under which all women who attended for DXA underwent VFA if they were over 65 and
physically able to do so. The BMD and VFA results along with basic patient details,
including age, sex, gender and menopause age, are routinely recorded on the Prodigy’s
database at the time of attendance. Using this database we identified all women over the
age of 65 at the time of their first DXA scan. Depending on the screening policy at the
time of attendance, women were identified as either the targeted screening group (pre-
August 2005) or the routine screening group (post-August 2005).
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Vertebral Fracture Assessment.
Our Centre has 3 Lunar Prodigy bone densitometers with VFA capability. The scanners
are subject to a rigorous quality assurance procedure which includes weekly scanning of
a purpose designed phantom for VFA (Steel et al 1999). The scans are performed and
analysed by qualified, experienced bone densitometrists following standardised protocols.
Women initially undergo a standard anterior-posterior DXA assessment of the spine and
femur in the supine position. If a VFA is to be performed then the woman is repositioned
into the left lateral decubitus position. The scanner is then passed over the whole of the
spine in order to obtain a view of the spine in the sagittal plane. A single energy x-ray
display is used for analysis of the VFA. Initially, T4-L4 are assessed by the
densitometrist for fractures using the semi-quantitative method described by Genant et al
(1993). Any vertebrae which are considered to be fractured subsequently undergo a six
point quantitative assessment using the Prodigy computer software to measure the
posterior, middle and anterior vertebral height. Fractures are graded as mild (grade 1),
moderate (grade 2) or severe (grade 3) if there is a 20-25%, 25-40% or greater than 40%
reduction in vertebral height respectively. VFA has been demonstrated to correlate well
with spinal x-ray for grade 2 and 3 fractures (Rea et al 2000, Rea et al 2000b, Binkley et
al 2005) as such these fractures are identified. 50% of mild fractures detected by VFA are
normal on x-ray (Binkley et al 2005) and therefore, grade 1 fractures are not identified.
The VFA and DXA scans are then validated by a clinical scientist specialised in bone
densitometry before the data is finally entered into the database. A final report to the
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women’s general practitioner is issued by an osteoporosis consultant who may also
review the VFA qualitatively but this report is not recorded on the database.
Analysis.
Basic population demographics were determined for the targeted screening group and the
routine screening group and then were compared using 2 sample t-test (with the
appropriate assumption of variance) or the Mann-Whitney U test depending on the
distribution of the data. Chi-square was used for categorical data. The routine screening
group was used to determine the prevalence, type and site of vertebral fractures in our
local population. Using this prevalence data, the number of women with vertebral
fractures that remained undetected by targeted screening was estimated.
The routine and targeted screening groups were then divided by hip BMD at the neck of
femur (NOF) into normal, osteopenic or osteoporotic. Hip BMD was used to define BMD
category as this avoids the artefactual increase in spine BMD due to vertebral fracture
and is the recommended site for the diagnosis of osteoporosis (Kanis and Gluer 2000).
Using this data we determined the number of osteopenic women in whom the knowledge
of vertebral fracture status may influence the treatment decision. Finally, the number of
women with vertebral fractures that remained undetected by targeted screening for each
category of BMD was estimated. Statistical analysis was performed using SPSS for
Windows (version 14.0 SPSS, Inc., Chicago, IL). The data collection and analysis was
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performed as part of a service review at our centre and therefore ethic approval was not
required although permission was obtained from the local audit committee.
Results.
Subjects.
A total of 8564 women over the age of 65 when attending for their first DXA were
identified. 6388 attended during the period of targeted VFA while 2176 women attended
during the routine screening period. The routine screening group were slightly, but
significantly, older (mean age 74.3 vs.72.5 years). The routine screening group also had a
slightly older menopause age, lower hip BMD and higher spine BMD. Although these
differences were statistically significant, the absolute differences between the groups for
these characteristics were all less than 2.5%. Subject demographics are demonstrated in
table 4.1.
Routine VFA screening for the detection of vertebral fractures.
Of the 2176 women attending during the period of routine screening, 2098 (96.4%)
women underwent VFA. Grade 2 and 3 vertebral fractures were identified in a total of
420 women (19.3% of the population, 20.0% of VFAs) of whom 185 (44.0%) had 2 or
more vertebral fractures (Table 4.2). Routine screening detected a total of 755 grade 2
and 3 vertebral fractures. Wedge and biconcave fractures were more frequent than
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compression fractures. Table 4.3 demonstrates the frequency of each type of vertebral
fracture. Vertebral fractures were commonest around T7 to T9 and the thoracolumbar
junction, T11-L1. Figure 4.1 shows the frequency of fracture at each vertebral level.





Difference test equal p
valueused variance
Age (yrs) 72.5 (5.9) 74.3 (6.1) 1.8 (2.5%) u na <0.001
Caucasian (%) 99.4 99.5 0.1 (0.1%) chi na 0.34
Menopause
age (yrs) 46.9 (5.9) 47.6 (6.0) 0.7 (1.5%) t y <0.001
Weight (kg) 65.0 (12.8) 65.6 (14.0) 0.6 (0.9%) t n 0.073
NOF BMD
(g/cm2) 0.784 (0.1) 0.776 (0.1)
-0.008
(1.0%) t y 0.017
Spine BMD
(g/cm2) 1.021 (0.2) 1.035 (0.2)
0.014
(1.4%) t y 0.006
Numbers represent mean (sd) or %. NOF = neck of femur
t = 2 sample t test, Chi= chi squared, u = Mann Whitney U test, na = not applicable

















Table 4.3): Type and severity of vertebral fractures detected in women undergoing
routine VFA
Moderate Severe Overall
n % n % %
Wedge 110 14.6 191 25.3 39.9
Biconcave 142 18.8 222 29.4 48.2
Compression 51 6.8 39 5.2 11.9
Total 303 40.1 452 59.9
Figure 4.1: Number of fractures detected at each vertebral level in women undergoing
routine VFA.
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Targeted VFA screening for the detection of vertebral fractures.
Of the 6388 women in the targeted group, a total of 332 (5.2%) underwent VFA resulting
in the detection of 122 women with grade 2 or 3 vertebral fractures. Targeted screening
resulted in a higher detection rate per VFA performed (36.7%) although only 1.9% of the
total population attending for DXA had vertebral fractures detected. If it is assumed that
the overall vertebral fracture prevalence rate was similar between the 2 groups then 1277
women in the targeted group would have been expected to have one or more prevalent
vertebral fractures on VFA. Only 122 (9.6%) of these women with fractures were
detected by targeted screening leaving undetected vertebral fractures in an estimated
1,155 women, 18.1% of the population attending for DXA.
Vertebral fracture detection by category of BMD
In the targeted and routine VFA groups similar proportions of women were in the 3
categories of hip BMD: normal (29.7 vs. 28.7%, p=0.37), osteopenia (55.1 vs. 55.6%,
p=0.70) and osteoporosis (15.2 vs. 16.6%, p=0.10). In the routine screening group, 300 of
the 420 (71.4%) women with prevalent vertebral fractures did not have BMD compatible
with osteoporosis. The majority of fractures occurred in women with osteopenia
(236/420, 56.2%). In the routine screening group the prevalence of vertebral fractures
was 10.3% in those women with normal BMD, 19.9% in osteopenic women and 33.2% in
those with osteoporosis (Table 4.4). For the 420 women with fractures detected on VFA a
history of known vertebral fracture was obtained from 8/64 (12.5%) of women with
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normal BMD, 53/236 (22.5%) of osteopenic women and 34/120 (28.3%) of osteoporotic
women. In total only 95 out of the 420 (22.6%) women with a vertebral fracture were
aware of the fracture prior to VFA.









(%) n % n % mean range
Targeted
Normal
(29.7%) 74 3.90 24 1.27 1.67 1 to 5
Osteopenia
(55.1%) 184 5.22 60 1.70 1.55 1 to 6
Osteoporosis
(15.2%) 74 7.64 38 3.92 2.32 1 to 7
Total 332 122 221
Routine
Normal
(28.7%) 597 95.67 64 10.26 1.34 1 to 4
Osteopenia
(55.6%) 1159 97.48 236 19.85 1.75 1 to 7
Osteoporosis
(16.6%) 341 94.20 120 33.15 2.13 1 to 9
Total 2097b 420 755
a BMD category relates to BMD at NOF. Spine BMD is used in cases with no data for
NOF BMD (n=207).
b 1 woman was unable to lie supine for axial BMD although a VFA was obtained.
In the targeted screening group vertebral fractures were detected in 1.3%, 1.7% and 3.9%
of the normal, osteopenic and osteoporotic women respectively. If it is again assumed
that the actual prevalence of vertebral fracture was similar between the two groups, then
targeted screening underestimated vertebral fracture prevalence in each BMD category.
The proportion of women with undiagnosed vertebral fractures increased with decreasing
BMD: 9% of women with normal BMD, 18% with osteopenia and 29% with osteoporosis
(Table 4.5).
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n=1897 195 24 171 9
Osteopenia,
n=3522 699 60 639 18
Osteoporosis,
n=969 321 38 283 29
* Estimate derived from the prevalence of vertebral fractures in the routine screening
group.
Discussion
We report the actual application of VFA as a screening tool for the detection of vertebral
fractures in women over 65 referred for bone densitometry. To our knowledge, this is the
largest study of routine population screening with VFA and there are no previous studies
comparing routine and targeted screening methods. Vertebral fractures are common and
knowledge of vertebral fracture status provides important information for assessing
fracture risk (Ismail et al 2001). However, despite their high prevalence and clinical
relevance only one third of women with vertebral fractures are aware of them (Melton et
al 1993). This suggests that there is a need for screening for vertebral fractures. Although
thoracic and lumbar spine x-rays are the gold standard for vertebral fracture detection,
VFA provides a more practical screening tool as it is available at the point of service for
women attending for DXA. Furthermore it has a lower cost and the radiation dose of
132
VFA (<0.02 millisieverts (mSv)) is a fraction of the radiation dose of conventional spine
radiographs (2-3 mSv) (Rea et al 2000).
When used routinely, over 95% of women were willing and physically able to undergo
VFA at our centre demonstrating that the procedure was acceptable for most women.
Overall, routine screening of all women over 65 identified one woman with grade 2 or 3
vertebral fractures for every 5 VFAs (20%) performed and almost half of these women
had multiple fractures. The majority of fractures detected by routine screening occurred
in the mid thoracic region and thoracolumbar junction which is consistent with previous
reports using both x-ray (Genant et al 1993, Genant et al 1996) and VFA (Rea et al 2000,
Chapurlat et al 2006). As with previous reports, the majority of fractures detected were
wedge or biconcave (Rea et al 1999, Rea et al 2000b) although we found biconcave
fractures to be the most common.
As would be expected, when women were divided up by BMD category, the number of
women with vertebral fractures detected by routine screening increased as BMD
decreased. VFA is performed after axial DXA and as such it would be possible to
perform routine VFA screening only in women with certain categories of BMD.
Adopting a policy of routine VFA screening for women over 65 only if they have
osteoporosis on their axial DXA would require VFA to be performed in only 16% of
women and would increase the rate of vertebral fracture detection to 1 in 3 women
screened. Routine VFA in this BMD category would also allow the identification of
women with the highest risk of future facture i.e. both osteoporosis and prevalent
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vertebral fractures. However, adopting this policy would miss the majority of women
with vertebral fractures as 71% of the women with vertebral fractures detected by routine
screening did not have BMD compatible with osteoporosis. This confirms the findings of
2 smaller studies in which 60-70% of women with vertebral fractures did not have
osteoporosis (Greenspan et al 2001, Schousboe et al 2002). Furthermore, knowledge of
vertebral fracture status in osteoporotic women is less likely to alter the patient’s
management as, over the age of 65, the majority of these women would receive treatment
anyway.
Vertebral fractures may have more significant therapeutic implications in women without
osteoporosis. Osteopenic women would not normally be considered for bone protective
treatment based on BMD alone. The presence of a vertebral fracture would increase the
risk of subsequent fracture making treatment appropriate. We found that 20% (1 in 5) of
osteopenic women had vertebral fractures detected by VFA. A similar 14-20% fracture
prevalence in osteopenic women has been reported although direct comparison is difficult
as these studies included grade 1 fractures and women less than 65 years of age
(Greenspan et al 2001, Schousboe et al 2002). Only 22.5% of osteopenic women with a
fracture on VFA gave a history of known vertebral fracture. Therefore, vertebral fractures
were identified for the first time in 15.8% of osteopenic women. This suggests that
routine VFA may directly alter the management of around 1 in 6 osteopenic women. It
has been demonstrated that antiresorptive therapy is effective at reducing the risk of
future fracture in women with osteopenia if they have a vertebral fracture (Kanis et al
2005, Quandt et al 2005) and a recent analysis suggests that this treatment is cost
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effective (Schousboe et al 2006). Osteopenic women are most likely to benefit from
routine screening with VFA given the high prevalence rate, the therapeutic and clinical
implications of a vertebral fracture and the cost effectiveness of treatment.
10% of women in our population with normal BMD had vertebral fractures which is
again similar to previous reports (Greenspan et al 2001, Schousboe et al 2002). There is
little evidence to suggest that bone protective treatment is of benefit or cost effective in
women with normal BMD. As such the clinical relevance of finding vertebral fractures
in women with normal BMD is less clear and the case for routine VFA in these women is
weaker.
In addition to affecting the initial treatment decision, routine screening may also aid
monitoring and future treatment decisions as it provides a pre-treatment image of the
spine. This is a reference for the future from which incident fractures occurring despite
treatment can be diagnosed. Osteoporotic women have the highest incidence of vertebral
fracture (Kanis et al 2005) and as such routine VFA in osteoporotic women will provide
valuable baseline information even though it may not effect the initial treatment decision.
Incident fractures are especially important in countries like the United Kingdom where
anabolic bone agents, such as teriparatide, can only be prescribed to women who have
been proven to suffer further fractures despite antiresorptive therapy.
We also report the outcomes of a targeted vertebral fracture screening policy for which
only women with reasons to suspect the presence of a fracture undergo a VFA. Adopting
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this approach to screening women over 65 greatly reduced the number of VFAs
performed as only 5% of the population underwent screening. With a targeted approach 1
in 3 women undergoing VFA had vertebral fractures detected compared to 1 in 5 with
routine screening. However, using the targeted approach to screening, only around 10%
of women with fractures were detected which confirms our hypothesis. Of all the women
referred for DXA during the period of targeted VFA, 18% are estimated to have had
vertebral fractures, which remained undetected. The proportion of women with vertebral
fractures which remain undetected increased to almost a third in women with
osteoporosis. We therefore do not consider our targeted screening policy to have been
effective.
The data for the targeted screening group were calculated using the assumption that the
vertebral fracture prevalence was the same during the two screening periods. There are 2
potential problems with this assumption. Firstly there were statistically significant
differences between the groups in terms of age and BMD, which are risk factors for
vertebral fracture. These differences may have arisen due to the non-randomised nature
of this study. However, the women were drawn from the same local population, from the
same age group, and the difference in these factors were all less than 2.5%, thus unlikely
to be of clinical significance or have a major effect on fracture prevalence. Secondly, this
study compares 2 different time periods and if there was a secular trend towards an
increased vertebral fracture incidence then this would lead to an overestimation of the
number of fractures missed by targeted VFA screening. However, the overall period of
time studied is only 7 years so any effect due to a secular trend should be small. In order
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to test the assumption that the vertebral fracture prevalence was the same during the two
screening periods it would have been interesting to apply the criteria for targeted
screening to the routine VFA group. If this lead to similar numbers of women with
fractures being missed then this would confirm that the assumption was valid.
Unfortunately some of the criteria for targeted screening were not on the database so this
analysis was not possible.
The women underwent screening as part of normal clinical practice, which, combined
with the large number of women involved, means that it was not possible to confirm the
VFA findings with spinal x-rays. However, our screening program only identifies grade 2
and 3 fractures. When compared to x-ray, VFA has been reported to have a sensitivity of
80-95% for detecting grade 2 and 3 fractures and a specificity of 82-96% for excluding
vertebral fractures (Rea et al 2000b, Binkley et al 2005, Schousboe and Debold 2006).
Therefore, we believe that the majority of grade 2 and 3 fractures we detected were
identified correctly. Our approach to screening is consistent with a recent position paper
by the International Society of Clinical Densitometry which recommends that only grade
2 and 3 fractures should be identified by VFA (Laster et al 2007).
It is well recognised that some vertebrae are uninterpretable on VFA. This can be due to
poor image quality, which most frequently occurs above T7, or due to the presence of
severe scoliosis or degenerative changes although similar limitations are recognised with
x-ray (Laster et al 2007). Previous studies report that around 90-95% of vertebrae are
interpretable (Rea et al 2000b, Schousboe and Debold 2006). The majority of
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uninterpretable vertebrae occur above T7 (Schousboe et al 2002, Binkley et al 2005)
where the prevalence of fracture is low which preserves the negative predictive value of
VFA (Chapurlat et al 2006). On our database any fractures which occurred in an
uninterpretable vertebra would not have been labelled as fractured which may have
reduced the number of fractures we detected. This has less of an impact when
categorising women, rather than individual vertebrae, as fracture or non-fracture cases.
Women with fractures in uninterpretable vertebrae would still be correctly classified if
they also had a fracture in an interpretable vertebra. At our centre, the final report issued
by the osteoporosis consultant provides an opportunity to recommend x-rays in women
with uninterpretable VFAs although this data is not available on our database.
With our screening program grade 1 fractures are not routinely identified and flagged.
Previous studies have demonstrated that around one third of vertebral fractures are grade
1 fractures (Rea et al 1999, Rea et al 2000b) and as such this approach reduces our
apparent yield from screening. This is reflected in our 20% vertebral fracture prevalence,
which is lower than the 33% prevalence on x-ray reported by Genant et al (1996) who
included grade 1 fractures. However, this is compensated for by the increased accuracy of
our screening method. Including grade 1 fractures in VFA reduces the sensitivity from
80-95% to 50-70% (Rea et al 2000b, Schousboe and Debold 2006). This is in part
because of difficulties in differentiating mild fractures from degenerative vertebral
remodelling due to the lower resolution of VFA. The impact of this is minimised by our
exclusion of grade 1 fractures. Grade 1 fractures may have less clinical significance.
Although there is an increased risk of subsequent fracture in women with grade 1
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fractures, the incidence is lower than in women with grade 2 and 3 fractures (Gallagher et
al 2005). Furthermore grade 1 fractures are associated with less morbidity (Crans et al
2004). Again, when the VFAs and DXA scans undergo their final report by the
osteoporosis consultant, possible grade 1 fractures may be identified and an x-ray
recommended but this data is not available.
We report the results of two screening programs actually used as part of normal clinical
practice at our centre involving a large number of women referred for routine bone
densitometry. Despite these strengths there are certain limitations. We have already
discussed the lack of x-ray confirmation of fracture, the differences between the 2 groups
and that some fractures may have remained undetected if they occurred in uninterpretable
vertebrae or were grade 1. Our results are only applicable to women over the age of 65.
VFA screening of men or younger women would be expected to result in a lower yield as
the prevalence of vertebral fracture is lower. Furthermore, we only targeted women with
reasons to believe that a fracture was actually present. If our targeted screening program
had also included women with risk factors for vertebral fracture, such as steroid use or
prior non-vertebral fracture, then more women would have undergone VFA and a greater
proportion of the women with fractures may have been detected.
Although spinal x-rays remain the gold standard for vertebral fracture detection and
differentiation, VFA is a more practical screening tool for the detection of women with
grade 2 and 3 fractures. This study demonstrates that routine screening results in the
detection of one woman with vertebral fractures for every 5 VFAs performed. The
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majority of women with fractures have osteopenia on their axial DXA and in these
women the knowledge of their fractures status may directly effect their treatment. As well
as potentially effecting the initial treatment decision, routine VFA allows better
assessment of fracture risk, provides a baseline record of fracture status and can indicate
the need for spinal x-rays in women with possible grade 1 fractures or uninterpretable
VFA. This study also demonstrates that targeted screening greatly reduces the number of
VFAs performed however this results in only around 10% of women with fractures being
selected for screening. For women over 65 who are referred for a DXA scan, routine
screening for vertebral fractures with VFA is more effective than targeted screening.
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Chapter 5:
The effects of short term Hormone Replacement Therapy on
long term bone mineral density.
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Introduction.
Previously HRT was the cornerstone of treatment for postmenopausal osteoporosis.
However, as discussed in chapter 2.1.1, the WHI study demonstrated an increased risk of
breast cancer and cardiovascular events with long term HRT use (Rossouw et al 2002).
This resulted in long term HRT no longer being considered an appropriate treatment
option for osteoporosis. Bisphosphonates are now first line therapy and it is
recommended by the MHRA that HRT is only used in the short term around the time of
the menopause for the relief of menopausal symptoms.
Bisphosphonates are effective treatments for osteoporosis but lately concerns have been
expressed regarding the efficacy and safety of the long term suppression of bone turnover
with bisphosphonates (Ott 2005). If there are concerns about long term bisphosphonate
use, how should we treat osteoporotic women in their 50’s who potentially require 30-40
years of treatment? HRT does not have the same prolonged effects on bone turnover as
bisphosphonates (Greenspan et al 2002) so one option may be to initially use a short
course of HRT.
With short term HRT BMD would be expected to increase during treatment but upon
discontinuation BMD will be lost. It is not known whether this loss of BMD will reduce
BMD to the same level as those women who do not take short term HRT or whether there
is an overall benefit compared to no treatment. In this study we test our hypothesis that
women who take short term HRT around the time of the menopause will have long term




In the 1990’s the Centre for Metabolic Bone Disease at Hull Royal Infirmary commenced
a feasibility study to investigate the logistics of population screening for osteoporosis
(Purdie et al 1996). All women in the local area aged 50-54 were invited by letter for a
BMD assessment by DXA of the spine and hip using a Lunar DPX-L densitometer (GE
Lunar, Madison, WI). The only exclusions from screening were terminal illness, weight
in excess of 125 Kg and physical inability to comply with the standard DXA scanning
technique. At baseline informed consent was obtained and data was collected regarding
menopause age, medical conditions, family history, smoking status, fractures and
medications.
Treatment.
As this study commenced prior to the WHO definition of osteoporosis, women were
deemed “at risk” if their BMD was in the lowest quartile for their age matched
population. These women were recommended for treatment with HRT, the bone
protective treatment of choice at the time for the early post-menopausal period. The
subject’s general practitioner made the final choice of HRT preparation from a list of
HRT regimes then known to be osteoprotective. Thus, treatment regimes contained either
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2mg oestradiol, 0.625mg conjugated equine oestrogen or a 50 μg transdermal patch.
Progestogens were prescribed to women with a uterus.
Follow up.
Those women considered at risk, and an equal number of randomly selected women not
recommended for treatment, were invited back for repeat assessment 2, 5 and 9 years
later. Patients were free to stop or change therapy under the guidance of their GP in
between visits. Patients were blinded to the 2 years scan results. As such, those
discontinuing HRT early did so due to intolerance rather than BMD changes. At each
follow up visit a medical history was taken documenting general health, medications
(including HRT) and clinical fractures. A repeat DXA was performed using the same
DXA machine as for the baseline visit. All details were recorded on the database at our
Centre.
Subjects for present analysis.
The present analysis included all women who were followed up for 9 years after the
screening program. From the database, we identified all women who could be allocated
to one of 3 groups: those who took no HRT; those who took 24 to 48 months of HRT
prior to the 5 year visit with no subsequent HRT use (short term HRT group); and those
who took at least 8.5 years HRT during the 9 year follow up period (long term HRT
group). The duration of treatment chosen for the short term HRT group was selected to
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represent patients who had received HRT for enough time to be able to detect a change in
BMD (2 years) but less than the time taken for the incidence of breast cancer to
differentiate from placebo in the WHI study (Rossouw et al 2002). The only exclusion
criteria were the use of bisphosphonates or raloxifene before or during the follow up
period and not meeting the above HRT treatment group requirements. Calcium
supplementation was permitted.
The primary end point was the difference in BMD after 9 years at the spine (L2-4) and
hip (neck of femur (NOF)) in the no HRT group compared to the short term HRT group.
The primary analysis was carried out on these 2 groups only as long term HRT is no
longer recommended and the aim of the study was to compare short term HRT to no
treatment. Secondary end points were change in BMD over 9 years within each group
and fracture rates in the no HRT and short term HRT groups.
The local ethics committee approved both the original screening program and the present
analysis of the 9 year data. As this study was a reanalysis of an existing database and
required no patient contact or access to the medical records the ethics committee deemed
that it was not necessary to re-consent the subjects.
Statistical analysis.
Baseline characteristic were analysed using a one way analysis of variance (ANOVA) for
continuous data and Pearson’s χ
2 test for categorical data. Means within groups were
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compared using a paired t-test. A Multivariate General linear model adjusted by
covariates (Multivariate ANCOVA) was used to examine the effect of treatment after 9
years follow-up on the dependent variables and to obtain adjusted means; the dependent
variables were Spine BMD and NOF BMD measured after 9 years follow-up, covariates
were Spine BMD and NOF BMD at baseline. A Fisher exact test was performed to test
the association between Fractures and HRT. The significance level chosen was 0.05. The
program package used was SPSS for Windows (version 12.5 SPSS, Inc., Chicago, IL).
Results.
1303 women were on the database and had been followed up for 9 years. 125 women
were excluded due to bisphosphonate or raloxifene use. Of the remaining 1178 women, a
further 591 women were excluded due to HRT use incompatible with the required
groups. 587 (49.8%) women could be allocated to one of the 3 groups: 340 no HRT
(57.9%); 60 Short term HRT (10.2%); and 187 Long term HRT (31.9%). Baseline
characteristics of each group are shown in table 5.1. The mean (sd) duration of HRT use
was 34.7 (8.5) months in the Short term HRT group and 107.4 (2.3) months in the Long
term HRT group.
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Age (yrs) 52.5 (1.4) 52.5 (1.33) 52.3 (1.4) 0.50
Weight (kg) 67.1 (10.6) 63.5 (9.6) 61.8 (9.8) <0.001
Menopause age (yrs) 49.3 (4.7) 49.1 (3.6) 47.3 (4.7) < 0.001
Family history (%) 38 (11.2) 15 (25) 30 (16) 0.06
Current smoking (%) 98 (28.8) 23 (38.3) 69 (36.9) 0.098
Alcohol (u/week) 2.4 (3.5) 2 (3) 2.3 (3.3) 0.72
BMD spine (g/cm2) 1.114 (0.16) 1.059 (0.12) 1.002 (0.12) <0.001
BMD NOF (g/cm2) 0.893 (0.11) 0.836 (0.09) 0.820 (0.09) <0.001
Values are expressed as mean (sd) or n (%).
Within group analysis.
The absolute 9 year change in BMD in each group is shown in table 5.2 and the
percentage change from baseline at each visit is shown in figures 5.1 and 5.2. Over the 9
year period those treated with long term HRT sustained a significant increase in BMD at
the spine (+8.0%, p<0.001) and hip (+2.4%, p<0.001). Those not taking HRT lost a
significant amount of BMD at the spine (-3.5%, p<0.001) and hip (-4.2%, p<0.001).
Despite a downward trend, the short term HRT group had no significant change in BMD
over the 9 years at the spine (-1.4%, p=0.18) or hip (-1.6%, p= 0.08). There was no
significant difference in weight gain between the 3 groups to confound the measurement
of BMD (no HRT +3.6kg, Short term HRT +3.8 kg and Long term HRT +3.6kg,
p=0.97).
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BMD spine (g/cm2) BMD NOF (g/cm2)
Year 1 1.114 1.059 1.002 0.893 0.836 0.820
Year 9 1.075 1.044 1.084 0.856 0.822 0.840
Mean change -0.039 -0.015 0.081 -0.037 -0.013 0.020
Percentage
change -3.5% -1.4% 8.0% -4.2% -1.6% 2.4%
p Value <0.001 0.18 <0.001 <0.001 0.08 <0.001
Figure 5.1: Mean ± standard error percentage change from baseline in BMD at the spine
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Figure 5.2: Mean ± standard error percentage change from baseline in BMD at the neck
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Between group analysis.
The BMD in the No HRT group and the Short term HRT group were compared after
adjusting for the difference in baseline BMD. At 9 years, those women taking short term
HRT had a significantly higher spinal BMD than those taking No HRT (adjusted BMD:
1.091 g/cm2 vs. 1.068 g/cm2, p = 0.048). The hip (NOF) BMD was also significantly
higher in the short term HRT group (0.865 g/cm2vs. 0.849 g/cm2, p=0.042).
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Fractures.
All fracture types were grouped together for analysis as the sample populations were too
small to allow specific fractures sites to be compared. In the No HRT group 54 (15.9%)
women suffered a total of 64 fractures compared to 6 (10.0%) women suffering a total of
7 fractures in the short term HRT group. Over the 9 year period, the short term HRT
group had a reduced risk of fracture compared to the No HRT group although this was
not statistically significant (RR = 0.63, p=0.33).
Discussion.
The WHI study confirmed the bone protective effects of HRT however this was offset by
an increase in vascular events and breast cancer (Rossouw et al 2002). The increase in
breast cancer did not occur until after 4 years of treatment and hence HRT is still licensed
for short term use for the relief of menopausal symptoms. The present study suggests that
women who take between 2 and 4 years of HRT in the early postmenopausal period have
a prolonged benefit in terms of BMD, as 4 to 5 years after discontinuing HRT they had a
higher BMD than the non-users. Furthermore, over 9 years there was no significant loss
of BMD in short term HRT users. It therefore appears that our hypothesis was correct.
This study also suggested that, compared to non-users of HRT, short term HRT users
may have a lower risk of fracture. The study was underpowered to detect a difference in
fractures and as such this reduction did not reach significance however the reduction in
fracture risk observed does support the findings of an earlier study which demonstrated
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that short term HRT reduced the risk of fracture in early postmenopausal women by 52%
(Bagger et al 2004).
Short term HRT may have a role to play in the overall treatment strategy for women with
low BMD during the early postmenopausal period. Recently concerns have been raised
regarding the long term safety and efficacy of bisphosphonates (Ott 2005). The 10 year
data for alendronate from the FLEX trial suggests that there are no benefits in continuing
treatment beyond 5 years in terms of non-vertebral fractures or morphometric vertebral
fractures (Black et al 2006). A smaller 10 year study also demonstrated that stopping
alendronate at 5 years resulted in little difference in terms of vertebral fracture compared
to continuing alendronate (Bone et al 2004). Of more concern is the possibility of harm
due to long term bisphosphonate use. Osteonecrosis of the mandible has been repeatedly
reported although predominantly with high dose bisphosphonates used for bone related
malignancy (Migliorati et al 2006, Woo et al 2006). A recent paper reported a series of
patients with low trauma fractures occurring after long term bisphosphonates who had
severely suppressed bone turnover on bone biopsy (Odvina et al 2005). Animal models
also demonstrate microdamage accumulation with long term bisphosphonate exposure
(Mashiba et al 2001). If there are concerns about long term bisphosphonate use, what
treatment should be offered to women with low BMD in their 50s who have, or are at risk
of developing, osteoporosis and therefore require a treatment strategy for the next 30-40
years? BMD will continue to decline if treatment is delayed, as in the No HRT group in
this study. Raloxifene could be used if the site of concern is the spine but this could
exacerbate the menopausal symptoms common in the early postmenopausal period and
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has no proven benefits in terms of non-vertebral fractures (Ettinger et al 1999). Our study
suggests that short term HRT in the early menopausal period may provide both relief of
menopausal symptoms and preservation of BMD, thus allowing bisphosphonate therapy
to be delayed.
Only 1 previous study by Bagger et al (2004) has examined the effects of short term HRT
in the early menopausal period. As in the present study, those women treated with short
term HRT had long term benefits in terms of BMD and this study also demonstrated a
significant reduction in the risk of both vertebral and all-fractures. The women in both
studies were of similar age and in the early postmenopausal period but there were several
differences in the methodology. Bagger et al amalgamated 4 randomized controlled trials
in which only otherwise healthy women were recruited and set treatment regimes were
used. Our study was an observational one in which the general population was screened,
appropriate clinical advice regarding treatment was given and the women were free to
change or stop their HRT under their GPs guidance. As such our study is more
representative of real clinical practice and suggests that the benefits of short term HRT
predicted by Bagger et al still occur when the general population is studied. This is
important as recent studies have demonstrated how patient selection for clinical trials can
bias the characteristics of study populations (Al-Shahi et al 2005, Junghans et al 2005).
Bagger et al also had to use different models of DXA scanner throughout their study, thus
requiring the use of a conversion factor, whereas in our study each patient was scanned
on the same machine at each visit allowing direct comparison. We also prospectively
152
followed up the patients at 2,5 and 9 years whereas Bagger et al followed up all patients
at one point in time, either 5, 11 or 15 years after the end of their original trial.
The main limitation is that this is not a randomised controlled trial as women were
allocated to HRT or no treatment depending on their BMD. Although this mirrors clinical
practice, it is possible that this could lead to selection bias which could confound the
study in different ways. Potentially, the women with lower BMD, and therefore allocated
to HRT, may have already undergone the period of rapid postmenopausal bone loss while
those women with higher BMD (no HRT group) may still be in the early stages of rapid
bone loss. If this was the case then the no HRT group would be expected to lose more
BMD during the follow up period and this could theoretically account for the results of
this study. However at baseline the short term HRT and no HRT groups had practically
identical age and menopause age which makes this less likely. An alternative way in
which selection bias could confound the results is that women with lower BMD at
baseline may be “fast losers” of BMD. This is certainly a possibility as, compared to the
no HRT group, women in the short term HRT group had a lower weight and a trend
towards a higher prevalence of smoking which are factors associated with an increased
rate of postmenopausal BMD loss (Ravn et al 1999, Law and Hackshaw 1997). If it is the
case that selection bias led to women who were “fast losers” being allocated into the
short term HRT group then this study provides a conservative estimate of the benefits of
short term HRT as these women should have lost even more BMD than the no HRT
group.
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There are other limitations to this study. As women were not randomised to each
treatment arm there were significant differences between the short term HRT and no
HRT groups at baseline in terms of BMD and weight. While the statistical analysis
corrected for the differences in BMD, it was not also adjusted for weight which is an
oversight although, as discussed above, not correcting for weight would be expected to
make our results more conservative. Women over 125kg were excluded and we have no
record of what proportion of the population were excluded due to this criteria as this was
not entered into the database or reported in the original study (Purdie et al 1996). Finally,
despite having a low BMD for their age the women in this study were not osteoporotic by
the WHO definition. T-scores at baseline were -0.75 and -1.17 in the no HRT group and
short term HRT group respectively. Bagger et al (2004) also looked at women with
normal BMD and as such there are no studies assessing the affect of short term HRT on
osteoporotic women in the early postmenopausal period.
When considering HRT it is important to balance the benefits of treatment with the risks
of vascular disease and breast cancer. The type of HRT required also needs consideration
as oestrogen only HRT, recently confirmed to also provide fracture protection (Jackson et
al 2006), does not have the increased incidence of coronary heart disease and breast
cancer associated with combined HRT (Anderson et al 2004). HRT may not be a suitable
treatment option for all patients. However, for women with low BMD in the early




The effect of prior bisphosphonate exposure on the treatment
response to teriparatide in clinical practice.
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Introduction.
Teriparatide is an effective treatment for osteoporosis which, unlike most other
treatments for osteoporosis, is an anabolic bone agent as it stimulates bone formation
(Jiang et al 2003). In the UK, the National Institute for Health and Clinical Excellence
(NICE) restricts the prescribing of teriparatide to those patients who suffer further
fragility fractures despite prolonged treatment with bisphosphonates. However, as
discussed in chapter 2.2, bisphosphonates have the opposite effect on bone remodelling
which persists after their discontinuation (Bone et al 2004, Black et al 2006) and in
theory this may blunt the anabolic effects of teriparatide. This is supported by a previous
small study demonstrating a diminished BMD response to teriparatide in patients with
prior alendronate exposure (Ettinger et al 2004).
This study reports the results of teriparatide therapy on patients attending our
osteoporosis centre. We hypothesize that the prolonged use of bisphosphonates, as
required by NICE, will impair the clinical response to by teriparatide as assessed by
BMD and BTMs.
Method.
At our centre, patients being considered for teriparatide therapy are initially assessed for
secondary causes of metabolic bone disease, which may be responsible for the fracture
despite bisphosphonate therapy. The conditions screened for are vitamin D deficiency,
hyperparathyroidism, hyperthyroidism, myeloma, coeliac disease and hepatic or renal
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disease. If no secondary cause is detected then patients are commenced on teriparatide if
they are eligible for treatment under the NICE guidelines. All patients commenced on
teriparatide receive supplementation with 1g calcium and 800iu vitamin D.
Once commenced on teriparatide, patients are treated for 18 months and followed up
regularly to ensure compliance and allow close monitoring. The treatment response is
determined using both bone turnover markers and BMD measurements. The early bone
formation response is assessed using P1NP measured pre-treatment and at 3 and 6
months by electrochemiluminescence immunoassay (total P1NP, Roche diagnostics, IN,
USA). P1NP is considered to be the best currently available marker of bone formation as
it has the lowest analytical variation, lowest degree of biological variation and does not
require the patient to be fasted (Seibel 2005). The BMD response is then assessed at the
spine and hip pre-treatment and at 12 and 18 months by DXA using a Lunar Prodigy
bone densitometer (GE Lunar, Madison, WI).
All patients treated with teriparatide have their details entered into a database at our
centre. This database is updated regularly using the patient’s medical record and includes
data on osteoporosis risk factors, fractures, medical history, medication, biochemical data
and BMD measurements. With the permission of Eli Lilly and company, this database
includes a small number of patients treated at our centre with teriparatide as part of a
phase 4 trial who are therefore bisphosphonate naïve and form the control group for this
study.
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For this study all patients on the database who had completed at least 12 months
treatment with teriparatide were identified. These patients were divided into 2 groups
depending on whether they had prior bisphosphonate exposure. The BMD and P1NP
response to teriparatide in those women with prior bisphosphonate exposure was
compared to the response in the bisphosphonate naïve group and to the published
literature.
The data collection and analysis was performed as part of a service review at our centre
and therefore ethic approval was not required although permission was obtained from the
local audit committee.
Statistical analysis.
The distribution of the data was determined using a Kolmogorov-Smirnov test for
normality. Baseline characteristic were analysed using a 2 sample T test or Mann
Whitney U test depending on the distribution of the data. A Chi-square test was used for
categorical data. A repeated measures ANOVA was used to assess the within group
change in BMD and P1NP from baseline. A multivariate ANOVA was used to examine
the difference in BMD and P1NP between the 2 groups at the different time points. The
significance level chosen was 0.05. The program package used was SPSS for Windows




A total of 52 postmenopausal women had been treated with teriparatide for more than 1
year. 38 had prior bisphosphonate use, 14 were bisphosphonate naïve. In the prior
bisphosphonate group, the mean duration (sd) of bisphosphonate use was 67 (37.6)
months and the bisphosphonate was discontinued a mean (sd) of 1 (1.7) month
previously. The prior bisphosphonate group had a significantly lower baseline P1NP as
expected with recent antiresorptive therapy. The prior bisphosphonate group were
required to have suffered a further fragility fracture in order to be eligible for teriparatide
and as such there was a higher baseline prevalence of vertebral fractures in this group.
Otherwise there were no significant differences between the 2 groups. Prior
bisphosphonate usage is described in table 6.1 and full baseline characteristics of the
study population are shown in table 6.2






Alendronate 22 (57.9) 30 (78.9)
Risedronate 8 (21.1) 12 (31.6)
Didronel 3 (7.9) 20 (52.6)
Pamidronate (IV) 5 (13.2) 7 (18.4)
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Table 6.2: Baseline characteristics.
BP naïve Prior BP Test equal p value
n=14 n=38 used variance
Age starting TP (yrs) 69 (5.8) 72.3 (9.0) t y 0.21
Menopause age (yrs) 49.2 (5.7) 46.6 (6.0) t y 0.16
BMI (kg/m2) 26.1 (4.8) 25.7(4.1) t y 0.73
Current Smoking (n) 2 (14.3) 6 (15.8) chi na 0.89
Alcohol >14u/w (n) 0 (0) 0 (0) na na na
Vitamin D (nmol/l) 78.8 (27.1) 70.9 (37.8) t y 0.66
PTH (pg/ml) 29.8 (13.2) 40.9 (20.8) t y 0.23
Vertebral fracture* 1.4 (1.5) 3.9 (2.9) t y <0.001
Non-vertebral fracture* 1.3 (1.1) 1.0 (1.0) t n 0.43
BMD spine (g/cm2) 0.797 (0.1) 0.782 (0.1) t y 0.71
T score -3.4 -3.5
BMD NOF (g/cm2) 0.719 (0.1) 0.667 (0.1) t y 0.08
T score -2.2 -2.6
P1NP (ug/l) 49.1 (18.5) 29.5 (15.4) t y 0.001
Numbers represent mean (sd) or n (%) BP = bisphosphonate, TP = teriparatide
* Mean (sd) number of fractures per patient
t = 2 sample t test, chi = chi squared test, na = not applicable
P1NP response.
At baseline bisphosphonate naïve patients had a significantly higher pre-treatment P1NP
than bisphosphonate treated patients (49.1ug/l and 29.5ug/l respectively, p=0.001). The
bisphosphonate naïve patients maintained a higher P1NP at 3 months (108.8 vs. 71.5ug/l,
p=0.036) and by 6 months the difference in P1NP had increased further (183.1 vs.
125.6ug/l, p=0.007). P1NP changes in the 2 groups are demonstrated in Figure 6.1.
In the prior bisphosphonate group, P1NP increased significantly from baseline by
42.0ug/l at 3 months and 96.1ug/l at 6 months. The bisphosphonate naive group also
experienced a significant increase in P1NP at both 3 months (59.7ug/l increase) and 6
months (134.0ug/l increase). Table 6.3 demonstrates the P1NP changes from baseline.
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The magnitude of the increase from baseline was not significantly different between the
groups at 3 (p=0.27) however by 6 months the change from baseline was significantly
greater in the bisphosphonate naive group (p=0.030).
Figure 6.1: Mean ± standard error serum P1NP response to teriparatide in women with
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Table 6.3: Mean change in P1NP from baseline at 3 and 6 months within each group.
P1NP (ug/l)
BP naïve Prior BP
Baseline 49.13 29.51
3 months 108.80 71.48
∆ 0-3
months 59.67 41.97
p value 0.01 <0.001
6 months 183.11 125.61
∆ 0-6
months 133.98† 96.10†
p value 0.001 <0.001
BP = bisphosphonate
† Significant difference between groups (p=0.03)
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BMD response.
Of the 52 patients, only 33 patients had completed 18 months of therapy to date, 25 with
prior bisphosphonate exposure and 8 bisphosphonate naïve patients. Figure 6.2
demonstrates the percentage change in spine BMD from baseline. In both groups the
increase in spine BMD after 18 months of teriparatide was significant (prior
bisphosphonate: p<0.001, bisphosphonate naïve: p=0.006). The change in BMD at the
spine was not significantly different between the bisphosphonate treated patients and the
bisphosphonate naïve patients at either 12 months (9.0% and 7.8% respectively, p=0.64)
or 18 months (9.8% and 6.1% respectively, p=0.43).
Figure 6.2: Mean ± standard error percentage change from baseline in BMD at the spine
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After 18 months of teriparatide there was a significant increase in hip BMD in the prior
bisphosphonate group but not the bisphosphonate naïve group (p=0.023 and p=0.15
respectively) (figure 6.3). Patients without prior bisphosphonate exposure had a small
reduction in BMD at the hip compared to a small increase seen in bisphosphonate treated
patients at 12 months although the difference was not significant (-0.3 vs. 1.0%
respectively, p=0.98). The change in BMD at the hip was not significantly different
between the groups after 18 months (1.3 vs. 2.8% respectively, p=0.82).
Figure 6.3: Mean ± standard error percentage change from baseline in BMD at the neck

































This is the first study to report the effects of prior bisphosphonate therapy on the
subsequent response to teriparatide prescribed as part of routine clinical practice.
Following the publication of the NICE guidelines, teriparatide is only prescribed in the
UK to patients who have had an inadequate response to prolonged treatment with
bisphosphonates. However, as discussed in chapter 2.2, there is concern that the response
to teriparatide may be blunted by the persistent suppression of bone turnover due to prior
bisphosphonate use. In the present study, patients who had previously taken
bisphosphonates did not achieve the same serum levels of P1NP as bisphosphonate naïve
patients. Although this suggests a degree of blunting of the anabolic effects of
teriparatide, bisphosphonate exposure did not prevent a significant increase in P1NP at 3
or 6 months and by 6 months the prior bisphosphonate group had achieved a 4.3 fold
increase in P1NP. Despite the lower serum P1NP levels in the prior bisphosphonate
group, in the present study there was no evidence of a reduction of the BMD response to
teriparatide. At both 12 and 18 months the increase in BMD at both the spine and hip was
not significantly different between the 2 groups. Furthermore, the increase from baseline
of 9.8% at the spine and 2.8% at the hip achieved in the prior bisphosphonate group at 18
months in this study is practically identical to the increase reported in treatment naive
patients in the main teriparatide fracture prevention trial (Neer et al 2001). This suggests
that our hypothesis is wrong and in fact prior bisphosphonates exposure does not reduce
the subsequent BMD response to teriparatide.
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One previous clinical trial has assessed the response to teriparatide after bisphosphonates.
Ettinger et al (2004) compared alendronate pre-treated women to women pre-treated with
raloxifene. Compared to the present study, Ettinger et al enrolled more bisphosphonate
naïve patients (22 women) but less bisphosphonate treated patients (26 women). The
women were similar in terms of age, BMI and BMD but the women in our study had a
greater duration of bisphosphonate exposure. As in our study, Ettinger et al demonstrated
a smaller increase in P1NP throughout the treatment period in those women with prior
alendronate exposure. However, contrary to our findings, those women with prior
alendronate use had a smaller increase in BMD than bisphosphonate naive women after
18 months at the spine (4.1% vs. 10.2%) and hip (0.3% vs. 1.8%) suggesting blunting of
the response to teriparatide. Interestingly the raloxifene pre-treated women achieved the
expected BMD and bone turnover marker response suggesting that raloxifene does not
cause prolonged suppression of bone turnover, which may subsequently inhibit the
response to teriparatide. This is supported by evidence that BMD declines immediately
upon the cessation of raloxifene (Neele et al 2002). This is likely to be due to raloxifene
being a weaker antiresorptive and it does not have the high affinity for bone which is
responsible for the prolonged duration of action of bisphosphonates (Russell 2007).
Other studies assessing the interaction between alendronate and PTH therapy have
demonstrated that the combination of the 2 therapies resulted in a profound reduction in
the increase in bone formation markers (Black et al 2003, Finkelstein et al 2003). Black
et al (2003) demonstrated a 16% reduction in P1NP at 12 months with combination
therapy compared to a 150% increase in those treated with PTH 1-84 alone. In a second
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study in men BSAP increased by 80% in response to teriparatide compared to around 10-
15% in those treated with combination therapy (Finkelstein et al 2003). Furthermore, in
both studies combining bisphosphonates with PTH therapy resulted in a 50% reduction in
trabecular bone formation compared to PTH mono-therapy. These studies demonstrate
that alendronate is capable of blunting the anabolic effects of teriparatide. However,
when teriparatide is given after bisphosphonates, as in the present study, teriparatide
seems able to overcome the effects of the bisphosphonates with only a small blunting of
the bone marker response and little effect on the BMD response.
Normally when alendronate is discontinued BMD remains stable at the spine and declines
slowly at the hip (Bone et al 2004, Black et al 2006). This suggests that the increase in
BMD in response to subsequent teriparatide therapy is due to the actions of teriparatide,
i.e. new bone formation. The findings of our study therefore suggests that NICE’s
recommendation that bisphosphonates should be used first line does not have a
detrimental effect on the subsequent anabolic actions of teriparatide.
Despite relatively similar baseline characteristics in our study and Ettinger et al’s study,
these studies demonstrated contrasting effects of prior bisphosphonate therapy on the
BMD response to teriparatide. This may be due to differences in study design. Ettinger et
al enrolled healthy women into a clinical trial whereas in our study only patients deemed
to have failed bisphosphonates were switched over to teriparatide, as is clinical practice
in the UK. By using patients deemed to have “failed” bisphosphonates, it may be that the
patients in our study were poorly complying with the bisphosphonates and as such
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suffered less blunting of the response to teriparatide. This is unlikely to be the case as a
significantly lower baseline P1NP was observed in the bisphosphonate users consistent
with suppressed bone turnover and compliance with treatment.
Another potential reason for the different BMD response in our study is that Ettinger et al
only included women with prior alendronate use whereas in our study the bisphosphonate
use was more varied. As discussed in chapter 2.1.2, it appears that different
bisphosphonates may have different characteristics in terms of potency and duration of
clinically relevant effect after discontinuation (Russell 2007). Other bisphosphonates may
have a quicker off-set of action than alendronate which may explain the normal BMD
response in our study. However, the majority of women in our study were on alendronate
prior to teriparatide. Furthermore, overall 79% of women were on either alendronate or
risedronate and these bisphosphonates have been demonstrated to result in an equal BMD
response to teriparatide (Boonen et al 2006b).
The main advantage of this study is that the prior bisphosphonate group represents “real
world” patients undergoing treatment with teriparatide as per clinical practice in the UK.
Our results may therefore be more applicable to the clinical setting than the results of
clinical trials as such trials only involve specific subsets of the population and it has been
previously demonstrated how this can skew the results (Al-Shahi et al 2005, Junghans et
al 2005). Furthermore, all patients were drawn from the same local population, the 2
groups were reasonably comparable and the bisphosphonate group had all had extensive
bisphosphonate therapy.
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There are limitations to this study. The size of the study population was governed by the
number of patients receiving teriparatide at our centre and, due to the NICE guidelines,
there were very few patients in the bisphosphonate naive group. As such the study was
very much underpowered to detect a difference in BMD with only a 28.4% probability of
detecting a significant difference in spine BMD between the 2 groups. The study had
even less power at the femoral neck (13.0%) where the overall BMD response in both
groups was small and the precision error of DXA is greater (Sheperd et al 2006). There
is therefore a risk of a type 2 statistical error with this study and we cannot say for certain
that there was no significant blunting in the prior bisphosphonate group. However,
against this are the facts that the magnitude of the BMD increase observed in our study is
practically identical to the increase reported in bisphosphonate naive women by Neer et
al (2001) and more than double the increase reported by Ettinger et al (2004) in women
with prior bisphosphonate exposure. Other limitations are that the patients received
different bisphosphonates before teriparatide and a larger study would have permitted a
comparison of the effects of different bisphosphonates on the subsequent response to
teriparatide. Also, like Ettinger et al, our study is too small to assess the effects of prior
bisphosphonate use on fracture risk, which is the most important outcome for
osteoporosis therapy, and instead we had to rely on BMD as a surrogate marker.
This study demonstrated a significant 4 fold increase in P1NP in response to teriparatide
in patients with prior bisphosphonate exposure. Although there was a smaller P1NP
response compared to bisphosphonate naive patients, in our clinic population this did not
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result in blunting of the gain in BMD. At both the spine and hip those women with prior
bisphosphonate use had a BMD response to teriparatide, which was similar to
bisphosphonate naïve patients in both this study and the existing literature. In clinical
practice the first line use of bisphosphonates does not impede the subsequent response to
teriparatide suggesting that NICE is correct to limit teriparatide, the more expensive
treatment, to women who fracture despite bisphosphonates.
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Chapter 7:
The effect of prior bisphosphonate therapy on the subsequent
BMD and bone turnover response to Strontium Ranelate.
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Introduction.
In clinical practice many women with osteoporosis are already receiving bisphosphonate
therapy and for newly diagnosed women bisphosphonates are recommended as the first
line therapy for osteoporosis (NICE guideline 2005). In the previous chapter we
discussed switching from bisphosphonate therapy to teriparatide. Women who develop
side effects from bisphosphonates, such as oesophagitis, or have a poor treatment
response and yet do not fulfil the NICE guidelines for teriparatide may be considered for
switching to strontium ranelate. However there is no evidence regarding the effect of
prior bisphosphonate therapy on the subsequent response to strontium ranelate as most
women in the SOTI and TROPOS studies were largely treatment naïve and women who
had taken bisphosphonates for more than 14 days in the 12 months preceding the study
were actively excluded.
There are 2 theoretical reasons why prior bisphosphonate therapy may inhibit the
subsequent BMD response to strontium ranelate. Firstly, bisphosphonates continue to
inhibit bone turnover, thus reducing new bone formation, even after discontinuation
(Bone et al 2004, Black et al 2006). As strontium is predominantly deposited in newly
formed bone, prior bisphosphonate exposure may inhibit the uptake of strontium (Boivin
et al 2006, Boivin et al 2007). Secondly, as discussed in chapter 2.2, alendronate has been
reported to blunt the anabolic properties of teriparatide and if strontium ranelate has
anabolic properties then similar blunting may occur (Ettinger et al 2004, Finkelstein et al
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2003, Black et al 2003). The inhibition of strontium uptake, leading to reduced x-ray
attenuation, and/or reduced bone formation should result in a reduction in the BMD
response to strontium ranelate.
This study investigates the effects of prior bisphosphonate exposure on the subsequent
treatment response to strontium ranelate. We hypothesise that women previously treated




We prospectively recruited women attending for either an outpatient appointment or bone
densitometry assessment at the Centre for Metabolic Bone Disease. Two groups of
women were recruited: bisphosphonate naïve women and women treated with an oral
bisphosphonate for more than 1 year and who had stopped treatment within the last 1
month due to an inadequate response or adverse side effects. All women were aged 50-
80 years and had either a T score of less than -2.5 at the hip/spine or a T score of less
than -2.0 at either site and one other risk factor for fracture (previous osteoporotic
fracture, maternal hip fracture, previous steroid use, body mass index <19). Women were
excluded if they had had prior treatment with strontium ranelate or teriparatide, were
unable to give informed consent, had impaired mobility resulting in difficulty undergoing
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DXA or had a lumbar spine which could not be evaluated by DXA. Women were also
excluded if they had current or likely future steroid use or medical conditions associated
with bone loss including renal disease (creatinine clearance < 30 ml/min), active
malignancy, osteomalacia, hyperparathyroidism and malabsorption syndromes.
Eligible women were enrolled after providing written informed consent. At their first
study visit women underwent a full medical history and physical examination. BMD was
measured at the spine (L2-4) and hip (total hip) by DXA (Lunar Prodigy, GE Lunar,
Madison, WI). Heel (right os calcis) BMD was also measured (Lunar PIXI, GE Lunar,
Madison, WI). Blood was collected for bone turnover markers between 9 and 11am after
an overnight fast and was transported to the laboratory within an hour for separation and
freezing. The bone turnover markers assessed were P1NP (Elecsys 2010, Roche
diagnostics, IN, USA), BSAP (Metra BAP, Quidel Corp, CA, USA) and CTX (β-
crosslaps, Elecsys 2010, Roche diagnostics, IN, USA).
Intervention and follow up.
All subjects received treatment with strontium ranelate 2g once a day at bed time (2 hours
after food) and 1.2g calcium and 800iu vitamin D daily. The women were followed up
for 1 year with visits at 3, 6 and 12 months between 9 and 11am. At each visit details
regarding compliance (based on returned medication), adverse side effects, concomitant
medication and incident fractures were recorded. All women fasted overnight prior to
each visit and blood for bone turnover markers was collected at the same time each visit.
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Axial and heel DXA was repeated at the 6 and 12 month visits. A VFA was performed at
baseline and the 12 month visit to identify incident vertebral fractures.
The primary endpoint was change in axial BMD after 12 months. The average lumbar
spine BMD was used for analysis however if there was a prevalent fracture at baseline or
an incident fracture during the study in one of these vertebrae then the fractured vertebra
was excluded from the analysis. At the hip, total hip BMD was used for the analysis as
this region of interest demonstrates the greatest increase in hip BMD in response to
strontium ranelate (Meunier et al 2004, Reginster et al 2005) and is the recommended
region of interest for assessing treatment response at the hip (Kanis and Gluer 2000). The
secondary endpoints were change in heel BMD, the change in bone turnover markers
(P1NP, CTX and BSAP) and fracture incidence.
Analysis.
The sample size was determined using data from previous studies of strontium ranelate
which demonstrated a mean annual increase in lumbar spine BMD of 7.3% (0.0512
g/cm2) with a standard deviation of 4.9% (0.0343 g/cm2) (Reginster and Meunier 2003).
Allowing for a 10% withdrawal rate, it was calculated that 120 women were needed to
detect a 30% difference in BMD gain between the 2 groups with a power of 90%.
The study was analysed on a per-protocol basis rather than as an intention to treat
analysis. This was so that the results accurately reflect the changes in BMD in women
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who successfully switch from a bisphosphonate to strontium ranelate. Initially, the
kolmogorov-smirnov test for normality was used to assess the distribution of the data.
Baseline characteristics were then analysed using either a 2 sample T test (with the
appropriate assessment of equality of variance (Levene’s test)) or Mann Whitney U test
depending on the distribution of the data. A Fisher exact test was used for categorical
data. The absolute change in BMD at the spine (L2-4), hip (total hip) and heel (right os
calcis) after 6 and 12 months of therapy was compared between the groups using a
multivariate ANOVA. Within each group a repeated measures ANOVA was used to
assess the change in BMD from baseline. For bone turnover markers, a multivariate
ANOVA was used to examine the difference between the 2 groups at each visit of the 4
visits. A repeated measures ANOVA was used to assess the overall change from baseline
of each bone marker during the course of the study. The significance level chosen was
0.05. The program package used was SPSS for Windows (version 14.0 SPSS, Inc.,
Chicago, IL).
Study approval and funding.
Ethical approval was obtained from the Hull and East Riding Local Research Ethics
Committee. Clinical trial authorisation was obtained from the Medicines and Healthcare
products Regulatory Agency, U.K (EudraCT number 2005-003138-16).
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Results.
Subjects and baseline demographics.
In total 120 caucasian women were recruited into the study: 60 women were currently
taking a bisphosphonate (prior bisphosphonate group) and 60 who had no prior
bisphosphonate use (bisphosphonate naïve group). Prior to the first follow up visit at 3
months 8 women discontinued from the prior bisphosphonate group and 4 discontinued in
the bisphosphonate naïve group. These women had no outcome data leaving 108 women
who made up the study population (52 and 56 women in each group respectively). A
further 3 women withdrew between the 6 and 12 month visits so overall 105 of the 108
women in the study population completed the full year.
The prior bisphosphonate group was older (66.9 vs. 62.5 years, p=0.001) and had a lower
baseline BMD at the spine (0.801 vs. 0.836 g/cm2, p=0.03) than the bisphosphonate naïve
group. BMD was similar between the groups for total hip and heel BMD. In the prior
bisphosphonate group bone turnover markers were significantly lower than in the
bisphosphonate naïve group consistent with recent antiresorptive therapy. There were no
other significant differences between the groups at baseline. Full baseline demographics
are demonstrated in table 7.1.
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Age (years) 62.5 (6.8) 66.9 (6.8) t y 0.001a
Menopause age (years) 47.3 (6.1) 46.8 (6.0) t y 0.68
Positive Family history (n) 15 (26.8%) 16 (30.8%) Fisher's na 0.68
Prior steroid use (n) 5 (8.9%) 4 (7.7%) Fisher's na 1
Current smoking (n) 7 (12.5%) 4 (7.7%) Fisher's na 0.53
Alcohol (u/week) 5.4 (9.0) 3.5 (4.7) u na 0.63
BMI (kg/m2) 24.9 (3.4) 24.3 (3.5) t y 0.37
Vertebral # on VFA, (n) 10 (17.9%) 15 (28.8%) Fisher's na 0.25
Prior non-vertebral #, (n) 26 (46.4%) 24 (46.2%) Fisher's na 1
Vitamin D (nmol/l) 72.9 (31.1) 71.9 (26.6) t y 0.86
Parathyroid hormone (ug/l) 31.4 (10.4) 32.3 (11.4) t y 0.66
BMD spine (g/cm2) 0.836 (0.08) 0.801 (0.09) t y 0.03 a
BMD total hip (g/cm2) 0.780 (0.11) 0.751 (0.11) t y 0.18
BMD heel (g/cm2) 0.391 (0.07) 0.369 (0.09) t y 0.15
P1NP (ug/l) 54.42 (18.9) 29.64 (13.9) t y <0.001 a
CTX (ug/l) 0.38 (0.14) 0.18 (0.11) t y <0.001 a
BSAP (U/l) 23.16 (6.7) 17.52 (6.6) t y <0.001 a
t = 2 sample t test, Fisher's =Fisher's exact test, u = Mann Whitney U, na = not applicable
Numbers are n (%) or mean (sd), a = significant difference between groups
# = fracture, BP = bisphosphonate, VFA = vertebral fracture assessment
In the prior bisphosphonate group the mean (sd) duration of bisphosphonate use was 64.3
(38.5) months. One woman discontinued her bisphosphonate 3 weeks before
commencing strontium ranelate, all the remaining women in the prior bisphosphonate
groups switched immediately from bisphosphonate to strontium ranelate. Details of prior
bisphosphonate usage are contained in table 7.2.
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Table 7.2: Bisphosphonate usage before switching to strontium ranelate in the prior
bisphosphonate group.
Immediately prior Ever used
n % n %
Alendronate 27 51.9 39 75.0
Risedronate 24 46.2 29 55.8
Ibandronate 1 1.9 1 1.9
Didronel 0 0.0 15 28.8
Pamidronate 0 0.0 1 1.9
Over the 12 month period the mean level of compliance with strontium ranelate was
95.6% in the bisphosphonate naïve group and 95.0% in the prior bisphosphonate group.
Change in spine BMD with strontium ranelate.
After 6 months of therapy, BMD at the spine had increased by 0.020 g/cm2 (2.4%
increase, p=0.001) in the bisphosphonate naïve group while there was no change in BMD
in the prior bisphosphonate group (-0.003 g/cm2, p=0.65). After 12 months, BMD at the
spine had increased significantly by 0.047 g/cm2 (5.6%, p<0.001) in the bisphosphonate
naïve group and by 0.017 g/cm2 (2.1%, p=0.002) in the prior bisphosphonate group.
These changes are demonstrated in figure 7.1.The increase in BMD was significantly
greater in the bisphosphonate naive group than in the prior bisphosphonate group at both
6 months (difference 0.023 g/cm2, p=0.005) and 12 months (difference 0.030 g/cm2,
p=0.003). After adjusting for the baseline differences in age and BMD, the
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bisphosphonate naïve group maintained a greater gain in spine BMD at both 6 (difference
0.028 g/cm2, p=0.002) and 12 months (difference 0.036 g/cm2, p=0.001). In contrast to
the lack of change in BMD in the prior bisphosphonate group during the first 6 months of
the study, between months 6 and 12 there was a similar gain in BMD at the spine in each
group (0.027 vs. 0.020 g/cm2, p=0.40).
Figure 7.1) Mean (± standard error) change from baseline in BMD at the lumbar spine
after 6 and 12 months treatment with strontium ranelate in bisphosphonate naïve women




























a = significant increase from baseline.
179
Change in total hip BMD with strontium ranelate.
In the bisphosphonate naïve group total hip BMD had increased by 0.014 g/cm2 (1.9%,
increase, p<0.001) at 6 months and by 0.027 g/cm2 (3.4% increase, p<0.001) at 12
months. In the prior bisphosphonate group there was no significant change in total hip
BMD during the 12 months (0.006 g/cm2 (0.8%) increase, p=0.096). These changes are
demonstrated in Figure 7.2. The increase in total hip BMD was significantly greater in
the bisphosphonate naïve group at 6 months (difference 0.013 g/cm2, p<0.001) and 12
months (difference 0.021 g/cm2, p<0.001). After adjusting for the baseline differences in
age and BMD, the difference in total hip BMD between the 2 groups remained significant
at both 6 (difference 0.014 g/cm2, p<0.001) and 12 months (difference 0.020 g/cm2,
p<0.001).
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Figure 7.2) Mean (± standard error) change from baseline in BMD at the total hip after 6
and 12 months treatment with strontium ranelate in bisphosphonate naïve women and in
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Change in heel BMD with strontium ranelate.
In the bisphosphonate naïve group, heel BMD had increased by 0.011 g/cm2 (2.9%,
p=0.002) after 6 months and 0.016 g/cm2 (4.0%, p<0.001) after 12 months. In the prior
bisphosphonate group there was no change in heel BMD over the 12 months (0.001
g/cm2 (0.3%) increase, p=0.93). These changes are demonstrated in Figure 7.3. The
increase in BMD was significantly greater in the bisphosphonate naive group at 6 months
(difference 0.011 g/cm2, p=0.013) and 12 months (difference 0.015 g/cm2, p=0.012).
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After adjusting for the baseline differences in age and BMD, the bisphosphonate naïve
group maintained a greater gain in heel BMD at both 6 (difference 0.013 g/cm2, p=0.006)
and 12 months (difference 0.015 g/cm2, p=0.010).
Figure 7.3). Mean (± standard error) change from baseline in BMD at the heel after 6 and
12 months treatment with strontium ranelate in bisphosphonate naïve women and in






















Bisphosphonate naïve Prior bisphosphonate
a
a
a = significant increase from baseline.
Change in bone turnover markers with strontium ranelate.
At baseline all bone markers were significantly lower in the prior bisphosphonate group
consistent with recent antiresorptive therapy. In the prior bisphosphonate group, 12
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months after switching to strontium ranelate there was a significant increase of 55.1%,
61.0% and 46.3% in P1NP, CTX and BSAP respectively. There was no longer a
significant difference in bone turnover markers between the 2 groups by 3 months for
BSAP and 6 months for P1NP and CTX. However, with CTX the difference between the
2 groups remained borderline at 12 months compared to P1NP and BSAP where the
difference was negligible. The change in bone markers at each visit is provided in table
7.3.
Table 7.3: Changes in CTX, P1NP and BSAP in response to strontium ranelate in women




0 3 6 12 p value
CTX (ug/l) Prior BP 0.18 0.26 0.29 0.29 <0.001
BP naïve 0.38 0.32 0.34 0.35 0.004
Between group p
value <0.001 0.016 0.069 0.046
P1NP (ug/l) Prior BP 29.64 38.00 41.54 45.98 <0.001
BP naïve 54.42 49.70 48.09 47.75 0.011
Between group p
value <0.001 0.001 0.065 0.603
BSAP (U/l) Prior BP 17.52 21.06 23.86 25.64 <0.001
BP naïve 23.16 24.14 23.81 24.45 0.498
Between group p
value <0.001 0.055 0.976 0.465
BP = Bisphosphonate
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In the bisphosphonate naive group, after 12 months of treatment with strontium ranelate
there was a significant decrease of 8.1% in CTX and 12.2% in P1NP (Figure 7.4). There
was an increase of 5.6% in BSAP although this was not significant.
Figure 7.4. Mean (± standard error) percentage change from baseline in P1NP, CTX and
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Fracture incidence during therapy with strontium ranelate.
During the year there were significantly more women who suffered an incident vertebral
fracture in the prior bisphosphonate group (2 vs. 8 women, p=0.047). During the study 1
woman suffered a wrist fracture in the bisphosphonate naïve group while 4 women
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reported non-vertebral fractures in the prior bisphosphonate group (2 rib fractures, wrist
and humerus). All fractures were confirmed on x-ray or VFA with the exception of rib
fractures. Fracture incidence is summarised in table 7.4.
Table 7.4. Fractures occurring during 12 months treatment with strontium ranelate.





Any fracture 3 12 0.014
Vertebral fractures 2 8 0.047
Non-vertebral fractures 1 4 0.194
Adverse events and subject withdrawal from the study.
There were a total of 6 serious adverse events during the study (4 prior bisphosphonate, 2
bisphosphonate naïve) none of which were felt to be likely to be related to the study
medication or lead to withdrawal from the study. For analysis adverse events were
divided into gastrointestinal (GI) (predominantly nausea, altered bowel habit and
bloating), central nervous system (CNS) (predominantly headache and lethargy),
musculoskeletal (arthralgia or leg cramps) and skin (itching or rashes). Only adverse
events considered by the investigators to be probably or definitely related to the study
medication were counted. Of the 12 women who withdrew from the study prior to visit 3
the reasons for withdrawal were GI (n=4), CNS (n=3), musculoskeletal (n=3), skin (n=1)
and one woman requested to change back to weekly therapy with bisphosphonates. Of the
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108 women in the study population the numbers of reported adverse events were: GI 26
(24.1%), CNS 3 (2.8%), musculoskeletal 1 (0.9%) and skin 1 (0.9%). The majority of
these (23/31, 74.1%) occurred in the first 3 months and settled without withdrawing
medication. The 3 women who withdrew from the study population between months 6
and 12 did so because of lost contact (n=1), disliked the taste of strontium ranelate (n=1)
and dyspepsia (n=1).
Discussion.
This is the first study to investigate the BMD response to switching osteoporosis therapy
from a bisphosphonate to strontium ranelate. In this study the bisphosphonate naive
group achieved increases in BMD at the spine and hip, which are comparable to those
seen in the phase 3 SOTI study (Meunier et al 2004). However, the prior bisphosphonate
group had significant blunting of the BMD response to strontium ranelate at all 3 sites
studied confirming our hypothesis. More than 50% of the BMD response to strontium
ranelate is thought to be due to the attenuation artefact caused by strontium’s high atomic
mass (Blake et al 2007). Therefore a large proportion of the blunting of the BMD
response to strontium is likely to reflect poor strontium uptake into the bone. This is
likely to occur because the bisphosphonate induced suppression of bone turnover reduces
the formation of new bone, which is the site at which strontium is predominantly
deposited (Boivin et al 2006, Boivin et al 2007). Also, if strontium ranelate does have
anabolic properties, then part of the blunting of the BMD response may also be due to
reduced gains in bone mass as discussed in chapters 2.2 and 6. Reassuringly the bone
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turnover markers all increased significantly after bisphosphonate discontinuation,
reflecting increased bone turnover, and by 6 months all bone markers were similar in the
2 groups. This suggests that the blunting of the response to strontium is likely to be
temporary. This is supported by the observation that the increase in BMD achieved at the
spine during the second 6 months of the study was the same in both groups.
In contrast to the spine, those women with prior bisphosphonate exposure had no increase
in total hip or heel BMD over the 12 months of the study. Therefore the blunting of the
BMD response appears to be more persistent at the heel and hip than the spine. The hip is
predominantly cortical bone, which is less metabolically active than trabecular bone
(Nobel and Reeve 2000). As such bone turnover may take longer to recover after
bisphosphonate therapy resulting in a more prolonged blunting of the BMD response to
strontium ranelate. Furthermore, the preferential incorporation of strontium into new
bone, compared to old bone, is greater in cortical than trabecular bone. This has been
demonstrated in monkeys with the strontium content in new cortical bone being 3-4 times
greater than that of old cortical bone while the new trabecular bone only contained 2.5
times more strontium (Boivin et al 1996). Therefore reduced new bone formation may
cause a greater impedance of strontium uptake at cortical sites than trabecular sites.
The heel, like the spine, is predominantly comprised of trabecular bone. In contrast to the
spine, in those women with prior bisphosphonate exposure there was no increase in heel
BMD throughout the whole year. The more persistent bisphosphonate induced blunting
of the BMD response at the heel may reflect the fact that the heel is a site of yellow
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(fatty) bone marrow while the spine has greater red bone marrow content (Liney et al
2007). Red bone marrow is the source of both osteoclasts and osteoblasts as well as a
variety of cytokines including macrophage colony-stimulating factor and receptor
activator of nuclear factor KB ligand which influence osteoclast differentiation (Rosen
and Bouxsein 2006). Therefore, the relative lack of these cells and cytokines in the
yellow marrow of the heel may lead to more prolonged suppression of bone turnover
after bisphosphonate discontinuation which may account for the longer lasting blunting
of the BMD response to strontium ranelate.
The clinical consequences of this blunting of the BMD response by prior bisphosphonate
therapy are uncertain as it is difficult to assess whether this has any effect on the ability
of strontium ranelate to reduce fracture incidence. Theoretically, if strontium uptake into
the skeleton is reduced then it is plausible that this will reduce the effect of strontium on
bone strength. However, it is also likely that prior bisphosphonate therapy will have a
period of residual effect on fracture risk (Black et al 2006) which may provide protection
from fractures while the strontium has time to overcome the blunting effect. While there
were significantly more fractures in those women with prior bisphosphonate exposure, it
is important to remember that this was not a randomised trial. The prior bisphosphonate
group were older and had a lower spine BMD at baseline suggesting that they had a
greater risk of fracture, which may account for the observed differences in fracture
incidence.
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The blunting of the BMD response to strontium ranelate may have other consequences
for clinical practice. Firstly, in treatment naïve women, strontium ranelate causes a large
increase in BMD making it possible to detect a treatment response as early as 1 year after
the initiation of therapy. However, the 2.1% increase in BMD at 1 year observed in the
prior bisphosphonate group is less than the most optimistic estimate of least significant
change for spine BMD (Delmas 2000). Therefore in clinical practice it may be necessary
to allow a greater time period before performing a follow up DXA scan to assess a
woman’s treatment response to strontium ranelate if there is a history of recent
bisphosphonate use. Secondly, if bisphosphonates inhibit the response to strontium
ranelate then it may be appropriate to consider strontium ranelate as a first line treatment,
especially in patients likely to tolerate strontium ranelate better than bisphosphonates,
such as women with coexisting gastrointestinal disease or other medication associated
with dyspepsia, and in women over 80 in whom strontium has very good evidence for
fracture reduction (Seeman et al 2006). Conversely, if a woman is intolerant of generic
alendronate, the first line bisphosphonate recommended by NICE, after more than 12
months on treatment then it may be prudent to try a better tolerated bisphosphonate or an
intravenous bisphosphonate before switching to strontium ranelate. Whether
bisphosphonate exposure for less than 12 months results in blunting of the BMD response
to strontium ranelate is uncertain as such women were excluded from our study.
This study also uses bone markers to provide insight into the changes in bone turnover in
each group of patients. CTX and BSAP were measured as these markers allow
comparison of our results with the SOTI study (Meunier et al 2004). P1NP was measured
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as it is potentially a better marker of bone formation, as it is derived directly from type 1
collage synthesis and has the lowest degree of analytical and biological variability (Seibel
2005). Unsurprisingly, in the prior bisphosphonate group all 3 bone turnover markers
were significantly suppressed at baseline and increased progressively throughout the
study. This is consistent with the increase in bone turnover, which has been observed
after the withdrawal of bisphosphonate therapy (Bone et al 2004, Black et al 2006). In the
bisphosphonate naïve group the change in CTX and BSAP were comparable to the
findings of the SOTI study, which reported an increase in BSAP and a reduction in CTX
(Meunier et al 2004). In our study similar divergent changes in these markers were
observed. The 5.6% increase in BSAP was not significant in our study but is of a similar
magnitude as the 8.1% increase reported in the SOTI study. The reduction observed in
CTX was also somewhat smaller in our study (8.1% vs. 12.2%) but was still significant.
Using these markers our study supports the theory that strontium ranelate is a “dual
action bone agonist”.
The change in P1NP in the bisphosphonate naive group is unexpected and interesting.
Like BSAP it is a marker of bone formation however, in contrast to BSAP, P1NP reduced
progressively throughout the study with a significant 12.2% reduction after 12 months.
Previous studies with antiresorptives and anabolic agents demonstrate that changes in
BSAP and P1NP usually mirror each other (Chen et al 2005, Black et al 2007). BSAP is
produced by osteoblasts and is a measure of osteoblast activity and number (Seibel 2005).
The increase in serum BSAP is consistent with reports that strontium ranelate increases
osteoblast proliferation and differentiation and increases osteoblast expression of alkaline
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phosphatase (Bonnelye et al 2007). P1NP is a direct quantitative measure of type 1
collagen synthesis (Seibel 2005). The reduction in P1NP in the face of increased BSAP
suggests that collagen synthesis is not actually increased despite the increased osteoblast
activity. In fact the P1NP response is similar to the CTX response. This would be more
consistent with a mild antiresorptive effect leading to a reduction in bone turnover with
reduced collagen breakdown and synthesis. This is somewhat at odds with the
histomorphometry data, which suggests that there is an increase in bone formation
parameters as well as evidence of increased osteoblast proliferation and differentiation
(Marie et al 1993, Buehler et al 2001, Arlot et al 2005). Furthermore, in-vitro studies
suggest that strontium increases collagen synthesis (Canalis et al 1996), which would be
expected to increase P1NP. Further studies of the effect of strontium ranelate on P1NP
are required but if our findings are confirmed then this suggests that strontium cannot
have an overall anabolic effect as bone cannot be formed without increased type 1
collagen synthesis. Instead strontium ranelate’s effects on bone strength may arise from a
mild antiresorptive effect coupled with an added effect on the crystalline structure of
bone.
There are limitations to this study. This was not a randomised study as women were
allocated into one of the 2 groups according to their prior bisphosphonate use. The lack of
randomisation did result in baseline differences in age and BMD. However, adjustment
for differences at baseline had no effect on the results and otherwise the 2 groups were
well matched. Another limitation was that different bisphosphonates, predominantly
alendronate and risedronate, were used immediately prior to enrolment in the study.
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Alendronate suppresses bone turnover for several years after discontinuation (Bone et al
2004, Black et al 2006) whereas with risedronate bone turnover normalises within one
year (Watts et al 2004). This difference in off-set time may mean that women with prior
alendronate use may experience greater blunting than those with risedronate. As this
study assesses the first year after discontinuation, the effects of this should be minimised
as even bisphosphonates with a rapid offset of action are still likely to cause blunting for
a large proportion of the first year. Furthermore, data with teriparatide suggests that the
BMD response to teriparatide is the same after risedronate and alendronate (Boonen et al
2006b). Finally, for ethical reasons, the majority of women in the prior bisphosphonate
group were switched to strontium ranelate on the basis of a poor clinical response to
therapy. As such there may have been selection bias leading to the recruitment of women
into the prior bisphosphonate group who, for some reason, were more resistant to
treatment which could explain the smaller gains in BMD observed. While this cannot be
ruled out, the baseline bone markers do demonstrate that the bisphosphonates were
successfully suppressing bone turnover prior to the study, suggesting a therapeutic effect
and compliance with treatment. Also against this is the observed increase in spine BMD
during the second 6 months of the study. Furthermore causes for a poor treatment
response, such as malabsorption and conditions affecting bone metabolism, were
excluded at baseline and the compliance with strontium ranelate was the same in each
group.
In conclusion, this study demonstrates that after the discontinuation of bisphosphonates
and switching to strontium ranelate there remains a significant suppression of bone
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turnover for 3-6 months. This is associated with a blunting of the BMD response to
strontium ranelate for 6 months at the spine and for longer at the hip and heel. The
clinical consequences of this in terms of fracture are uncertain but it does imply that after
switching from bisphosphonates to strontium ranelate a greater time period should be
allowed before performing a follow up DXA to assess the treatment response. It may also
be prudent to switch women with intolerance of alendronate to an alternative
antiresorptive or bisphosphonate and to consider strontium ranelate as a first line
treatment in certain groups of women. Finally, this study casts some doubt on the claims








Vertebral fractures are a significant consequence of osteoporosis, as well as trauma and
malignancy, and are associated with a substantial degree of morbidity (Nevitt et al 2000,
Cauley et al 2000). Chapter 4 demonstrates that there is a high prevalence of vertebral
fractures in our local population. After an acute fracture pain often eases with time but
not uncommonly patients are left with persistent pain (Matthis et al 1998, Bianchi et al
2005). Increasingly vertebroplasty is being performed as a means of treating persistently
painful vertebral fractures, or lesions which are refractory to analgesia. In large case
series (see table 2.4.1) this relatively minimally invasive procedure has proven to be very
successful at rapidly relieving pain with a low complication rate.
To date the majority of studies assessing vertebroplasty use PMMA cement. Recently, a
bis-GMA resin has been developed as an alternative cement (Cortoss™, Orthovita, PA,
USA). Cortoss has several potential advantages over PMMA, which are discussed in
chapter 2.4. Yet, despite these advantages, PMMA is more widely used and there is little
in the current literature regarding the clinical outcomes of Cortoss vertebroplasty. In this
study we aim to assess the safety and efficacy of vertebroplasty using Cortoss cement.
Method.
Patients with vertebral fractures or other painful vertebral lesions were reviewed in either
the osteoporosis or neurosurgical outpatient’s clinic. A full medical assessment was
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performed including measurement of BMD (Lunar Prodigy, GE Lunar, Madison, WI)
and screening for other causes of metabolic bone disease. Patients were considered
potentially eligible for vertebroplasty if their symptoms were consistent with the site of
the fracture/lesion and either they had pain despite analgesia or they were unable to take
adequate analgesia due to adverse effects. All potentially eligible patients underwent a
STIR sequence MRI of their spine to assess the age of the vertebral fracture/lesion and
the local anatomy.
The MRI results and case history were subsequently discussed at a multidisciplinary team
(MDT) meeting between bone physicians, neurosurgeons and the musculoskeletal
radiologist. Patients were confirmed as eligible for vertebroplasty if the MRI
demonstrated bone oedema, suggesting acute or ongoing changes, in a vertebral
fracture/lesion which was consistent with the site of their pain (Figure 8.1). The only
absolute contraindication to vertebroplasty was an inability to tolerate the procedure,
usually due to respiratory disease.
After written consent, all vertebroplasties were performed with the patient in the prone
position by the same radiologist using c-arm fluoroscopy guidance. Local anaesthetic and
mild sedation with fentanyl and midazolam was used in all cases. An 11 gauge needle
was placed via a unipedicular approach into the affected vertebral body and Cortoss
cement was injected (Figure 8.2). Patients were given antibiotic prophylaxis and
observed overnight as an inpatient. A plain x-ray was performed post procedure to check
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the position of the Cortoss cement (Figure 8.3). The patients were subsequently followed
up in the outpatient clinic.
Figure 8.1): Sagittal STIR MRI demonstrating bone oedema (arrow) at the superior
endplate of T12 prior to vertebroplasty.
All patient details were recorded on a database, which was updated on a regular basis
using the patient’s medical records. The data collected included medical history,
indication for procedure, details of the procedure, complications and pre and post
procedure analgesic requirements. The data collection and analysis was performed as part
of a service review at our centre and therefore ethic approval was not required although
permission was obtained from the local audit committee.
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Figure 8.2): Injection of Cortoss into the vertebral body of T12 via a left unipedicular
approach.
Figure 8.3): Plain X-Ray of T12 post vertebroplasty demonstrating Cortoss distribution.
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Results.
112 patients were discussed at the MDT as possible candidates for vertebroplasty. Of
those discussed, 34 (30%) patients had consistent MRI and clinical findings leading to a
vertebroplasty being performed on a total of 42 vertebrae. 22 patients were female and 12
male. The mean (sd) age at vertebroplasty was 66.7 (11.2). Patient demographics are
summarised in table 8.1. The mean age of the vertebral fracture/lesion was 21.4 months
however all lesions had ongoing symptoms and an MRI demonstrating bone oedema
within a mean of 4.8 months. All procedures used Cortoss injected by a unipedicular
approach (73.5% via left pedicle). A mean (sd) of 2.2ml (0.4) of Cortoss was injected
into each vertebra. A total of 5 patients had multiple vertebrae treated during the same
session: 2 patients had 2 vertebral levels treated and 3 patients had 3 levels treated.






Total vertebral lesions, n (%)
Median (range) 2.5 (1-12)
Lesions vertebroplastied, n (%)
Median (range) 1 (1-3)
Duration of lesion, months
Overall: Mean (SD) 21.4 (23.5)
Since MRI: Mean (SD) 4.8 (4.7)





Pre-treatment analgesia, n (%)
None documented 1 (2.9)
Single analgesia 4 (11.8)
Multiple analgesia 29 (85.2)
Strong Opioid 11 (32.4)
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Efficacy of vertebroplasty.
Patients were followed for a mean (sd) duration of 9.5 (4.9) months. In 1 (2.9%) case the
effect of vertebroplasty on their back pain was not recorded in the medical records. Of the
33 patients with outcome data, 27 (81.8%) patients reported an overall improvement in
symptoms following the vertebroplasty. Of these patients, 5 (15.2%) later reported a
reoccurrence of their pain to some degree. 1 (3.0%) patient had a transient worsening of
their back pain before it improved. There was no improvement in 5 (15.2%) patients.
Only 1 (3.0%) patient reported an overall worsening of their pain although this patient
had an asymmetrical distribution of the cement within the vertebral body and is currently
awaiting a repeat procedure. Of the 34 patients, 27 (79.4%) required less analgesia post
procedure while 7 (20.6%) had the same analgesic requirements.
Safety of vertebroplasty.
Twenty (58.8%) patients had no complications due to the procedure. In 13 (38.2%)
patients there was leakage of Cortoss, 11 extraosseous and 2 static venous leaks. In all
cases Cortoss leakage was asymptomatic. There were 4 (11.8%) significant
complications. During one procedure venous embolisation of cement was noted on
fluoroscopy and a subsequent CT pulmonary angiogram confirmed a pulmonary embolus
but there were no associated clinical features or decline in lung function. One (2.9%)
patient developed a generalised rash, which settled with chlorphenamine and
hydrocortisone. One (2.9%) patient developed a transient radicular leg pain although no
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nerve root compression due to Cortoss was demonstrated on CT. Finally, one year after a
vertebroplasty, one patient (2.9%) with malignancy suffered further metastatic spinal
disease resulting in retropulsion of the Cortoss cement requiring surgical intervention.
Discussion.
To our knowledge, this is only the second report in the literature regarding the outcomes
of Cortoss vertebroplasty and the first report of its use in the clinical setting. Cortoss
vertebroplasty is effective in reducing pain from a variety of spinal lesions. In this patient
series subjective pain reduction was achieved in 82% of patients. Overall, 79% of
patients required less analgesia post vertebroplasty. Furthermore the complication rate in
our study was low with 88.2% of patients suffering no significant complications.
Palussiere et al (2005) reported on a prospective study using Cortoss. The 53 patients in
this study were similar to our study population in terms of age, sex and indications for
vertebroplasty although slightly fewer patients were on strong opiate analgesia in our
study (32% vs. 41%). In our study a smaller mean volume of Cortoss was used (2.2ml vs.
4.3ml). In contrast to the present study, 60% of the vertebroplasties performed by
Palussiere et al (2005) were under general anaesthesia leading directly to the death of one
patient and, possibly contributing to, pneumonia in a second. In both studies the
commonest complication was leakage of Cortoss although the frequency in our study was
lower (38% vs. 76%), possibly related to our use of smaller volumes of Cortoss. In both
studies the vast majority of cement leakage was asymptomatic and serious complications
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due to Cortoss leakage were uncommon - 1 asymptomatic PE (our study) and 1 soft
tissue leakage (Palussiere et al). Other complications were varied and infrequent in either
study and occurred in only 2-3% of cases. Palussiere et al also reported significant
benefits in terms of pain relief and reductions in analgesic use although Palussiere et al
were able to use validated efficacy measures as the vertebroplasties were performed as
part of a clinical trial.
Studies using validated efficacy measures confirm that PMMA vertebroplasty reduces
pain, reduces disability and improves quality of life as assessed by the visual analogue
scale, Barthel index and the SF-36 questionnaire. These measures permit actual
quantification of the degree of improvement following a vertebroplasty. Studies which
only include osteoporotic vertebral fractures report that 90-100% of patients achieve an
improvement in back pain after a PMMA vertebroplasty (Kobayashi et al 2005, Pitton et
al 2007). However in those studies which, like our study, included a variety of vertebral
lesions, 76-86% of patients reported reductions in pain after a PMMA vertebroplasty
(Martin et al 1999, Barr et al 2000, Anselmetti et al 2007). The efficacy of vertebroplasty
with Cortoss cement seems comparable with these studies, as 82% of our patients
reported an improvement in their pain. The lack of a validated efficacy measure is a
limitation of our study however 79% of our patients reduced their analgesic requirements
providing further evidence of symptomatic benefit in these patients. This is again
comparable to reports from PMMA vertebroplasty in which 71-90% of patients had a
reduction in their analgesic requirements (Afzal et al 2007, Diamond et al 2006, Jensen et
al 1997).
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Asymptomatic Cortoss leakage was noted in 38% of patients in our study. Comparison
with the literature from PMMA vertebroplasty is hindered by many studies not reporting
asymptomatic leakage rates. Studies using CT scans report that asymptomatic cement
leakage is very common occurring in 55-76% of cases (Pitton et al 2007, Kobayashi et al
2005). Studies which, like our study, describe the rates of asymptomatic cement leakage
detected by fluoroscopy at the time of vertebroplasty or on a subsequent x-ray report
lower asymptomatic leakage rates of 3-50% (Yu et al 2008, Afzal et al 2007). This wide
range of leakage rates may in part reflect differing degrees of radiopacity of the different
types of PMMA used. The 38% leakage rate with Cortoss in our study does seem to fall
within the range reported for PMMA. Palussiere et al (2005) reported a 76%
asymptomatic leakage rate for Cortoss which is greater than most PMMA studies. This
may be related to the high degree of radiopacity of Cortoss combined with leakage being
specifically looked for on fluoroscopy as part of the study design. Other possible reasons
for a high rate of cement leakage with Cortoss may be due to differences in viscosity and
setting time although it is difficult to assess this without a head-to-head comparative
study.
Although a 38% leakage rate is high this is an acceptable complication rate for the
procedure due to the absence of any associated morbidity or mortality. However, it is
important that Cortoss vertebroplasty has a low incidence of serious complications. In our
study there were only a few clinically significant complications of Cortoss vertebroplasty,
which is consistent with the reports of PMMA vertebroplasty. A cement pulmonary
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embolus is a potentially life threatening complication which has been reported in 0%
(Anselmetti et al 2007), 4% (Grados et al 2000) and 7% (Jensen et al 1997) of PMMA
vertebroplasties which is comparable to the 2.9% incidence observed in the present study.
In our study 1 patient (2.9%) experienced transient nerve root pain which has been
reported in 1% (Evans et al 2003), 3.9% (Anselmetti et al 2007) and 8% (Grados et al
2000) of PMMA vertebroplasties. Grados et al (2000) also reported a 4% incidence of a
transient increase in back pain, which is again similar to the 3.0% incidence observed in
the present study.
Our vertebroplasty service is newly established and the results in this paper are derived
from the first 34 patients treated. Prior to the vertebroplasty service the radiologist had
limited experience at vertebroplasty. Therefore our results may underestimate the benefits
and exaggerate the complication rates, which occur from Cortoss vertebroplasty as the
radiologist’s technique could improve with increasing experience leading to better
clinical outcomes with time. There was no evidence of a secular trend in the benefits and
complication rate in this study although this may be due to the short time period and the
small number of vertebroplasties studied. Our results however can be expected to
represent the results achievable when a vertebroplasty service is first established and may
be a conservative estimate of the potential benefit to risk ratio of the procedure.
There are limitations to this study. This study is retrospective and therefore is dependent
on the information documented in the medical records. Our results are compared to the
published literature rather than a direct comparison with PMMA vertebroplasty. This
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would require a head to head comparative study and as yet no such study has been
reported. The size of the study population is comparable to many other reports regarding
the outcomes of vertebroplasty, however a larger study would better identify the
incidence of the less common adverse events (e.g. PE).Finally this study lacks an
objective measure of quantifying pain such as a visual analogue scale. This is because we
report the outcomes of a clinical vertebroplasty service rather than a specifically designed
clinical trial although we do provide results from the “real life” clinical setting.
Vertebroplasty is not a panacea for all patients with back pain but in patients with active
vertebral fractures or lesions vertebroplasty provides an effective means of reducing back
pain with an acceptable complication rate. Cortoss cement has several potential
advantages over PMMA and in the clinical setting the outcomes of vertebroplasty using
Cortoss are comparable to those published for PMMA.
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Chapter 9:




1): Routine VFA screening detects vertebral fractures in 20% of women attending for
DXA, the majority of these will have osteopenia and as such the presence of a fracture
may directly effect their treatment.
2) Targeted VFA screening greatly reduce the number of women undergoing VFA
however only around 10% of women with vertebral fractures are detected.
3): A short course of HRT during the early postmenopausal period has a prolonged
benefit in terms of BMD compared to no treatment and may reduce the incidence of
fractures even after discontinuation.
4): Prior bisphosphonate use reduces, but does not prevent, the increase in P1NP in
response to teriparatide however this does not result in blunting of the BMD response.
5): The BMD response to strontium ranelate is blunted by prior bisphosphonate use for
the first 6 months of therapy at the spine and for at least 12 months at the hip and heel.
6): The P1NP response to strontium ranelate suggests that collagen synthesis is reduced
which contradicts evidence supporting its potential anabolic properties.
7): Vertebroplasty using Cortoss cement provides an effective means of reducing pain
from painful vertebral fractures with a low complication rate and the results are
comparable to the literature for PMMA vertebroplasty.
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Summary, changes to the treatment of osteoporosis suggested by this thesis (in red).
Women identified as being at risk according to the Royal College of Physicians guidelines on
osteoporosis case finding.
BMD measured at spine and hip. Perform VFA, preferably on all women, at least on
all osteopenic women to improve accuracy of patients fracture risk assessment.
Low risk / normal
BMD, reassure.
Intermediate risk / osteopenia, life
style advice, consider calcium and
vitamin D supplementation.
High risk / osteoporosis, life
style advice, calcium and
vitamin D supplements
1st line treatment: Bisphosphonates.
Consider initial course of short term HRT
if early postmenopausal period or
strontium ranelate if GI disease or elderly










































This thesis studies several different aspects of osteoporosis management. The early
disease period is studied in chapters 4 and 5. Chapter 4 examines the potential for routine
VFA to effect the initial decision regarding the need for bone protective treatment.
Chapter 5 investigates one of the treatment options available to postmenopausal women
in their 50’s for whom treatment decisions can be complicated. Chapters 6 and 7 study
women with osteoporosis who are on bisphosphonates, the current first line treatment for
osteoporosis, and require a change in therapy. These chapters investigate the interactions
between different types of osteoporosis treatments and the clinical effects of switching
between therapies, an area which is poorly studied. Finally, chapter 8 studies
vertebroplasty, which is one of the treatment options for women who suffer a vertebral
fracture as a result of their osteoporosis.
One of the most important decisions to make regarding the treatment of osteoporosis is
whether or not to initiate treatment. To withhold treatment will allow the age related
decline in BMD to continue and may leave the women at a high risk of fracture.
However, initiating treatment too freely may result in many women who do not have a
high fracture risk being treated. This would expose many women to the potential side
effects of bisphosphonate therapy for little gain and would have important cost
implications for a health system with finite resources. The key to determining the initial
treatment decision is to estimate each individual woman’s fracture risk and only treating
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those women with a fracture risk, which is deemed to be high. This approach has been
adopted by the WHO, which has recently produced a fracture risk calculator (FRAX)
(www.shef.ac.uk/FRAX/tool.jsp).
FRAX is designed to estimate an individual’s 10 year risk of suffering a hip or other
major osteoporotic fracture (clinical spine, forearm or proximal humerus) based on
clinical risk factors with or without BMD. The clinical risk factors used by FRAX have
been determined to increase fracture risk independent of BMD by meta-analyses of 9
prospective population-based cohorts with a total follow-up of over 250,000 person years
(Kanis et al 2008). The risk factors used by FRAX are prior fragility fracture, parental
history of hip fracture, current smoking, ever use of long term steroids, alcohol (≥3
units/day) and rheumatoid arthritis. BMI is also entered into FRAX although BMD is
optional. This provides an overall estimation of an individual’s 10 year risk of fracture
however the optimum “cut off” level of risk above which treatment should be initiated
has not yet been determined.
Vertebral fractures are the commonest osteoporotic fracture however two thirds of
women with vertebral fractures are reported to be unaware of them (Melton et al 1993).
In chapter 4 the proportion of women with vertebral fractures who were unaware of their
presence was even higher at 77%. In these women with undiagnosed vertebral fractures
there will be an underestimation of their fracture risk when using FRAX which may
consequently lead to treatment being withheld inappropriately. In this thesis I
demonstrated that routine VFA screening detects vertebral fractures in 20% of women
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screened suggesting that routine VFA will improve fracture risk assessment in up to 1 in
5 women. Furthermore, almost half of all women with vertebral fractures in chapter 4 had
2 or more fractures detected. This knowledge is also important as FRAX states that
“fracture probability is underestimated with multiple fractures” so fracture risk
assessment should be adjusted to take account of the number of vertebral fractures.
Overall routine VFA screening is likely to improve the accuracy of fracture risk
assessment by FRAX.
Although routine VFA screening is very much the ideal scenario for risk assessment it
has significant implications in terms of DXA scanner resources and not all DXA units
will have the capacity to perform VFA routinely. In this situation it will be important to
target certain groups of patients to undergo a VFA. However, I also demonstrated that
simply targeting women with reasons to suspect a fracture fails to detect 90% of women
who have a fracture suggesting that this is not an effective means of targeting VFA. In
chapter 4 I discussed the implications of using BMD category to target VFA screening
however there are other potential methods of targeting VFA. One option may be to target
all women with no prior history of fracture as the detection of an unknown vertebral
fracture in these women would increase their fracture risk. Alternatively, it may be
beneficial to perform the axial DXA, calculate the fracture risk using FRAX and then
target VFA at women who are below but approaching the treatment threshold. Finally it
may be possible to use clinical risk factors to determine the probability of a vertebral
fracture being detected by VFA and then targeting screening at women above a certain
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level of probability. Defining which groups of women should undergo VFA screening is
a research area, which requires further work.
One consequence of FRAX is that women in their 50s are unlikely to reach the treatment
threshold as increasing age is a major determinant of fracture risk. However, despite a
low 10 year fracture risk, a women aged 50 with a T score compatible with osteoporosis
has a high life time risk of fracture as, with time, there is a substantial increase in fracture
risk due to increasing age and declining BMD. There is also logic to using antiresorptives
early while there is bone to prevent being resorbed rather than waiting until there has
been a significant decline in bone mass and microarchitecture. Finally withholding
treatment from women with perceived “brittle bones” may cause significant anxiety and
distress. In clinical practice drug treatments need to be cost effective. As such it may be
that a lower treatment threshold can be used for drugs such as generic alendronate and
HRT which are considerably cheaper than branded osteoporosis therapies. Interestingly a
recent cost effectiveness analysis of generic alendronate demonstrated that it was cost
effective (<£20,000/QALY gained) to treat women in their 50s with osteoporosis, even if
they had not yet suffered an osteoporotic fracture, despite their low 10 year fracture risk
(Kanis et al 2008b).
HRT may still be one of the first line treatment options for those women in the early
postmenopausal period who either want or need treatment for their bones. In this age
group HRT will not only preserve BMD but it will also relieve menopausal symptoms. It
may also delay the initiation of bisphosphonates which may be important in this age
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group given the potential concerns regarding long term bisphosphonate therapy discussed
in chapter 5. Since the WHI study it is recommended that HRT is only prescribed as a
short term therapy. In line with this recommendation, in this thesis, I have demonstrated
that even a short period of HRT can have lasting benefits in terms of BMD. Furthermore
both my study and Bagger et al (2004) suggest that short term HRT may produce long
term benefits in terms of fracture reduction. Therefore, if the treatment threshold for
bisphosphonates is set at a level of risk, which denies treatment to most osteoporotic
women in their early 50s, then short term HRT may provide an alternative treatment
option. This may enable the preservation of BMD and protection from fracture while age,
and therefore fracture risk, increases to a level at which bisphosphonates may be used.
However, this is an area which requires further research as the recently published WHI
follow up study suggests that the HRT benefits in terms of fracture reduction are rapidly
lost when HRT is discontinued (Heiss et al 2008). The reason for these contrasting results
is uncertain but may reflect the difference between delaying the menopause with early
HRT use and inducing an artificial period of increased hormone levels in an already
postmenopausal women followed by a second “menopause” when these are withdrawn.
Chapter 5 also demonstrated that with long term HRT BMD continues to increase over a
9 year period which is consistent with the findings from the WHI study. HRT does offer
effective bone protection, however the future of long term HRT as a treatment option for
osteoporosis depends on its other health effects. The WHI study has cast serious doubts
on the health benefits of long term HRT however, as discussed in chapter 2.1.1, the WHI
study has certain limitations and as such it is not necessarily the end of HRT. Oestrogen
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only HRT may reduce the incidence of breast cancer and there is evidence to support the
timing hypothesis which predicts that oestrogen started at the menopause provides long
term protection from cardiac events. Furthermore, transdermal oestrogen may not cause
the increased risk of venous thrombosis observed with oral therapy (Scarabin et al 2003).
Therefore, for osteoporotic women in their early 50s, transdermal oestrogen only HRT
may have overall health benefits and reduce menopausal symptoms making it potentially
first line treatment. For women with an intact uterus progestogen must also be
administered to prevent an increase in endometrial cancer. While the WHI study
demonstrated that systemic progestogen is associated with an increased risk of breast
cancer and cardiac events this could be negated by the use of topical progestogen in the
form of the Mirena coil. Further research is clearly needed on HRT and we await with
interest for the results of the KEEPS study which is investigating the cardiovascular
effects of starting low dose HRT within 3 years of the menopause (Harman 2006).
My thesis also studies the clinical effects of switching between osteoporosis therapies.
Bisphosphonates are currently regarded as first line therapy although women may
subsequently switch to other classes of therapy due to side effects or a poor clinical
response. Bisphosphonates have a profound affect on bone turnover, which persists after
discontinuation. When therapy is switched, the persistent action of bisphosphonates may
interfere with the subsequent response to a different class of treatment. However this area
of management is poorly studied. To my knowledge there are no such studies with
fracture as the primary endpoint as such a study would require thousands of women and
would be very expensive. Fracture prevention studies are usually funded by
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pharmaceutical companies who have little to gain, and perhaps a lot to lose, by
investigating whether their already licensed therapy interacts negatively with other
osteoporosis therapies. As such most switching studies, including the 2 studies in this
thesis, rely on surrogate markers such as BMD and BTMs. While such surrogate markers
are a poor substitute for actual fracture data, they at least provide evidence regarding
whether the treatment is having the expected results on bone tissue.
Chapter 6 investigates the effects of switching from bisphosphonates to teriparatide. This
is an important area of study for countries like the UK where, due to the NICE guidelines,
teriparatide can only be prescribed to women who have already been treated with
bisphosphonates. Using teriparatide in this way is outside the evidence base for fracture
reduction as in the teriparatide fracture prevention trial the vast majority of women were
treatment naive (Neer et al 2001). Chapter 6 demonstrated that prior bisphosphonate
users had a lower baseline P1NP and a smaller increase in P1NP. However, reassuringly
there was still a 4 fold increase in P1NP in response to teriparatide and the BMD
response was the same as both the bisphosphonate naïve group and the published
literature. These findings contrasted with the study by Ettinger et al (2004), which was
the only similar study available at the time chapter 6 was published. Since then data from
the large multicentred Eurofors study has been published which also demonstrates a large
increase in BMD at both spine (7.8%) and hip (1.6%) in response to 18 months
teriparatide despite prior antiresorptive therapy (Boonen et al 2008). These BMD changes
are double those reported by Ettinger et al (2004) suggesting that if the BMD response is
blunted by prior bisphosphonates then the effect is small. Boonen et al (2008) also
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reported that the response to teriparatide is equivalent in prior users of risedronate and
alendronate, which accounted for 79% of the women in my study. Prior didronel users,
8% of my study population, achieved a better BMD response to teriparatide in the
Eurofors study which may explain the slightly better BMD response in prior
bisphosphonate users reported in this thesis. Overall, in chapter 6 and the Eurofors study
there was a good BMD response despite prior antiresorptive therapy. This suggests that
bisphosphonates can be used first line, as stated by NICE, with teriparatide, the more
expensive treatment, reserved for those patients who suffer a further fragility fracture
despite bisphosphonates.
In a similar vein, chapter 7 investigates the effect of prior bisphosphonate use on the
subsequent response to strontium ranelate. In contrast to the teriparatide study, chapter 7
demonstrated significant blunting of the BMD response to strontium ranelate at the spine,
during the first 6 months, and at the hip and heel throughout the whole year of the study.
So why might prior bisphosphonate use blunt the BMD response to strontium ranelate but
not teriparatide? The answer may be due to the different effect that these 2 drugs have on
the rate of bone turnover. Both teriparatide and strontium ranelate are thought to induce a
positive balance at the level of the BMU leading to an increase in bone mass. However
the overall rate at which bone mass is gained is governed by the rate of bone turnover.
Teriparatide actually increases bone turnover and will therefore quickly reverse the
bisphosphonate induced suppression of bone turnover causing bone mass to be gained
rapidly. On the other hand, strontium ranelate has no effect on the rate of bone turnover
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(Arlot et al 2005). Therefore, if bone turnover is suppressed by prior bisphosphonate use
then any gain in bone mass will occur at a slower rate. Secondly, the persistent
suppression of bone turnover, due to the inability of strontium ranelate to increase bone
turnover, will reduce the amount of new bone available for strontium uptake, which
accounts for a large proportion of the BMD response to strontium ranelate.
When treating a woman for osteoporosis care is required when deciding whether or not to
switch her from a bisphosphonate to a different treatment. The type of subsequent therapy
to be used is very important. Prior bisphosphonate therapy is unlikely to have a major
detrimental effect on subsequent therapy with an alternative antiresorptive or
bisphosphonate as the overall effect on bone turnover is similar. This thesis also
demonstrates that switching from a bisphosphonate to teriparatide is effective with a
significant increase in BMD. However, not all women who are considered for a change in
therapy will fulfil the NICE criteria for teriparatide. In these women one must be cautious
when considering whether or not to switch them to strontium ranelate. The effect of
switching to strontium ranelate on the risk of fracture is not known. However, the risk of
a poor response to strontium ranelate, during the first year at least, must be considered
and until more information is available it may be better to switch to an alternative
bisphosphonate rather than strontium ranelate. Conversely, as discussed in chapter 7, if
blunting is going to occur then it may also be prudent to use strontium ranelate first line
in certain groups of women.
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Finally, this thesis investigates vertebroplasty as a treatment option for women who
suffer a painful vertebral fracture. Chapter 8 adds to a large body of evidence
demonstrating that vertebroplasty effectively reduces pain due to vertebral fractures with
a low complication rate. The role of vertebroplasty in the treatment of osteoporosis is still
not entirely clear. The procedure is highly effective at relieving pain and reducing
hospital stay when performed acutely however Diamond et al (2006) demonstrated that,
compared to conservative therapy, the benefits were marginal at 6 weeks and non-
existent at 6 months. This is because the majority of vertebral fractures become non-
painful with time. Of more benefit maybe the reduction in pain achieved when
vertebroplasty is performed on fractures, which remain painful despite several months of
conservative treatment as was the case in chapter 8. However, all studies of
vertebroplasty for chronically painful vertebra, including chapter 8, are uncontrolled and
therefore the benefit reported relies on the assumption that the vertebra would remain
painful if left untreated. A randomised controlled trial comparing vertebroplasty to local
anaesthetic injection for the treatment of fractures which have failed to settle
conservatively (INVEST trial), is currently underway and hopefully will confirm the
benefits of vertebroplasty (Gray et al 2007). Finally, chapter 8 is almost unique in the
type of cement used for the vertebroplasty. Although Cortoss has been demonstrated to
have potential advantages in-vitro whether or not this translates in to additional clinical
benefit needs further investigation, preferably with a head to head comparison to PMMA.
To conclude, osteoporosis and the resulting fragility fractures have significant
consequences for both postmenopausal women and society as a whole. Fortunately, in
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recent years there have been many advances in the field of osteoporosis leading to an
increase in the number of treatments available. While modern treatments are all proven to
reduce fractures in treatment naïve women their place in the overall treatment of women
with osteoporosis is less well studied. This thesis provides further insight into areas such
as improving fracture risk assessment in order to guide treatment initiation, initial
treatment options, the effects of switching between treatments and finally the treatment of
painful vertebral fractures.
Future research:
Although my MD is now complete I plan to continue my osteoporosis research. All
women in the strontium study completed the first year in July 2008 and a final report has
been submitted for publication. The strontium study has also been extended for a second
year in order to see if the women with prior bisphosphonate use begin to experience an
increase in BMD or even “catch up” with the bisphosphonate naïve group. The second
year will complete in July 2009. I also have a study underway assessing the effects of
strontium ranelate on heel ultrasound although the results will not be ready in time for
this thesis. Finally using the large database of women who underwent routine VFA I have
recently derived an algorithm, which uses simple clinical risk factors to give a probability
score for a vertebral fracture being present on VFA. The use of this probability score to
target which women should be selected for VFA screening is soon to be published in
Calcified Tissue International.
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Appendix: Publications and presentations.
Full articles and papers:
1): The effects of short-term hormone replacement therapy on long-term bone mineral
density. Climacteric. 2007 Jun;10(3):257-63.
2): The effect of prior bisphosphonate exposure on the treatment response to teriparatide
in clinical practice. Calcif Tissue Int. 2007 Nov;81(5):335-40.
3): The effect of short-term and low dose hormone replacement therapy on long term
bone mineral density. RAD Magazine. Jan 2008;34(392):19.
4): The safety and efficacy of vertebroplasty using Cortoss cement in a newly established
vertebroplasty service. Br J Neurosurg. 2008 Apr;22(2):252-6.
5): Routine versus targeted vertebral fracture assessment for the detection of vertebral
fractures. Osteoporos Int. 2008 Aug;19(8):1167-73.
Poster presentations and abstracts:
1): The implications of the NICE osteoporosis guidelines for women aged 60-70.
Presented: British Society for Rheumatology, 2006.
Abstract: Rheumatology 2006:45;supp1;i89;194.
3): Vertebral compression facture, an unusual presentation of Hodgkin’s lymphoma.
Presented: British Society for Rheumatology, 2006.
Abstract: Rheumatology 2006:45;supp1;i147;373.
4): Short term Hormone Replacement Therapy results in long term gains in BMD. †
Presented: European Calcified Tissue Society, 2006.
Abstract: Calcif Tissue Int:2006;78;supp1;s147;p422.
6): Is serum PTH or vitamin D or both required to assess calcium homeostasis?*
Presented: National Osteoporosis Society, 2006
Abstract: Osteoporosis internation:2006;17;supp3;p132.
7): The effect of prior bisphosphonate therapy on the early treatment response to
Teriparatide in clinical practice. †
Presented: European Calcified Tissue Society, 2007.
Calcif Tissue Int:2007;80;supp1;p380-T;s138.
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8): Bisphosphonate exposure prior to Teriparatide for osteoporosis: Does it matter in
clinical practice?.
Presented: British Society for Rheumatology, 2007.
Abstract: Rheumatology 2007:46;supp1;i129;335.
9): The safety and efficacy of vertebroplasty using Cortoss cement in a newly established
vertebroplasty service. †
Presented: British Society for Rheumatology, 2007.
Abstract: Rheumatology 2007:46;supp1;i132;349.
10): The routine use of lateral vertebral assessment for vertebral fracture detection is
more effective than opportunistic screening. † *
Presented: National Osteoporosis Society, 2007
Abstract: Osteoporosis international 2007:18 (supp3):s74
11): The effect of Strontium Ranelate on heel BMD and ultrasound.
Accepted for presentation: British Society for Rheumatology 2008 and European
Calcified Tissue Society 2008
12): The effect of prior bisphosphonate exposure on the treatment response to Strontium
Ranelate.
Accepted for presentation: British Society for Rheumatology 2008 and European
Calcified Tissue Society 2008
† = Presented at more than one meeting, only first presentation referenced.
* = nominated for prize.
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